Find Paid Research Studies in Texas

Browse Locations ... United States» ... Texas

Multi-center, Randomized, Double-blind Efficacy and Safety of CD0271 0.3%/CD1579 2.5 % Topical Gel in Acne Vulgaris

Condition: Acne Vulgaris
Interventions: Drug: CD0271 0.3% / CD1579 2.5%; Drug: CD0271 0.1% / CD1579 2.5%; Drug: Topical Gel Vehicle
Sponsors: Galderma R&D; Galderma R&D
Not yet recruiting - verified June 2013
Identification of Herpes Simplex Virus (HSV) Shedding in the Female Genital Tract of Pregnant and Nonpregnant Women by GeneXpert PCR, Routine PCR, and Culture

Condition: Herpes Simplex Virus
Intervention: Device: Genexpert assay
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham
Not yet recruiting - verified June 2013
A Study of LY2605541 in Healthy Participants

Condition: Healthy Volunteers
Intervention: Drug: LY2605541
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Not yet recruiting - verified June 2013
Prospective Cohort for the Evaluation of Biomarkers Following HCT

Condition: Recipients of Allogeneic Hematopoietic Stem Cell Transplantation
Intervention:
Sponsors: Medical College of Wisconsin; Medical College of Wisconsin; National Heart, Lung, and Blood Institute (NHLBI); National Cancer Institute (NCI); Blood and Marrow Transplant Clinical Trials Network
Not yet recruiting - verified June 2013
Safety and Efficacy of Vilazodone in Adolescent Patients With Major Depressive Disorder

Condition: Major Depressive Disorder
Interventions: Drug: Placebo; Drug: Vilazodone; Drug: Vilazodone
Sponsors: Forest Laboratories; Forest Laboratories
Not yet recruiting - verified June 2013
Point-of-care Health Literacy and Activation Information to Improve Diabetes Care

Condition: Diabetes Mellitus
Interventions: Behavioral: Empowering Patients in Chronic Care (EPIC); Behavioral: Enhanced Usual Care (EUC)
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Not yet recruiting - verified June 2013
Study to Assess Preference Between Two Autoinjectors for Rheumatoid Arthritis and Plaque Psoriasis Subjects Treated With Etanercept

Condition: Rheumatoid Arthritis and Plaque Psoriasis
Intervention: Drug: Etanercept
Sponsors: Amgen; Amgen
Not yet recruiting - verified June 2013
Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis

Condition: Bacterial Conjunctivitis
Interventions: Drug: Auriclosene Ophthalmic Solution; Drug: Vehicle Ophthalmic Solution
Sponsors: NovaBay Pharmaceuticals, Inc.; NovaBay Pharmaceuticals, Inc.
Not yet recruiting - verified June 2013
Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy

Condition: Diabetic Nephropathies
Interventions: Drug: BAY94-8862; Drug: Placebo
Sponsors: Bayer; Bayer
Not yet recruiting - verified June 2013
Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene

Conditions: Leukemia; Myeloma; Myeloproliferative Diseases
Interventions: Drug: Fludarabine; Drug: Melphalan; Drug: Alemtuzumab; Procedure: Stem Cell infusion; Drug: Tacrolimus; Drug: Mini Methotrexate; Drug: G-CSF; Procedure: Donor Lymphocyte Infusion (DLI); Drug: AP1903; Drug: Methylprednisolone; Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Bellicum Pharmaceuticals
Not yet recruiting - verified June 2013
Duchenne Muscular Dystrophy Clinical Trial

Condition: Duchenne Muscular Dystrophy
Intervention: Device: VECTTOR
Sponsors: Alan Neuromedical Technologies, LLC; Alan Neuromedical Technologies, LLC
Recruiting - verified June 2013
A Phase 1 Study of Substance P-Saporin in Terminal Cancer Patients With Intractable Pain

Condition: Intractable Pain in Terminal Cancer Patients.
Intervention: Drug: Substance P-Saporin
Sponsors: Scott and White Hospital & Clinic; Arthur E. Frankel
Not yet recruiting - verified June 2013
A Study of Lebrikizumab in Patients With Idiopathic Pulmonary Fibrosis

Condition: Idiopathic Pulmonary Fibrosis
Interventions: Drug: lebrikizumab; Drug: placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified June 2013
Seizure Detection and Warning System for Epilepsy Patients

Condition: Epilepsy
Intervention: Device: Night Watch Seizure Detection Device and Warning System
Sponsors: Brain Sentinel; Brain Sentinel
Not yet recruiting - verified June 2013
Nepafenac Once Daily for Macular Edema - Study 2

Conditions: Non-Proliferative Diabetic Retinopathy; Cataract
Interventions: Drug: Nepafenac Ophthalmic Suspension, 0.3%; Other: Nepafenac Vehicle; Drug: Prednisolone acetate ophthalmic suspension
Sponsors: Alcon Research; Alcon Research
Not yet recruiting - verified June 2013
A Study of LY3023703 Testing Pain Relief After Wisdom Teeth Removal

Condition: Acute Pain
Interventions: Drug: Placebo; Drug: LY3023703; Drug: Celecoxib
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified June 2013
Impact of Monthly High Dose Oral Cholecalciferol on Serum 25 Hydroxy Vitamin D Levels in Bariatric Surgery Subjects

Condition: Bariatric Surgery
Intervention:
Sponsors: Texas Tech University; Texas Tech University
Recruiting - verified February 2012
Lid Wiper Epitheliopathy Trial

Condition: Lid Wiper Epitheliopathy
Interventions: Device: Spectacles; Device: Delefilcon A contact lenses; Device: Etafilcon A contact lenses
Sponsors: Alcon Research; Alcon Research
Not yet recruiting - verified June 2013
A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -304)

Condition: Plaque Psoriasis
Interventions: Drug: 000-0551 Lotion; Drug: Vehicle Lotion
Sponsors: Therapeutics, Inc.; Therapeutics, Inc.
Recruiting - verified June 2013
Nutrition Intervention During Chemotherapy

Condition: Cancer Patients Receiving Platinum-based Chemotherapy
Intervention: Dietary Supplement: Daily intake for 12 weeks
Sponsors: Texas A&M University; Texas A&M University
Recruiting - verified June 2013
Miravirsen in Combination With Telaprevir and Ribavirin in Null Responder to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C Virus Infection

Condition: Hepatitis C, Chronic
Interventions: Drug: Miravirsen; Drug: Telaprevir; Drug: Ribavirin
Sponsors: Santaris Pharma A/S; Santaris Pharma A/S
Not yet recruiting - verified June 2013
Study of Ixekizumab in Participants With Active Ankylosing Spondylitis (AS)

Condition: Spondylitis, Ankylosing
Interventions: Drug: Ixekizumab; Drug: Placebo; Drug: Adalimumab
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Not yet recruiting - verified June 2013
Phenotypic Properties in Individuals Affected With XLHED

Condition: X Linked Hypohidrotic Ectodermal Dysplasia
Intervention:
Sponsors: Edimer Pharmaceuticals; Edimer Pharmaceuticals
Recruiting - verified June 2013
Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder

Condition: Overactive Bladder
Interventions: Drug: dexmecamylamine; Drug: Placebo
Sponsors: Targacept Inc.; Targacept Inc.
Recruiting - verified June 2013
Validity and Reliability of Diagnostic Findings of SI Joint Blocking

Condition: SI Joint Pain
Interventions: Drug: 2% lidocaine, saline; Drug: 2% lidocaine, saline; Drug: 2% lidocaine, saline
Sponsors: SI-BONE, Inc.; SI-BONE, Inc.
Not yet recruiting - verified June 2013
Phase I, Open Label,Crossover Food-Effect and Absolute Bioavailability Study of WCK2349 and WCK771 in Healthy Adult Human Volunteers

Condition: Effect of Food
Interventions: Drug: Oral WCK2349; Drug: IV WCK771
Sponsors: Wockhardt; Wockhardt
Not yet recruiting - verified June 2013
Glutathione and Fuel Oxidation in Aging

Conditions: Glutathione Deficiency; Elderly; Impaired Mitochondrial Fatty-acid Oxidation
Intervention: Dietary Supplement: Glycine, cysteine, alanine
Sponsors: Baylor College of Medicine; Rajagopal V Sekhar; National Institute on Aging (NIA)
Recruiting - verified June 2013
Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension

Condition: Open-angle Glaucoma or Ocular Hypertension
Interventions: Drug: DE-117 ophthalmic solution; Drug: latanoprost ophthalmic solution; Other: Placebo
Sponsors: Santen Inc.; Santen Inc.
Recruiting - verified June 2013
Salvage Ovarian FANG Vaccine + Carboplatinum

Conditions: Stage III Ovarian Cancer; Stage IV Ovarian Cancer
Interventions: Biological: Vaccine: FANG™ Vaccine; Drug: Carboplatinum
Sponsors: Gradalis, Inc.; Gradalis, Inc.
Not yet recruiting - verified May 2013
Validation of Lower Body Negative Pressure (LBNP) Model of Human Hemorrhage in Trauma Patients

Condition: Physical Trauma
Intervention:
Sponsors: University of Colorado, Denver; University of Colorado, Denver; Department of Defense
Not yet recruiting - verified June 2013
A Study of Multiple Doses of LY2922470 in Participants With Diabetes

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: LY2922470
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Not yet recruiting - verified June 2013
A Study of Tadalafil for Duchenne Muscular Dystrophy

Condition: Muscular Dystrophy, Duchenne
Interventions: Drug: Tadalafil; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Not yet recruiting - verified June 2013
IMPACT: Inactivity Monitoring and Physical Activity Controlled Trial

Conditions: Obesity; Cardiovascular Disease; Cancer; Diabetes; Sarcopenia
Intervention: Behavioral: Monitor intervention
Sponsors: The University of Texas, Galveston; The University of Texas, Galveston
Not yet recruiting - verified May 2013
Study Comparing the Pharmacokinetics of FTD as a Component of TAS-102 With FTD Alone

Condition: Advanced Solid Tumors
Interventions: Drug: TAS-102; Drug: Trifluridine
Sponsors: Taiho Pharma USA, Inc.; Taiho Pharma USA, Inc.
Recruiting - verified June 2013
A Study to Evaluate the Pharmacokinetics of JNJ-38518168 in Patients With Mild and Moderate Hepatic Impairment Compared With Patients With Normal Hepatic Function

Condition: Hepatic Impairment
Intervention: Drug: JNJ-38518168
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified June 2013
Phase 1 TheraSphere + Everolimus With Neuroendocrine Tumors (NETs) + Liver Only or Liver Dominant Disease

Condition: Liver Cancer
Interventions: Other: TheraSphere; Drug: Everolimus; Other: Phone Call
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Nordion (Canada) Inc.; Novartis Pharmaceuticals
Not yet recruiting - verified May 2013
Efficacy, Safety and Dose-Response Study of Lofexidine in the Treatment of Opioid Withdrawal Followed by Open-Label Lofexidine Treatment

Conditions: Opioid Dependence; Acute Opioid Withdrawal Syndrome
Interventions: Drug: Lofexidine HCl; Drug: Lofexidine-matching sugar pill
Sponsors: US WorldMeds LLC; US WorldMeds LLC; National Institute on Drug Abuse (NIDA)
Recruiting - verified June 2013
An Ocular Safety Study of Ivacaftor-Treated Pediatric Patients 11 Years of Age or Younger With Cystic Fibrosis

Condition: Cystic Fibrosis
Interventions: Other: Ophthalmologic examinations; Drug: Ivacaftor Exposed
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated; Cystic Fibrosis Foundation
Recruiting - verified June 2013
A Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Drug: GDC-0032; Drug: GDC-0032; Drug: Docetaxel; Drug: Paclitaxel
Sponsors: Genentech; Genentech
Recruiting - verified May 2013
Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-110 in Subjects With Rheumatoid Arthritis

Condition: Rheumatoid Arthritis
Interventions: Biological: AMP-110; Other: Placebo
Sponsors: Amplimmune; Amplimmune; Daiichi Sankyo Co., Ltd.
Recruiting - verified June 2013
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML

Conditions: Lymphoblastic Leukemia, Acute, Childhood; Myelogenous Leukemia, Acute, Childhood
Interventions: Drug: Azacitidine; Drug: Fludarabine; Drug: Cytarabine
Sponsors: Therapeutic Advances in Childhood Leukemia Consortium; Therapeutic Advances in Childhood Leukemia Consortium; Gateway for Cancer Research; USC/Norris Comprehensive Cancer Center
Not yet recruiting - verified May 2013
Effect of Empagliflozin Kinetics on Renal Glucose Reabsorption in Patients With Type II Diabetes and Healthy Controls

Conditions: Diabetes Mellitus, Type 2; Healthy
Interventions: Drug: Empagliflozin; Drug: BI 10773
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Not yet recruiting - verified June 2013
Study of Dupilumab (REGN668/ SAR231893) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

Condition: Atopic Dermatitis
Interventions: Drug: Dupilumab (REGN668/ SAR231893); Drug: Placebo
Sponsors: Regeneron Pharmaceuticals; Regeneron Pharmaceuticals; Sanofi
Recruiting - verified May 2013
Safety and Effectiveness of the CustomFlex Artificial Iris Prosthesis for the Treatment of Iris Defects

Conditions: Full Iris Defects; Partial Iris Defects
Intervention: Device: Artificial Iris (CustomFlex)
Sponsors: HumanOptics AG; HumanOptics AG
Not yet recruiting - verified June 2013
Effects of Lumbopelvic Manipulation on Neuromuscular Activity of Back and Hip Muscles in Adults With Chronic Low Back Pain

Condition: Chronic Low Back Pain
Intervention: Other: Lumbopelvic Manipulation
Sponsors: Texas Woman's University; Texas Woman's University
Recruiting - verified May 2013
Mechanisms of Increased Ambulatory Blood Pressure in Patients With Intradialytic Hypertension

Condition: Intradialytic Hypertension
Intervention: Drug: Carvedilol vs. Prazosin
Sponsors: University of Texas Southwestern Medical Center; University of Texas Southwestern Medical Center; American Heart Association
Recruiting - verified May 2013
Neuroimaging of Diet in ADHD: Phase I

Condition: Attention Deficit Disorder With Hyperactivity
Interventions: Dietary Supplement: Restricted Diet; Dietary Supplement: Ruse Diet
Sponsors: The University of Texas Health Science Center at San Antonio; The University of Texas Health Science Center at San Antonio
Recruiting - verified May 2013
Effects of an Antioxidant-Enriched Multivitamin Supplement on Inflammation and Oxidative Stress in Cystic Fibrosis

Condition: Cystic Fibrosis
Interventions: Drug: AquADEKs-2; Dietary Supplement: vitamins A, B, D, E, and K without added antioxidants
Sponsors: University of Colorado, Denver; University of Colorado, Denver; Cystic Fibrosis Foundation; Yasoo Health
Not yet recruiting - verified May 2013
Phase I Study of Subcutaneous Ocaratuzumab in Patients With Previously Treated CD20+ B-Cell Malignancies

Condition: Previously Treated CD20+ B-cell Malignancies
Intervention: Biological: ocaratuzumab
Sponsors: Mentrik Biotech, LLC; Mentrik Biotech, LLC
Not yet recruiting - verified May 2013
A Multi-Center Study To Evaluate Multiple Doses of NT100 Following IVF In Women With Repeated IVF Failures (Thrive-IVF)

Condition: Repeated IVF Failure
Interventions: Drug: NT100; Drug: Placebo
Sponsors: Nora Therapeutics, Inc.; Nora Therapeutics, Inc.
Recruiting - verified May 2013
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 1)

Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: GFF MDI; Drug: GP MDI; Drug: FF MDI; Drug: Open-label tiotropium bromide inhalation powder; Drug: Placebo MDI
Sponsors: Pearl Therapeutics, Inc.; Pearl Therapeutics, Inc.
Recruiting - verified June 2013
P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies

Conditions: Acute Myelogenous Leukemia; Acute Lymphoblastic Leukemia; Non-Hodgkin's Lymphoma; Hodgkin's Disease
Interventions: Biological: Infusion of one MPC expanded cord unit and one unexpanded cord unit; Biological: Infusion of two unexpanded cord blood units.
Sponsors: Mesoblast, Ltd.; Mesoblast, Ltd.
Recruiting - verified June 2013
Glioblastoma Multiforme (GBM) Proton vs. IMRT

Condition: Brain Cancer
Interventions: Radiation: IMPT; Radiation: IMRT; Behavioral: Cognitive Tests; Behavioral: Questionnaires
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013
An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma

Condition: Asthma
Interventions: Drug: dupilumab SAR231893 (REGN668); Drug: placebo
Sponsors: Sanofi; Sanofi; Regeneron Pharmaceuticals
Recruiting - verified June 2013
Phase 2 Study of SOF+GS-5816 in Treatment Naive Subjects With Chronic HCV

Condition: Hepatitis C
Intervention: Drug: SOF in combination with GS-5816
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified June 2013
Study To Evaluate D-Ribose For The Treatment of Congestive Heart Failure

Condition: Congestive Heart Failure
Interventions: Drug: D-ribose; Other: Placebo
Sponsors: RiboCor, Inc.; RiboCor, Inc.
Not yet recruiting - verified May 2013
Phase 4 GI Tolerability Study of DMF in Patients With Relapsing Forms of MS in the US

Condition: Relapsing Forms of Multiple Sclerosis
Interventions: Drug: Dimethyl fumarate (DMF); Drug: Dimethyl fumarate (DMF)
Sponsors: Biogen Idec; Biogen Idec
Recruiting - verified June 2013
Mexiletine in Sporadic Amyotrophic Lateral Sclerosis (SALS)

Condition: Sporadic Amyotrophic Lateral Sclerosis
Interventions: Drug: Mexiletine; Drug: Placebo
Sponsors: University of Washington; University of Washington
Not yet recruiting - verified May 2013
Safety and Efficacy of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3)

Condition: Chronic Hepatitis C Virus
Interventions: Drug: Sofosbuvir/Ledipasvir 400/90 mg; Drug: Ribavirin
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013
Progel® Pleural Air Leak Sealant (PALS) in Video and Robotic Assisted Thoracoscopic Surgery

Condition: Pulmonary Disease
Intervention: Device: Progel® Pleural Air Leak Sealant
Sponsors: Neomend, Inc.; Neomend, Inc.
Recruiting - verified June 2013
A Synovial Biopsy Study of JNJ-38518168 in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy

Condition: Rheumatoid Arthritis
Interventions: Drug: JNJ-38518168; Drug: Placebo; Drug: Placebo / JNJ-38518168
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified June 2013
Teprotumumab Treatment in Patients With Active Thyroid Eye Disease

Conditions: Thyroid Associated Ophthalmopathies; Thyroid-Associated Ophthalmopathy
Interventions: Drug: teprotumumab; Drug: Placebo
Sponsors: River Vision Development Corporation; River Vision Development Corporation
Recruiting - verified June 2013
A Study Of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Condition: Non-Small Cell Lung Cancer
Intervention: Drug: MPDL3280A
Sponsors: Genentech; Genentech
Recruiting - verified May 2013
Relative Bioavailability of 2 Fixed Dose Combinations of Linagliptin/Metformin Compared With Single Tablets

Condition: Healthy
Interventions: Drug: 2x500 mg Metformin (Glumetza); Drug: 5 mg Linagliptin/1000 mg Metformin FDC; Drug: 5 mg Linagliptin (Tradjenta); Drug: 5 mg Linagliptin (Tradjenta); Drug: 3x500 mg Metformin (Glumetza); Drug: 5 mg Linagliptin (Tradjenta); Drug: 2 x 500 mg Metformin (Glumetza); Drug: 5 mg Linagliptin/1000mg Metformin FDC; Drug: 2 x 2.5 mg Linagliptin/750 mg Metformin FDC
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified June 2013
CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Subjects With Type 1 Diabetes (T1DM)

Condition: Type 1 Diabetes Mellitus
Interventions: Drug: Commercial Hylenex® recombinant (hyaluronidase human injection); Drug: Pre-commercial formulation of Hylenex recombinant (hyaluronidase human injection); Procedure: Preadministration of commercial Hylenex® recombinant (hyaluronidase human injection); Procedure: Preadministration of pre-commercial Hylenex recombinant (hyaluronidase human injection); Device: Continuous Subcutaneous Insulin Infusion (CSII) via insulin infusion pumps
Sponsors: Halozyme Therapeutics; Halozyme Therapeutics
Recruiting - verified June 2013
Safety, Efficacy and Tolerability of Vilazodone in (GAD) Generalized Anxiety Disorder

Condition: Generalized Anxiety Disorder
Interventions: Drug: Placebo; Drug: Vilazodone
Sponsors: Forest Laboratories; Forest Laboratories
Recruiting - verified May 2013
Study to Evaluate Safety & Efficacy of WC3011 in Postmenopausal Women With Dyspareunia

Condition: Vulvovaginal Atrophy
Interventions: Drug: Estradiol Vaginal Gel; Drug: Vehicle
Sponsors: Warner Chilcott; Warner Chilcott
Recruiting - verified June 2013
PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Untreated Pancreatic Cancer

Condition: Metastatic Pancreatic Cancer
Interventions: Drug: PEGPH20+nab-paclitaxel+gemcitabine; Drug: nab-paclitaxel + gemcitabine
Sponsors: Halozyme Therapeutics; Halozyme Therapeutics
Recruiting - verified June 2013
Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma

Condition: Unresectable Pleural or Peritoneal Malignant Mesothelioma
Interventions: Drug: Tremelimumab; Drug: Placebo
Sponsors: MedImmune LLC; MedImmune LLC
Recruiting - verified May 2013
Evaluation of Safety and Efficacy of TriPollar Device for Treatment of Wrinkles

Condition: Facial Wrinkles
Intervention: Device: TriPollar
Sponsors: Pollogen; Pollogen
Recruiting - verified May 2013
Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

Condition: Multiple Myeloma
Intervention:
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; AbbVie
Recruiting - verified June 2013
Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa

Condition: Hidradenitis Suppurativa
Interventions: Biological: MEDI8968; Biological: Saline
Sponsors: AstraZeneca; AstraZeneca; ICON plc; Covance; PHT Corporation
Recruiting - verified June 2013
Randomized Endo-Vein Graft Prospective

Condition: Coronary Artery Bypass Grafting
Intervention: Procedure: Vein Harvesting Procedures
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Not yet recruiting - verified June 2013
Pilot Study to Evaluate the Safety and Biological Effects of Orally Administered Reparixin in Early Breast Cancer Patients

Condition: Breast Cancer
Intervention: Drug: Reparixin
Sponsors: Dompé s.p.a.; Dompé s.p.a.
Recruiting - verified May 2013
Effect of SAR302503 on ECG Activity in Patients With Solid Tumors

Condition: Neoplasm Malignant
Interventions: Drug: SAR302503 (TG101348); Drug: Placebo SAR302503; Drug: Panolosetron
Sponsors: Sanofi; Sanofi
Recruiting - verified June 2013
Study of Oasis Ultra in Diabetic Foot Ulcers

Condition: Diabetic Foot Ulcer
Interventions: Device: Oasis; Other: Standard
Sponsors: Healthpoint; Healthpoint
Recruiting - verified June 2013
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD

Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: QVA149; Drug: fluticasone/salmeterol
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified June 2013
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD

Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: QVA149; Drug: fluticasone/salmeterol
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified June 2013
Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients

Condition: Acute Myeloid Leukemia
Intervention: Drug: BL-8040 +Ara-C
Sponsors: BioLineRx, Ltd.; BioLineRx, Ltd.
Recruiting - verified April 2013
Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma

Condition: Sarcoma
Intervention: Drug: Ra-223 Dichloride
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Bayer
Not yet recruiting - verified June 2013
Effects of USP Methylene Blue on Cognitive and fMRI Brain Activity

Condition: Brain Activity
Interventions: Drug: Methylene Blue (USP grade, 280mg oral); Drug: Placebo
Sponsors: The University of Texas Health Science Center at San Antonio; Timothy Q. Duong
Not yet recruiting - verified April 2013
Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib

Condition: Tumor Pathway Activations Inhibited by Dovitinib
Intervention: Drug: Dovitinib (TKI258)
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2013
68-Ga-DOTATATE PET-CT Scan for Diagnosis and Staging of Neuroendocrine Tumors

Condition: Neuroendocrine Carcinoma
Intervention: Drug: 68Ga-DOTATATE PET scan
Sponsors: Radio Isotope Therapy of America; Radio Isotope Therapy of America; RadioMedix; Excel Diagnostics and Nuclear Oncology Center
Recruiting - verified June 2013
A Phase 2/3 Open-label Extension Study to Evaluate Long-Term Safety and Efficacy With VX-509 in Subjects With Rheumatoid Arthritis

Condition: Rheumatoid Arthritis
Intervention: Drug: VX-509
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated
Recruiting - verified May 2013
Fentanyl Pectin Nasal Spray (FNPS) for Exercise-Induced Breakthrough Dyspnea

Condition: Advanced Cancers
Interventions: Drug: Fentanyl Pectin Nasal Spray; Drug: Placebo Nasal Spray; Other: Walk Test; Behavioral: Questionnaires; Behavioral: Mental Ability Tests
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Archimedes Development Ltd
Recruiting - verified June 2013
A Phase I Study of MRX34 Given Intravenously in Patients With Unresectable Primary Liver Cancer or Metastatic Cancer With Liver Involvement

Conditions: Primary Liver Cancer; Solid Tumors; Lymphoma
Intervention: Drug: MRX34
Sponsors: Mirna Therapeutics, Inc.; Mirna Therapeutics, Inc.; Cancer Prevention Research Institute of Texas (CPRiT)
Recruiting - verified May 2013
An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

Condition: Relapsed or Refractory Mantle Cell Lymphoma
Intervention: Drug: Ibrutinib
Sponsors: Janssen Biotech, Inc.; Janssen Biotech, Inc.; Pharmacyclics
Recruiting - verified June 2013
Birinapant With 5-azacitidine in MDS Subjects Who Relapsed or Are Refractory to 5-azacitidine Therapy

Condition: Myelodysplastic Syndrome
Interventions: Drug: TL32711; Drug: 5-Azacitidine
Sponsors: TetraLogic Pharmaceuticals; TetraLogic Pharmaceuticals
Not yet recruiting - verified April 2013
Phase II Trial to Assess Safety and Immunogenicity of IMVAMUNE®

Condition: Smallpox
Intervention: Biological: IMVAMUNE®
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified April 2013
Pharmacokinetics Study of Oral MLN9708 Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients

Condition: Multiple Myeloma
Interventions: Drug: MLN9708; Drug: dexamethasone
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified June 2013
A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years

Condition: Meningococcal Vaccine
Interventions: Biological: rLP2086; Biological: rLP2086; Biological: rLP2086; Biological: Havrix (HAV); Biological: Saline
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
A Multi-center, Randomized Study in Subjects With Primary Hypercholesterolemia or Mixed Dyslipidemia

Condition: Primary Hypercholesterolemia or Mixed Dyslipidemia
Intervention: Device: AMG 145
Sponsors: Amgen; Amgen
Not yet recruiting - verified June 2013
A Study of Tadalafil in Pediatric Participants With Pulmonary Arterial Hypertension (PAH)

Condition: Hypertension, Pulmonary
Interventions: Drug: Tadalafil; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Not yet recruiting - verified June 2013
Tofacitinib Ointment For Chronic Plaque Psoriasis

Conditions: Psoriasis Vulgaris; Psoriasis
Interventions: Drug: tofacitinib ointment 20 mg/g; Drug: tofacitinib ointment 10 mg/g; Drug: placebo ointment (vehicle); Drug: tofacitinib ointment 20 mg/g; Drug: tofacitinib ointment 10 mg/g; Drug: placebo ointment (vehicle)
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
A Study of JNJ-38518168 in Symptomatic Adult Participants With Uncontrolled, Persistent Asthma

Condition: Asthma
Interventions: Drug: Placebo; Drug: JNJ-38518168
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Not yet recruiting - verified June 2013
Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose

Condition: Meningococcal Disease
Intervention: Biological: MenACWY
Sponsors: Novartis; Novartis Vaccines
Recruiting - verified May 2013
A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma

Condition: Persistent or Recurrent Cutaneous T-Cell Lymphoma
Intervention: Drug: E7777
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified June 2013
Natural Killer (NK) Cells With HLA Compatible Hematopoietic Transplantation for High Risk Myeloid Malignancies

Condition: Leukemia
Interventions: Drug: Busulfan; Drug: Fludarabine; Procedure: Alloreactive NK infusion; Drug: Interleukin-2; Drug: Thymoglobulin; Procedure: Stem Cell Infusion; Drug: G-CSF; Drug: Tacrolimus; Drug: Methotrexate
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; CPRIT Grant; CML Program Project Grant
Recruiting - verified June 2013
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy

Conditions: Muscular Dystrophy, Duchenne; Muscular Dystrophies; Muscular Disorders, Atrophic; Muscular Diseases; Musculoskeletal Diseases; Neuromuscular Diseases; Nervous System Diseases; Genetic Diseases, X-Linked; Genetic Diseases, Inborn
Interventions: Drug: Ataluren; Drug: Placebo
Sponsors: PTC Therapeutics; PTC Therapeutics
Recruiting - verified April 2013
Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients With Pancreatic Cancer

Conditions: Acinar Cell Adenocarcinoma of the Pancreas; Duct Cell Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage II Pancreatic Cancer; Stage III Pancreatic Cancer
Interventions: Drug: oxaliplatin; Drug: irinotecan hydrochloride; Drug: leucovorin calcium; Drug: 5-fluorouracil; Drug: capecitabine; Radiation: radiation; Procedure: surgery; Drug: gemcitabine hydrochloride
Sponsors: Alliance for Clinical Oncology Trials; Alliance for Clinical Oncology Trials; National Cancer Institute (NCI)
Recruiting - verified April 2013
A Study of LY2605541 in Healthy Participants and in the Elderly

Condition: Healthy Volunteers
Intervention: Drug: LY2605541
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified June 2013
Mild Cognitive Impairment (MCI) in Patients With Atrial Fibrillation (AF), Trajectories of the Progression of MCI and Factors Associated With the Progression

Conditions: Atrial Fibrillation; Mild Cognitive Impairment; Dementia
Intervention:
Sponsors: Texas Cardiac Arrhythmia Research Foundation; Texas Cardiac Arrhythmia Research Foundation
Not yet recruiting - verified May 2013
A Study Exploring Two Strategies of Rivaroxaban and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention

Conditions: Atrial Fibrillation; Percutaneous Coronary Intervention
Interventions: Drug: rivaroxaban 2.5 mg; Drug: rivaroxaban 15 mg; Drug: rivaroxaban 10 mg; Drug: aspirin (ASA); Drug: vitamin K antagonist (VKA); Drug: clopidogrel; Drug: prasugrel; Drug: ticagrelor
Sponsors: Janssen Scientific Affairs, LLC; Janssen Scientific Affairs, LLC; Bayer Pharma AG
Recruiting - verified May 2013
Open-Label Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Combination Single Tablet Regimen (STR) in Virologically-Suppressed, HIV-1 Positive Subjects

Conditions: HIV; HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide; Drug: E/C/F/TDF, EFV/FTC/TDF, ritonavir + atazanavir + FTC/TDF, or GS-9350 + atazanavir + FTC/TDF
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013
A Study in Men With Low Testosterone to Measure the Effects of Testosterone Solution on Testosterone Levels, Sex Drive and Energy

Condition: Hypogonadism
Interventions: Drug: Testosterone Solution; Drug: Placebo Solution
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified June 2013
An Open-Label Phase 3 Study of BMN 165 for Adults With PKU Not Previously Treated w/ BMN 165

Condition: Phenylketonuria
Intervention: Drug: BMN 165
Sponsors: BioMarin Pharmaceutical; BioMarin Pharmaceutical
Recruiting - verified June 2013
GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound

Condition: Hypercholesterolemia
Interventions: Drug: AMG 145; Other: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified June 2013
Patient Centered Outcomes in Rosacea: An Exploratory Multi-media Analysis of the Patient Experience on Oracea

Condition: Papulopustular Rosacea
Intervention: Drug: Oracea
Sponsors: Galderma Laboratories, L.P.; Galderma Laboratories, L.P.
Recruiting - verified June 2013
A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer

Conditions: Neoplasms; Neoplasms, Ovarian; Neoplasms, Breast
Interventions: Drug: DOXIL/CAELYX (doxorubicin) Treatment Sequence AB; Drug: DOXIL/CAELYX (doxorubicin) Treatment Sequence BA
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified June 2013
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: TAK-700; Drug: Bicalutamide
Sponsors: Southwest Oncology Group; Southwest Oncology Group; Millennium Pharmaceuticals, Inc.; National Cancer Institute (NCI)
Recruiting - verified June 2013
Comparison Study of ISV-303 to Durasite Vehicle in Cataract Surgery Subjects

Condition: Cataract
Interventions: Drug: ISV-303; Other: DuraSite Vehicle
Sponsors: InSite Vision; InSite Vision
Recruiting - verified March 2013
Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis

Condition: Myeloma
Interventions: Drug: Pomalidomide; Drug: Melphalan; Drug: Dexamethasone; Behavioral: Questionnaires
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Celgene Corporation; Tufts Medical Center
Not yet recruiting - verified May 2013
A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation (TRANSPORT)

Condition: Cystic Fibrosis, Homozygous for the F508del CFTR Mutation
Interventions: Drug: Ivacaftor; Drug: Lumacaftor; Drug: Ivacaftor Placebo; Drug: Lumacaftor Placebo
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated
Recruiting - verified June 2013
A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation (TRAFFIC)

Condition: Cystic Fibrosis, Homozygous for the F508del CFTR Mutation
Interventions: Drug: Ivacaftor; Drug: Lumacaftor; Drug: Ivacaftor Placebo; Drug: Lumacaftor Placebo
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated
Recruiting - verified June 2013
A Long-term Extension Study of PCI-32765 (Ibrutinib)

Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Mantle Cell Lymphoma; Follicular Lymphoma; Diffuse Large B-cell Lymphoma
Intervention: Drug: PCI-32765 (Ibrutinib)
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC; Pharmacyclics
Not yet recruiting - verified June 2013
Safety and Blood Immune Cell Study of Anakinra Plus Physician's Chemotherapy Choice in Metastatic Breast Cancer Patients

Condition: Metastatic Breast Cancer
Intervention: Drug: Anakinra plus Standard of Care
Sponsors: Baylor Research Institute; Baylor Research Institute
Recruiting - verified June 2013
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection

Condition: Chronic Hepatitis C Infection
Interventions: Drug: ABT-450/r/ABT-267; Drug: ABT-333; Drug: Ribavirin; Drug: Placebo for Ribavirin
Sponsors: AbbVie; AbbVie
Recruiting - verified May 2013
Inhaled Amikacin Solution BAY41-6551 as Adjunctive Therapy in the Treatment of Gram-Negative Pneumonia

Condition: Pneumonia, Bacterial
Interventions: Drug: Amikacin Inhalation Solution (BAY41-6551); Drug: Aerosolized Placebo
Sponsors: Bayer; Bayer; Nektar Therapeutics
Recruiting - verified May 2013
Edoxaban in Peripheral Arterial Disease

Condition: Peripheral Arterial Disease
Interventions: Drug: edoxaban; Drug: Clopidogrel; Drug: Aspirin
Sponsors: Daiichi Sankyo Inc.; Daiichi Sankyo Inc.; UMC Utrecht
Recruiting - verified June 2013
First Time Use of SD-809 in Huntington Disease

Condition: Chorea
Interventions: Drug: SD-809; Drug: Placebo
Sponsors: Auspex Pharmaceuticals, Inc.; Auspex Pharmaceuticals, Inc.
Recruiting - verified June 2013
A Clinical Evaluation Of The Safety Of Baclofen Er Capsules (Grs) When Administered Once Daily To Subjects With Spasticity Due To Multiple Sclerosis (Ms): An Open Label, Long Term, Safety Trial

Condition: Spasticity
Intervention: Drug: Baclofen
Sponsors: Sun Pharma Advanced Research Company Limited; Sun Pharma Advanced Research Company Limited
Recruiting - verified April 2013
A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes

Conditions: Type 2 Diabetes; Comparative Effectiveness of Glycemia-lowering Medications
Interventions: Drug: Sulfonylurea (glimepiride); Drug: DPP-4 inhibitor (sitagliptin); Drug: GLP-1 receptor agonist (liraglutide); Drug: Insulin (glargine)
Sponsors: GRADE Study Group; GRADE Study Group; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Becton, Dickinson and Company; Bristol-Myers Squibb; Merck; Novo Nordisk; Hoffmann-La Roche; Sanofi
Recruiting - verified May 2013
A Phase 2 of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies

Conditions: Chronic Lymphocytic Leukemia; Mantle Cell Lymphoma; Diffuse Large B-cell Lymphoma; Indolent Non-Hodgkin's Lymphoma
Intervention: Drug: GS-9973
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified June 2013
A Study of RoActemra/Actemra (Tocilizumab) in Patients With Giant Cell Arteritis

Condition: Giant Cell Arteritis
Interventions: Drug: tocilizumab [RoActemra/Actemra]; Drug: tocilizumab [RoActemra/Actemra]; Drug: tocilizumab placebo; Drug: prednisone; Drug: prednisone placebo; Drug: tocilizumab [RoActemra/Actemra]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified June 2013
Tyvaso Dosing and Titration Evaluation: TyTRATE Registry

Condition: Pulmonary Arterial Hypertension
Intervention:
Sponsors: United Therapeutics; United Therapeutics
Recruiting - verified June 2013
Switching Undetectables to Selzentry

Conditions: Human Immunodeficiency Virus; AIDS
Intervention: Drug: Maraviroc
Sponsors: St. Hope Foundation; St. Hope Foundation; GlaxoSmithKline
Recruiting - verified May 2013
Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets for Moderate to Severe Chronic Low Back Pain

Condition: Low Back Pain
Interventions: Drug: Hydrocodone bitartrate extended-release tablets; Drug: Matching placebo
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Recruiting - verified May 2013
Open-Label Long-Term Safety and Efficacy Study of Fixed Dose Combination of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Subjects With Moderate to Severe Essential Hypertension

Condition: Hypertension
Interventions: Drug: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106); Drug: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106); Drug: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106); Drug: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)
Sponsors: Bayer; Bayer
Recruiting - verified May 2013
20120230: Assess the Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease on Hemodialysis

Condition: Hyperparathyroidism, Secondary
Interventions: Drug: AMG 416; Drug: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified June 2013
Study of Meloxicam Capsules to Treat Osteoarthritis Pain

Condition: Osteoarthritis
Interventions: Drug: Meloxicam Test Capsules; Drug: Meloxicam Test Capsules; Drug: Placebo Capsules
Sponsors: Iroko Pharmaceuticals, LLC; Iroko Pharmaceuticals, LLC
Recruiting - verified June 2013
Evaluation of RUX and AZA Combination as a Therapy For Patients With Myelofibrosis And Myelodysplastic Syndrome/ Myeloproliferative Neoplasm

Condition: Leukemia
Interventions: Drug: Ruxolitinib (RUX); Drug: Azacitidine (AZA); Behavioral: Questionnaires
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013
IL-21-Expanded NK Cells for Induction of Acute Myeloid Leukemia (AML)

Condition: Leukemia
Interventions: Drug: G-CSF; Drug: Fludarabine monophosphate; Drug: Cytarabine; Procedure: Natural Killer (NK) Cell Infusion
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Not yet recruiting - verified June 2013
20120229: Assess the Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease on Hemodialysis

Condition: Hyperparathyroidism, Secondary
Interventions: Drug: AMG 416; Drug: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified June 2013
Finite Androgen Ablation vs. Finite Androgen Ablation in Combination With Abiraterone Acetate and Prednisone

Condition: Prostate Cancer
Interventions: Drug: Lupron; Drug: Zoladex; Drug: Degarelix; Drug: Abiraterone Acetate; Drug: Prednisone
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Janssen Services, LLC
Recruiting - verified May 2013
A Safety Study of SGN-CD19A for B-Cell Lymphoma

Conditions: Burkitt Lymphoma; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Precursor B-cell Lymphoblastic Leukemia-Lymphoma
Intervention: Drug: SGN-CD19A
Sponsors: Seattle Genetics, Inc.; Seattle Genetics, Inc.
Recruiting - verified May 2013
Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

Condition: Hypertension, Pulmonary
Intervention: Drug: Riociguat (BAY 63-2521)
Sponsors: Bayer; Bayer
Available - verified May 2013
A Twelve Week Safety and Efficacy Study in Rosacea

Condition: Papulopustular Rosacea
Interventions: Drug: omiganan; Drug: placebo
Sponsors: Cutanea Life Sciences, Inc.; Cutanea Life Sciences, Inc.
Recruiting - verified June 2013
Study of an Investigational Nasal Aerosol or Placebo in Children (Ages 4 to 11) With Perennial Allergic Rhinitis (PAR)

Condition: Allergic Rhinitis
Interventions: Drug: BDP Nasal Aerosol; Drug: Placebo
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Recruiting - verified May 2013
Safety and Tolerability Study of GlaxoSmithKline (GSK)1557484A Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure

Condition: Pandemic Avian (H5N1) Influenza
Intervention: Biological: GSK1557484A vaccine
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
An Evaluation of Rigid Sternal Fixation in Supporting Bone Healing and Improving Postoperative Recovery

Conditions: Coronary Artery Disease; Angina Pectoris; Cardiac Valve Disease
Interventions: Device: SternaLock Blue closure system; Device: Suture Wire
Sponsors: Biomet, Inc.; Biomet, Inc.
Recruiting - verified June 2013
Trial to Evaluate The Efficacy Of Rotigotine on Parkinson's Disease-Associated Motor Symptoms And Apathy

Condition: Idiopathic Parkinson's Disease
Interventions: Drug: Rotigotine; Other: Placebo
Sponsors: UCB, Inc.; UCB BIOSCIENCES GmbH
Recruiting - verified May 2013
A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma

Condition: Mantle Cell Lymphoma
Interventions: Drug: Bendamustine; Drug: Rituximab; Drug: Ibrutinib; Drug: Placebo
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC; Pharmacyclics
Recruiting - verified June 2013
Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: BI 10773; Drug: BI 10773 Placebo; Drug: BI 10773 / BI 1356; Drug: BI 10773; Drug: BI 10773 / BI 1356; Drug: BI 10773; Drug: BI 10773; Drug: BI 10773 / BI 1356 Placebo; Drug: BI 10773 / BI 1356 Placebo; Drug: BI 10773; Drug: BI 10773 / BI 1356 Placebo; Drug: BI 10773 Placebo; Drug: BI 10773; Drug: BI 10773 / BI 1356 Placebo
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified June 2013
A Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Cardiac Surgery

Condition: Acute Kidney Injury
Interventions: Drug: ABT-719; Drug: Placebo
Sponsors: AbbVie; AbbVie
Recruiting - verified May 2013
ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas

Conditions: Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell
Interventions: Drug: cyclophosphamide; Drug: doxorubicin; Drug: vincristine; Drug: prednisone; Drug: brentuximab vedotin
Sponsors: Seattle Genetics, Inc.; Seattle Genetics, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified June 2013
Efficacy and Safety Study of Inhaled CVT 301 in Parkinson's Disease Patients for Treatment of OFF Episodes

Condition: Idiopathic Parkinson's Disease
Interventions: Drug: CVT-301; Drug: Placebo
Sponsors: Civitas Therapeutics; Civitas Therapeutics
Recruiting - verified June 2013
Carfilzomib in Refractory Renal Cell Carcinoma (RCC)

Condition: Kidney Cancer
Intervention: Drug: Carfilzomib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Onyx Therapeutics, Inc.
Not yet recruiting - verified May 2013
Study of Human Regular U-500 Insulin in Adult Participants With Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Intervention: Drug: Human Regular U-500 Insulin
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified June 2013
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma

Condition: Carcinoma, Hepatocellular
Interventions: Drug: Regorafenib (BAY73-4506); Drug: Placebo
Sponsors: Bayer; Bayer
Recruiting - verified May 2013
Pharmacokinetics, Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age

Condition: Venous Thromboembolism
Intervention: Drug: dabigatran etexilate
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified June 2013
A Study of RO5503781 as Single Agent or in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia

Condition: Myelogenous Leukemia, Acute
Interventions: Drug: RO5503781; Drug: cytarabine
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified June 2013
Dose Ranging Study of the Salmeterol Component of Fluticasone /Salmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma Subjects

Condition: Asthma
Interventions: Drug: FS Spiromax; Drug: Fluticasone propionate Spiromax; Drug: Advair Diskus
Sponsors: Teva Pharmaceutical Industries; Teva Branded Pharmaceutical Products, R&D Inc.
Recruiting - verified May 2013
A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)

Condition: Breast Cancer
Interventions: Drug: trastuzumab emtansine; Drug: trastuzumab
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche; National Surgical Adjuvant Breast and Bowel Project (NSABP); German Breast Group
Recruiting - verified June 2013
Safety, Efficacy and Pharmacokinetics of ALD403

Condition: Migraine
Intervention: Biological: ALD403
Sponsors: Alder Biopharmaceuticals, Inc.; Alder Biopharmaceuticals, Inc.
Recruiting - verified May 2013
A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease

Condition: Crohns Disease
Interventions: Biological: PDA001; Drug: Vehicle Controlled Placebo
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified June 2013
Phase I Study to Evaluate the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients

Condition: Advanced Solid Tumor
Interventions: Drug: LDE225; Drug: Wafarin; Drug: Bupropion
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013
Study Comparing Clindamycin Phosphate and Benzoyl Peroxide Gel to Acanya® Gel and Both to a Vehicle Control in the Treatment of Acne Vulgaris

Condition: Acne Vulgaris
Interventions: Drug: Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%; Drug: Acanya® Gel, 1.2%/2.5%; Drug: Vehicle of test product
Sponsors: Taro Pharmaceuticals USA; Taro Pharmaceuticals USA
Recruiting - verified June 2013
A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung Cancer

Condition: Squamous Non Small Cell Lung Cancer
Interventions: Drug: Necitumumab; Drug: Paclitaxel; Drug: Carboplatin
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified June 2013
Safety and Efficacy of Desensitization Therapy in Sensitized Participants Awaiting Heart Transplantation

Conditions: Transplantation; Organ Transplantation; Heart Transplantation
Interventions: Drug: Bortezomib; Procedure: Plasmapheresis on days 0, 1 and 2.
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); Clinical Trials in Organ Transplantation (CTOT)
Recruiting - verified June 2013
A Phase 2 Study to See if Simtuzumab (GS-6624) is Safe and Works in Idiopathic Pulmonary Fibrosis (IPF)

Condition: Idiopathic Pulmonary Fibrosis
Interventions: Drug: Simtuzumab (GS-6624); Drug: Placebo
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified June 2013
Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients

Condition: Type 2 Diabetes
Interventions: Drug: lixisenatide (AVE0010); Drug: insulin glulisine (HMR1964)
Sponsors: Sanofi; Sanofi
Recruiting - verified June 2013
To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)

Condition: Rheumatoid Arthritis
Interventions: Drug: sarilumab SAR153191 (REGN88); Drug: tocilizumab
Sponsors: Sanofi; Sanofi; Regeneron Pharmaceuticals
Recruiting - verified June 2013
Study Evaluating the Effects of Avanafil on Semen Parameters

Condition: Erectile Dysfunction
Interventions: Drug: avanafil; Drug: Placebo
Sponsors: VIVUS, Inc.; VIVUS, Inc.
Recruiting - verified May 2013
The Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF)

Conditions: Amnestic Mild Cognitive Impairment; Alzheimer's Disease
Interventions: Drug: Insulin (Humulin® R U-100); Drug: Placebo
Sponsors: Alzheimer's Disease Cooperative Study (ADCS); Alzheimer's Disease Cooperative Study (ADCS)
Not yet recruiting - verified June 2013
STEAM: A Study of Sequential and Concurrent FOLFOXIRI/Avastin (Bevacizumab) Regimens Versus FOLFOX/Avastin in First-Line in Patients With Metastatic Colorectal Cancer

Condition: Colorectal Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: leucovorin; Drug: 5-fluorouracil; Drug: irinotecan; Drug: oxaliplatin; Drug: capecitabine [Xeloda]; Drug: fluoropyrimidine-based chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified June 2013
A Pharmacokinetics Study to Investigate the Effect of Ketoconazole on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma

Condition: Malignant Melanoma, Neoplasms
Interventions: Drug: vemurafenib; Drug: ketoconazole
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified June 2013
A Pharmacokinetics Study to Investigate the Effect of Vemurafenib on Digoxin in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma

Condition: Malignant Melanoma, Neoplasms
Interventions: Drug: vemurafenib; Drug: digoxin
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified June 2013
Study Comparing AEZS-108 to Doxorubicin as a Second Line Therapy of Endometrial Cancer

Condition: Endometrial Cancer
Interventions: Drug: AEZS-108 / zoptarelin doxorubicin; Drug: doxorubicin
Sponsors: AEterna Zentaris; AEterna Zentaris
Recruiting - verified May 2013
A Study to Evaluate the Pharmacokinetics of PCI-32765 in Participants With Varying Degrees of Hepatic Impairment

Condition: Hepatic Impairment
Intervention: Drug: PCI-32765
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2013
A Pharmacokinetics Study to Investigate the Effect of Rifampin on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy

Condition: Malignant Melanoma, Neoplasms
Interventions: Drug: vemurafenib; Drug: rifampin
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified June 2013
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk

Condition: Dyslipidemia
Interventions: Device: AMG 145; Device: Placebo; Drug: Atorvastatin
Sponsors: Amgen; Amgen
Recruiting - verified June 2013
A Study to Evaluate Safety, Tolerability, and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease

Condition: Alzheimer's Disease
Interventions: Drug: BAN2401 2.5 mg/kg; Drug: BAN2401 5.0 mg/kg; Drug: BAN2401 10 mg/kg; Drug: BAN2401 5.0 mg/kg; Drug: BAN2401 10 mg/kg
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified June 2013
LDL-C Assessment w/ PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2

Condition: Hyperlipidemia
Interventions: Drug: AMG 145; Other: Ezetimibe; Other: Placebo (administered subcutaneously); Other: Placebo (administered orally); Drug: Statin therapy
Sponsors: Amgen; Amgen
Recruiting - verified June 2013
Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)

Conditions: Parkinson's Disease; Motor Symptoms; Akinesia; Hypomobility; Delayed Levadopa Onset
Interventions: Drug: APOKYN; Drug: L-dopa; Drug: Trimethobenzamide
Sponsors: US WorldMeds LLC; US WorldMeds LLC; Cape Cod Clinical Research Inc.; ClinData Services, Inc.
Recruiting - verified June 2013
Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2

Condition: Hyperlipidemia
Interventions: Drug: AMG 145; Other: Placebo (administered subcutaneously); Drug: Ezetimibe; Other: Placebo (administered orally)
Sponsors: Amgen; Amgen
Recruiting - verified June 2013
Efficacy and Safety Study of Oral Solithromycin (CEM-101) Compared to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia

Condition: Community-acquired Bacterial Pneumonia
Interventions: Drug: Solithromycin; Drug: Moxifloxacin
Sponsors: Cempra Pharmaceuticals; Cempra Pharmaceuticals
Recruiting - verified May 2013
Long-term Open-Label Safety Study to Evaluate EN3409

Conditions: Low Back Pain; Osteoarthritis; Neuropathic Pain
Intervention: Drug: EN3409
Sponsors: Endo Pharmaceuticals; Endo Pharmaceuticals; BioDelivery Science International, Inc. (BDSI)
Recruiting - verified February 2013
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma Who Have Been Treated With One Prior Therapy

Condition: Hepatocellular Carcinoma
Interventions: Drug: Tivantinib; Drug: Placebo
Sponsors: Daiichi Sankyo Inc.; Daiichi Sankyo Inc.; ArQule; Covance
Recruiting - verified June 2013
A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthritis Receiving VX-509, an Oral JAK3 Inhibitor

Condition: Rheumatoid Arthritis
Interventions: Drug: VX-509; Drug: VX-509 matching placebo
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated
Recruiting - verified May 2013
Safety and Efficacy of CEM-102 With Rifampin Compared to Standard Intravenous Therapy in Patients With Prosthetic Joint Infections

Condition: Prosthetic Joint Infections of Hip or Knee Joints
Interventions: Drug: CEM-102 plus Rifampin; Drug: IV vancomycin, nafcillin, oxacillin, ceftriaxone or cefazolin
Sponsors: Cempra Pharmaceuticals; Cempra Pharmaceuticals
Recruiting - verified June 2013
Phase 1b Study Investigating Safety & Immunogenicity of DENVax Given Intradermally by Needle or Needle Free PharmaJet Injector

Condition: Normal Healthy Adult
Interventions: Biological: DENVax; Device: PharmaJet Injector
Sponsors: Inviragen Inc.; Inviragen Inc.; National Institutes of Health (NIH)
Recruiting - verified June 2013
A Study of RG7667 for the Prevention of Cytomegalovirus Disease in Kidney Transplant Recipients

Condition: Cytomegalovirus Infections
Interventions: Drug: RG7667; Drug: Placebo
Sponsors: Genentech; Genentech
Recruiting - verified May 2013
An Open-Label Extension Study To Assess Long Term Safety And Effectiveness Of Dysport In Adults With Cervical Dystonia (CD)

Condition: Cervical Dystonia
Intervention: Drug: Dysport
Sponsors: Ipsen; Ipsen
Not yet recruiting - verified May 2013
A Randomised Placebo-Controlled Study Evaluating the Efficacy and Safety of DYSPORT Using 2mL Dilution in Adults With Cervical Dystonia (CD).

Condition: Cervical Dystonia
Interventions: Drug: Dysport; Drug: Placebo, Up to 2mL
Sponsors: Ipsen; Ipsen
Recruiting - verified May 2013
Best Systemic Therapy or Best Systemic Therapy (BST) Plus Definitive Treatment (Radiation or Surgery)

Condition: Prostate Cancer
Interventions: Other: Best Systemic Therapy (BST); Other: Best Systemic Therapy (BST) + Surgery or Radiation Therapy; Behavioral: Questionnaires; Other: Phone Call/Email
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013
Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors

Condition: Malignant Solid Tumor - Malignant Nervous System Neoplasm
Intervention: Drug: Cabazitaxel (XRP6258)
Sponsors: Sanofi; Sanofi
Recruiting - verified June 2013
A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease

Conditions: Inflammation; Crohn's Disease
Interventions: Drug: NNC0114-0006; Drug: NNC0114-0006
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified June 2013
A Study of RO4917523 in Pediatric Patients With Fragile X Syndrome

Condition: Fragile X Syndrome
Interventions: Drug: RO4917523; Drug: RO4917523; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified June 2013
Efficacy, Tolerability, and Safety of NXN-462 in Patients With Post-Herpetic Neuralgia

Condition: Post Herpetic Neuralgia
Interventions: Drug: NXN-462; Drug: Placebo
Sponsors: NeurAxon Inc.; NeurAxon Inc.
Recruiting - verified June 2013
Efficacy and Safety Study of Z160 in Subjects With Postherpetic Neuralgia

Condition: Postherpetic Neuralgia
Interventions: Drug: Z160; Drug: Placebo
Sponsors: Zalicus; Zalicus
Recruiting - verified June 2013
Efficacy of Inhaled Albuterol Spiromax® in Subjects With Persistent Asthma With Steady State Pharmacokinetics

Condition: Asthma
Interventions: Drug: Albuterol Spiromax® 90 mcg/inhalation; Drug: Placebo Spiromax
Sponsors: Teva Pharmaceutical Industries; Teva Branded Pharmaceutical Products, R&D Inc.
Recruiting - verified May 2013
Efficacy and Safety Study of AeroVanc for the Treatment of Persistent MRSA Lung Infection in Cystic Fibrosis Patients

Condition: Cystic Fibrosis
Interventions: Drug: Vancomycin inhalation powder; Drug: Placebo inhalation powder
Sponsors: Savara Inc.; Savara Inc.; Synteract, Inc.
Recruiting - verified June 2013
A Phase II Study of Minocycline and Armodafinil for Reducing the Symptom Burden Produced by Chemoradiation Treatment for Esophageal Cancer

Condition: Esophageal Cancer
Interventions: Drug: Armodafinil; Other: Placebo; Drug: Minocycline; Behavioral: Questionnaires
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified May 2013
Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCT

Conditions: Acute Myeloid Leukemia (AML); Myelodysplastic Syndrome (MDS)
Intervention: Drug: Treosulfan
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; National Marrow Donor Program; Resource for Clinical Investigation in Blood and Marrow Transplantation (RCI BMT); Pediatric Blood and Marrow Transplant Consortium; St. Baldrick's Foundation; medac GmbH
Not yet recruiting - verified May 2013
Attain Performa(TM) Quadripolar Lead Study

Condition: Heart Failure
Intervention: Device: Device: Attain Performa Pacing Lead (along with a standard CRT-D system)
Sponsors: Medtronic Cardiac Rhythm Disease Management; Medtronic Cardiac Rhythm Disease Management
Recruiting - verified May 2013
A Phase 3 Study to Evaluate the Efficacy of Lifitegrast in Subjects With Dry Eye

Condition: Dry Eye
Interventions: Drug: Lifitegrast; Drug: Placebo
Sponsors: SARcode Bioscience; SARcode Bioscience
Recruiting - verified June 2013
Study Comparing Adapalene and Benzoyl Peroxide Gel 0.1%/2.5% to Epiduo® and Both to a Placebo Control in the Treatment of Acne Vulgaris

Condition: Acne Vulgaris
Interventions: Drug: Adapalene and Benzoyl Peroxide Gel 0.1%/2.5%; Drug: Epiduo® Gel; Drug: Placebo
Sponsors: Taro Pharmaceuticals USA; Taro Pharmaceuticals USA
Recruiting - verified June 2013
A Multicenter Phase 2 Study of PCI-32765 (Ibrutinib) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion

Conditions: Chronic Lymphocytic Leukemia With 17p Deletion; Small Lymphocytic Lymphoma With 17p Deletion
Intervention: Drug: PCI-32765
Sponsors: Pharmacyclics; Pharmacyclics
Recruiting - verified May 2013
Identification of a Plasma Proteomic Signature for Lung Cancer

Conditions: Precancerous Conditions; Carcinoma
Intervention:
Sponsors: Integrated Diagnostics; Integrated Diagnostics
Recruiting - verified May 2013
T-Cells Transduced With Either CXCR2 or Nerve Growth Factor Receptor (NGFR)

Condition: Melanoma
Interventions: Drug: Cytoxan; Drug: Mesna; Drug: Fludarabine monophosphate; Procedure: T cell Infusion; Drug: IL-2; Other: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Institutes of Health (NIH); National Cancer Institute (NCI)
Not yet recruiting - verified June 2013
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext

Condition: Alzheimer's Disease
Interventions: Drug: AC-1204; Drug: Placebo
Sponsors: Accera, Inc.; Accera, Inc.
Recruiting - verified June 2013
An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)

Condition: Alzheimer's Disease
Interventions: Drug: MK-8931; Drug: Placebo
Sponsors: Merck; Merck
Recruiting - verified May 2013
MAESTRO (Macitentan in Eisenmenger Syndrome To Restore Exercise Capacity)

Condition: Eisenmenger Syndrome
Interventions: Drug: Macitentan 10 mg, oral tablet, to be taken once daily.; Drug: Matching placebo oral tablet, to be taken once daily.
Sponsors: Actelion; Actelion
Recruiting - verified June 2013
Phase I Study of GNKG168 in Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia

Conditions: Relapsed Acute Lymphoblastic Leukemia; Relapsed Acute Myelogenous Leukemia
Intervention: Drug: GNKG168
Sponsors: Therapeutic Advances in Childhood Leukemia Consortium; Therapeutic Advances in Childhood Leukemia Consortium
Recruiting - verified May 2013
Methotrexate Infusion Into the Fourth Ventricle in Children With Malignant Fourth Ventricular Brain Tumors: A Pilot Study

Conditions: Brain Tumor; Malignant Neoplasm of Fourth Ventricle of Brain
Interventions: Procedure: Ommaya Reservoir; Drug: Methotrexate; Drug: Leucovorin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013
Evaluation of Purified Poloxamer 188 in Children in Crisis (EPIC)

Conditions: Vaso-occlusive Crisis; Sickle Cell Disease
Interventions: Drug: ANX-188; Drug: Saline
Sponsors: Mast Therapeutics, Inc.; Mast Therapeutics, Inc.
Recruiting - verified June 2013
A Safety, Efficacy and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric and Adult Subjects With Primary Generalized Tonic-Clonic (i.e., Grand Mal) Seizures.

Condition: Generalized Tonic Clonic Seizures
Interventions: Drug: Pregabalin Dose Level 1; Drug: Pregabalin Dose Level 2; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
An Extension (Rollover) Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol

Condition: Neoplasms
Intervention: Drug: vemurafenib
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified June 2013
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Condition: Alzheimer's Disease
Interventions: Drug: ELND005; Drug: Placebo
Sponsors: Elan Pharmaceuticals; Elan Pharma International Limited; Elan Pharmaceuticals
Recruiting - verified June 2013
Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: Pomalidomide; Drug: Bortezomib; Drug: Dexamethasone
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified June 2013
Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia in Complete Remission

Condition: Leukemia, Myeloid, Acute
Interventions: Drug: 300 mg Oral Azacitidine; Drug: Placebo
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified June 2013
Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers >12 cm2 to ≤ 36 cm2

Condition: Venous Leg Ulcers
Interventions: Biological: HP802-247; Biological: Vehicle
Sponsors: Healthpoint; Healthpoint
Recruiting - verified May 2013
Study to Evaluate Safety/Efficacy of a Single Pre-Op Dose of AYX1 Injection to Treat Pain After Knee Replacement Surgery

Condition: Postsurgical Pain
Interventions: Drug: Placebo Injection; Drug: AYX1 Injection 110 mg; Drug: AYX1 Injection 330 mg
Sponsors: Adynxx, Inc.; Adynxx, Inc.
Recruiting - verified May 2013
Spinal Muscular Atrophy (SMA) Biomarkers Study in the Immediate Postnatal Period of Development

Condition: Spinal Muscular Atrophy (SMA)
Intervention:
Sponsors: Ohio State University; Ohio State University; National Institute of Neurological Disorders and Stroke (NINDS); Families of SMA; Massachusetts General Hospital; University of Iowa
Recruiting - verified June 2013
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Linagliptin; Drug: Empagliflozin + Linagliptin; Drug: Empagliflozin + Linagliptin; Drug: Empagliflozin + Linagliptin; Drug: Empaglifozin placebo + Linagliptin placebo; Drug: Empagliflozin + Linagliptin
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified June 2013
Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma

Conditions: Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Recurrent Adult Brain Tumor
Interventions: Biological: bevacizumab; Radiation: intensity-modulated radiation therapy; Radiation: 3-dimensional conformal radiation therapy; Radiation: proton beam radiation therapy
Sponsors: Radiation Therapy Oncology Group; Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013
Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer

Conditions: Adult Primary Hepatocellular Carcinoma; Advanced Adult Primary Liver Cancer; Recurrent Adult Primary Liver Cancer
Interventions: Drug: sorafenib tosylate; Radiation: stereotactic body radiation therapy
Sponsors: Radiation Therapy Oncology Group; Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2013
Safety Study of CC-292 and Lenalidomide in Subjects With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma

Condition: Leukemia Lymphocytic Chronic B-Cell
Interventions: Drug: CC-292; Drug: Lenalidomide
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified June 2013
Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese

Condition: Type 2 Diabetes in Obese Subjects
Interventions: Device: EndoBarrier; Procedure: Sham Procedure
Sponsors: GI Dynamics; GI Dynamics
Recruiting - verified May 2013
A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.

Condition: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Drug: QVA149; Drug: Long acting muscarinic antagonist (LAMA); Drug: Long acting B2 agonist (LABA); Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified June 2013
A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients With Severe Haemophilia A

Conditions: Congenital Bleeding Disorder; Haemophilia A
Intervention: Drug: NNC 0129-0000-1003
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified June 2013
PK of Antistaphylococcal Antibiotics in Infants (NICHD-2012-02-Staph Trio)

Condition: Systemic Infection
Intervention: Drug: Antibiotic
Sponsors: Duke University; Phillip Brian Smith
Recruiting - verified June 2013
Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT)

Condition: Hypercholesterolemia
Interventions: Drug: alirocumab (REGN727/ SAR236553); Other: placebo; Drug: Rosuvastatin; Drug: Ezetimibe
Sponsors: Regeneron Pharmaceuticals; Regeneron Pharmaceuticals; Sanofi
Recruiting - verified May 2013
Relaxation Response Training for PTSD Prevention in US Military Personnel

Condition: Posttraumatic Stress Disorder
Intervention: Behavioral: Relaxation Response training
Sponsors: Samueli Institute for Information Biology; Samueli Institute for Information Biology; William Beaumont Army Medical Center
Recruiting - verified May 2013
The Collection and Storage of Umbilical Cord Blood for Transplantation

Conditions: Cord Blood Stem Cell Transplantation; Cord Blood Transplantation; Hematopoietic Stem Cell Transplantation
Intervention:
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified June 2013
Cord Blood Natural Killer Cells for Myeloma

Condition: Myeloma
Interventions: Drug: Lenalidomide; Drug: Melphalan; Procedure: NK Cell Infusion; Drug: Interleukin-2; Procedure: Stem Cell Infusion; Drug: G-CSF
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Celgene Corporation
Recruiting - verified June 2013
Oligometastatic Disease

Condition: Lung Cancer
Interventions: Other: No LCT; Other: LCT
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; University of Chicago; University of Colorado, Denver
Recruiting - verified May 2013
Motivational Incentives to Reduce Secondhand Smoke in NICU Infants' Homes

Condition: Exposure to Secondhand Smoke in Neonatal Infants
Interventions: Behavioral: Motivational Interviewing plus Incentives; Behavioral: Conventional Care (CC)
Sponsors: The University of Texas Health Science Center, Houston; The University of Texas Health Science Center, Houston; Memorial Hermann Hospital; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified June 2013
Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease

Condition: Parkinson's Disease
Interventions: Drug: Rasagiline; Drug: Placebo
Sponsors: Teva Pharmaceutical Industries; Teva Branded Pharmaceutical Products, R&D Inc.
Recruiting - verified June 2013
Detecting EGFR T790M Mutations From Circulating Tumor Cells

Condition: Non Small Cell Lung Cancer
Intervention: Device: Circulating tumor cell chip
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Dana-Farber Cancer Institute; Memorial Sloan-Kettering Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013
An Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (PCI-32765 Versus Chlorambucil)

Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Intervention: Drug: PCI-32765
Sponsors: Pharmacyclics; Pharmacyclics
Recruiting - verified June 2013
A Study of LY2940680 in Small Cell Lung Cancer

Condition: Small Cell Lung Carcinoma
Interventions: Drug: LY2940680; Drug: Carboplatin; Drug: Etoposide; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified June 2013
Study of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Squamous Cell Non-Small Cell Lung Cancer Who Have Received At Least Two Prior Systemic Regimens

Condition: Squamous Cell Non-small Cell Lung Cancer
Intervention: Drug: Nivolumab (BMS-936558)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified May 2013
Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of Cancer

Condition: Cancer
Interventions: Drug: REGN1400; Drug: Erlotinib; Drug: Cetuximab
Sponsors: Regeneron Pharmaceuticals; Regeneron Pharmaceuticals
Recruiting - verified May 2013
A Moderate to Severe Rheumatoid Arthritis Study

Condition: Rheumatoid Arthritis
Interventions: Drug: Placebo; Drug: Baricitinib
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified June 2013
A Study in Moderate to Severe Rheumatoid Arthritis Participants

Condition: Rheumatoid Arthritis
Interventions: Drug: Placebo; Drug: Baricitinib
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified June 2013
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes

Conditions: Diabetes Mellitus, Type 2; Hyperglycemia
Interventions: Drug: Empagliflozin low dose qd; Drug: Metformin 500 mg bid; Drug: Metformin 1000 mg bid; Drug: Empagliflozin high dose qd; Drug: Empagliflozin low dose bid; Drug: Metformin 500 mg bid; Drug: Empagliflozin high dose bid; Drug: Empagliflozin low dose bid; Drug: Metformin 1000 mg bid; Drug: Metformin 500 mg bid; Drug: Metformin 1000 mg bid; Drug: Empagliflozin high dose bid; Drug: Metformin 1000 mg bid; Drug: Empagliflozin high dose bid
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified June 2013
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder

Condition: Binge Eating Disorder
Interventions: Drug: SPD489 (Lisdexamfetamine dimesylate); Drug: Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified May 2013
A Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 Versus Chlorambucil in Patients 65 Years or Older With Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (RESONATE™-2)

Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Interventions: Drug: PCI-32765; Drug: Chlorambucil
Sponsors: Pharmacyclics; Pharmacyclics
Recruiting - verified June 2013
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder

Condition: Binge Eating Disorder
Interventions: Drug: SPD489 (Lisdexamfetamine dimesylate); Drug: Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified May 2013
MLN 9708 With Lenalidomide as Maintenance Post Autologous Stem Cell Transplant for Multiple Myeloma Patients

Condition: Myeloma
Interventions: Drug: Lenalidomide; Drug: MLN9708; Radiation: Questionnaires
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Millennium Pharmaceuticals, Inc.
Recruiting - verified June 2013
FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer

Condition: Colorectal Cancer Metastatic
Interventions: Drug: FOLFOX6m; Device: SIR-Spheres microspheres
Sponsors: Sirtex Medical; Sirtex Medical
Recruiting - verified June 2013
Abraxane in CIMP-High Colorectal and Small Bowel Adenocarcinomas

Conditions: Colorectal Cancer; Cancer of Gastrointestinal Tract
Intervention: Drug: Abraxane
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Celgene Corporation
Recruiting - verified May 2013
A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities

Condition: Cardiovascular Disease, Diabetes Mellitus, Type 2
Interventions: Drug: aleglitazar; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified June 2013
RAMP Study: A Study Comparing Two Lumbar Fusion Procedures

Conditions: Spinal Stenosis; Spondylolisthesis; Degenerative Disc Disease
Intervention:
Sponsors: Baxano Surgical, Inc.; Baxano Surgical, Inc.
Recruiting - verified June 2013
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis

Condition: Lupus Nephritis
Interventions: Biological: BMS-188667; Drug: Mycophenolate mofetil; Drug: Prednisone; Biological: Placebo matching with BMS-188667
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified June 2013
A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy

Condition: Atrial Fibrillation
Interventions: Drug: rivaroxaban; Drug: uninterrupted vitamin K antagonist (VKA)
Sponsors: Janssen Scientific Affairs, LLC; Janssen Scientific Affairs, LLC
Recruiting - verified June 2013
Dabrafenib and Pazopanib Hydrochloride in Treating Patients With Advanced Malignant Tumors

Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: dabrafenib; Drug: pazopanib hydrochloride; Other: Correlative studies
Sponsors: Ohio State University Comprehensive Cancer Center; Manisha Shah; National Comprehensive Cancer Network
Recruiting - verified June 2013
Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer

Conditions: Follicular Thyroid Cancer; Insular Thyroid Cancer; Papillary Thyroid Cancer; Recurrent Thyroid Cancer
Interventions: Drug: dabrafenib; Drug: trametinib; Other: Correlative Studies
Sponsors: Ohio State University Comprehensive Cancer Center; Manisha Shah; National Comprehensive Cancer Network
Recruiting - verified June 2013
A Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt Nephropathy

Condition: Diabetic Nephropathy
Interventions: Drug: PF-04634817; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil

Condition: Alzheimer's Disease
Interventions: Drug: PF-05212377 (SAM-760); Other: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
A Study of the Comparable Efficacy and Safety of Pulmozyme (Dornase Alfa) Delivered by the eFlow Rapid Nebulizer System in Patients With Cystic Fibrosis

Condition: Cystic Fibrosis
Interventions: Drug: dornase alfa [Pulmozyme]; Drug: dornase alfa [Pulmozyme]
Sponsors: Genentech; Genentech
Recruiting - verified May 2013
A Study in Participants With Moderate to Severe Rheumatoid Arthritis

Condition: Rheumatoid Arthritis
Interventions: Drug: Baricitinib; Drug: Methotrexate; Drug: Placebo; Drug: Folic Acid
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified June 2013
Evaluation of the Immune Response to Clostridium Difficile in Adults With Clostridium Difficile Infection (CDI)

Condition: Bacterial Vaccines
Interventions: Procedure: Blood sampling; Other: Stool sample collection
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified March 2013
Study of Sotatercept (ACE-011) in Subjects With Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) and Anemia

Condition: Leukemia
Intervention: Drug: Sotatercept
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013
Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Condition: Refractory Multiple Myeloma
Interventions: Drug: dinaciclib; Drug: bortezomib; Drug: dexamethasone; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified June 2013
A Study in Moderate to Severe Rheumatoid Arthritis

Condition: Rheumatoid Arthritis
Interventions: Drug: Placebo; Drug: Adalimumab; Drug: Baricitinib
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified June 2013
Targeted Laser With Lucentis 0.5mg Verses L Lucentis 0.5mg Monotherapy for Ischemic Central Vein, Hemi Retinal Vein Occlusion and Branch Retinal Vein Occlusion

Condition: Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, Branch Retinal Vein Occlusion
Interventions: Drug: 0.5mg Ranibizumab; Procedure: Targeted Pan Retinal Photocoagulation
Sponsors: Greater Houston Retina Research; Charles C Wykoff, PhD, MD; Genentech
Recruiting - verified June 2013
Safety and Efficacy Study of GRT6005 in Patients With Osteoarthritis (OA) Knee Pain

Condition: Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee
Interventions: Drug: GRT6005 Low-Dose Range; Drug: GRT6005 High-Dose Range; Drug: Placebo; Drug: Oxycodone CR
Sponsors: Forest Laboratories; Forest Laboratories; Grünenthal GmbH
Recruiting - verified May 2013
Secukinumab Efficacy and Safety Study in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-TNFα Agents.

Condition: Rheumatoid Arthritis
Interventions: Drug: AIN457; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013
Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)

Condition: Amyotrophic Lateral Sclerosis
Interventions: Drug: CK-2017357; Other: Placebo tablets
Sponsors: Cytokinetics; Cytokinetics
Recruiting - verified June 2013
Pharmacokinetic Study of Pediatric Subjects With Tinea Cruris and Tinea Pedis

Conditions: Tinea Pedis; Tinea Cruris
Interventions: Drug: NAFT500 (pediatric); Drug: NAFT600 (pediatric); Drug: NAFT500 (adult); Drug: NAFT600 (adult)
Sponsors: Merz Pharmaceuticals, LLC; Merz Pharmaceuticals, LLC
Recruiting - verified June 2013
Study Of The Mechanism Of Action Of CP-690,550 In The Skin Of Subjects With Moderate To Severe Chronic Plaque Psoriasis

Condition: Plaque Psoriasis
Interventions: Drug: (CP-6890,550) Tofacitinib; Drug: Placebo; Drug: (CP-690,550) Tofacitinib; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
VERtebral Fracture Treatment Comparisons in Osteoporotic Women

Condition: Postmenopausal Osteoporosis
Interventions: Drug: Teriparatide; Drug: Risedronate; Drug: Placebo; Drug: Calcium; Drug: Vitamin D
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified June 2013
Cabozantinib in Treating Younger Patients With Recurrent or Refractory Solid Tumors

Conditions: Recurrent Melanoma; Recurrent Thyroid Cancer; Thyroid Gland Medullary Carcinoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: cabozantinib-s-malate; Other: pharmacological study; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified June 2013
A Study of Brentuximab Vedotin in Adults Age 60 and Above With Newly Diagnosed Hodgkin Lymphoma (HL)

Condition: Hodgkin Disease
Intervention: Drug: brentuximab vedotin
Sponsors: Seattle Genetics, Inc.; Seattle Genetics, Inc.
Recruiting - verified May 2013
Vitamin D3 in Pediatric SLE

Condition: Systemic Lupus Erythematosus
Intervention: Drug: Vitamin D3
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); Autoimmunity Centers of Excellence
Recruiting - verified June 2013
To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)

Condition: Rheumatoid Arthritis
Interventions: Drug: sarilumab SAR153191 (REGN88); Other: placebo
Sponsors: Sanofi; Sanofi; Regeneron Pharmaceuticals
Recruiting - verified June 2013
A Phase III Study of Oral LDE225 Versus (vs) Temozolomide (TMZ) in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB)

Condition: Medulloblastoma
Interventions: Drug: LDE225; Drug: TMZ
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified June 2013
Phase 3B Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Women

Conditions: Acquired Immunodeficiency Syndrome; HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir df; Drug: ritonavir + atazanavir + emtricitabine/tenofovir df
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified June 2013
Belimumab Assessment of Safety in SLE

Condition: Systemic Lupus Erythematosus
Interventions: Biological: Placebo plus standard therapy; Biological: Belimumab 10 mg/kg plus standard therapy; Other: Standard therapy
Sponsors: GlaxoSmithKline; Human Genome Sciences Inc., a GSK Company; GlaxoSmithKline
Recruiting - verified June 2013
A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures

Condition: Tuberous Sclerosis Complex-associated Refractory Seizures
Interventions: Drug: RAD001; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013
Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer

Conditions: Breast Cancer; HER2-negative Breast Cancer
Interventions: Drug: Paclitaxel; Drug: Eribulin; Drug: Doxorubicin; Drug: Cyclophosphamide
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Surgical Adjuvant Breast and Bowel Project (NSABP); Eisai Inc.
Recruiting - verified June 2013
Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix®) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M M R®II), in Children 12 to 15 Months of Age

Condition: Measles, Mumps and Rubella Diseases
Interventions: Biological: GSK Biologicals measles, mumps and rubella vaccine live (GSK 209762).; Biological: Merck & Co., Inc.'s M-M-R®II (also called M-M-R Vax Pro®), combined measles-mumps-rubella virus vaccine.; Biological: Varivax® (Merck & Co., Inc.); Biological: Havrix®; Biological: Prevnar 13® (Pfizer Inc.)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
A Safety Study of NNZ-2566 in Patients With Rett Syndrome

Condition: Rett Syndrome
Interventions: Drug: NNZ-2566; Drug: Placebo
Sponsors: Neuren Pharmaceuticals Limited; Neuren Pharmaceuticals Limited; Baylor College of Medicine; Texas Children's Hospital; International Rett Syndrome Foundation
Recruiting - verified June 2013
Placebo-controlled Safety and Efficacy Study of Pregabalin in Subjects With Post-traumatic Peripheral Neuropathic Pain

Condition: Neuropathic Pain
Interventions: Drug: pregabalin; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)

Condition: Atrial Fibrillation
Intervention: Other: Patients with Atrial Fibrillation
Sponsors: Janssen Scientific Affairs, LLC; Janssen Scientific Affairs, LLC; Duke Clinical Research Institute
Recruiting - verified May 2013
Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors.

Condition: Advanced Solid Tumors, Excluding Breast Cancer
Interventions: Drug: dovitinib (TKI258); Drug: fluvoxamine
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified June 2013
IADAPT-Third Phase

Condition: Musculoskeletal Diseases
Interventions: Other: Multimedia Patient Decision Aids (MM-PtDAs); Other: Comparative Effectiveness Research Summary Guide (CERSG); Behavioral: Questionnaires
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Agency for Healthcare Research and Quality (AHRQ); Harris County Hospital District; Kelsey-Seybold Clinics
Recruiting - verified May 2013
Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children Under 18 Years of Age (MK-0517-029 AM3)

Condition: Chemotherapy-induced Nausea and Vomiting
Interventions: Drug: Fosaprepitant 150 mg; Drug: Fosaprepitant 60 mg; Drug: Fosaprepitant 20 mg; Drug: Placebo Fosaprepitant; Drug: Ondansetron
Sponsors: Merck; Merck
Recruiting - verified May 2013
Does Atrial Fibrillation (AF) Termination Without Additional Ablation Influence Outcome?

Condition: Atrial Fibrillation
Interventions: Procedure: PVAI; Procedure: PVAI + ablation of extraPV triggers
Sponsors: Texas Cardiac Arrhythmia Research Foundation; Texas Cardiac Arrhythmia Research Foundation; California Pacific Medical Center
Recruiting - verified September 2012
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Tiotropium; Drug: Placebo matching Olodaterol; Drug: Tiotropium; Drug: Olodaterol
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified June 2013
First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma

Condition: Gastric Cancer
Interventions: Drug: Rilotumumab; Other: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified June 2013
Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia

Condition: High Risk Acute Myeloid Leukemia
Interventions: Drug: CPX-351; Drug: 7+3 (cytarabine and daunorubicin)
Sponsors: Celator Pharmaceuticals; Celator Pharmaceuticals; The Leukemia and Lymphoma Society
Recruiting - verified May 2013
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma

Condition: Malignant Melanoma
Intervention: Biological: Ipilimumab
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified June 2013
A Study of Ixekizumab in Participants With Active Psoriatic Arthritis

Condition: Psoriasis, Arthritic
Interventions: Drug: ixekizumab; Drug: Placebo; Drug: Adalimumab
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified June 2013
A Randomized, Double Blind, Multiple Dose Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects With Moderate to Severe Ulcerative Colitis

Condition: Ulcerative Colitis
Interventions: Biological: AMG 181; Other: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified June 2013
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects

Condition: Moderate to Severe Plaque Psoriasis
Interventions: Drug: 210 mg brodalumab; Drug: 140 mg brodalumab; Drug: ustekinumab; Drug: placebo
Sponsors: Amgen; Amgen
Recruiting - verified June 2013
Minocycline Study in Pancreatic Cancer Patients

Condition: Pancreatic Cancer
Interventions: Drug: Minocycline; Other: Placebo; Behavioral: Questionnaires
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified May 2013
E7070, Idarubicin and Cytarabine in Relapsed AML and High-Risk Myelodysplastic Syndromes

Condition: Leukemia
Interventions: Drug: E7070; Drug: Idarubicin; Drug: Cytarabine; Drug: Dexamethasone
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Eisai Inc.
Recruiting - verified May 2013
A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Alone

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: aleglitazar; Drug: placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified June 2013
Surgical Treatment of Aortic Stenosis With a Next Generation, Rapid Deployment Surgical Aortic Valve

Conditions: Aortic Valve Stenosis; Aortic Valve Stenosis With Insufficiency; Regurgitation, Aortic Valve; Aortic Valve Incompetence
Intervention: Device: EDWARDS INTUITY valve
Sponsors: Edwards Lifesciences; Edwards Lifesciences
Recruiting - verified April 2013
Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis

Conditions: Psoriasis; Psoriatic Arthritis
Interventions: Drug: Apremilast 30 mg; Drug: Etanercept 50 mg; Drug: Placebo tablet; Drug: Placebo injection (saline)
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified June 2013
Safety and Efficacy of Fidaxomicin Versus Placebo for Prophylaxis Against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation

Condition: Clostridium Difficile-Associated Diarrhea (CDAD)
Interventions: Drug: fidaxomicin; Drug: placebo
Sponsors: Optimer Pharmaceuticals; Optimer Pharmaceuticals
Recruiting - verified June 2013
Adult Attention Deficit Hyperactivity Disorder

Condition: Adult Attention Deficit Hyperactivity Disorder
Interventions: Drug: SEP-225289; Drug: SEP-225289; Drug: Placebo
Sponsors: Sunovion; Sunovion
Recruiting - verified June 2013
Efficacy and Safety Study With Diltiazem Hydrochloride Cream to Treat Anal Fissures

Condition: Chronic Anal Fissures
Interventions: Drug: VEN 307; Drug: Placebo
Sponsors: Ventrus Biosciences, Inc; Ventrus Biosciences, Inc
Recruiting - verified June 2013
A Study of MK-8109 (Vintafolide) Given With Chemotherapy in Participants With Advanced Cancers (MK-8109-001)

Condition: Advanced Cancer
Interventions: Drug: Vintafolide; Drug: Carboplatin; Drug: Paclitaxel
Sponsors: Merck; Merck
Recruiting - verified May 2013
Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Postherpetic Neuralgia (PHN)

Conditions: Postherpetic Neuralgia; Pain
Interventions: Drug: V116517 50-mg tablets; Drug: V116517 30-mg tablets; Drug: Pregabalin capsules; Drug: Placebo
Sponsors: Purdue Pharma LP; Purdue Pharma LP
Recruiting - verified June 2013
Nesvacumab (REGN910/ SAR307746) and Aflibercept ("Ziv-aflibercept" in the U.S.) in Patients With Advanced Solid Malignancies

Condition: Solid Tumors
Interventions: Drug: nesvacumab (REGN910/ SAR307746); Drug: nesvacumab (REGN910/ SAR307746); Drug: nesvacumab (REGN910/ SAR307746); Drug: aflibercept (ziv-aflibercept); Drug: aflibercept (ziv-aflibercept)
Sponsors: Regeneron Pharmaceuticals; Regeneron Pharmaceuticals; Sanofi
Recruiting - verified May 2013
A Study of DCDT2980S in Combination With MabThera/Rituxan or DCDS4501A in Combination With MabThera/Rituxan in Patients With Non-Hodgkin's Lymphoma

Condition: Lymphoma, B-Cell, Lymphoma, Follicular
Interventions: Drug: DCDT2980S; Drug: DCDS4501A; Drug: rituximab [MabThera/Rituxan]
Sponsors: Genentech; Genentech
Recruiting - verified June 2013
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease

Condition: Alzheimer's Disease
Interventions: Drug: TRx0237 150 mg/day; Drug: TRx0237 250 mg/day; Drug: Placebo
Sponsors: TauRx Therapeutics Ltd; TauRx Therapeutics Ltd
Recruiting - verified May 2013
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease

Condition: Alzheimer's Disease
Interventions: Drug: TRx0237 200 mg/day; Drug: Placebo
Sponsors: TauRx Therapeutics Ltd; TauRx Therapeutics Ltd
Recruiting - verified May 2013
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE)

Condition: Lupus Erythematosus
Interventions: Drug: ABT-199; Other: Placebo
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified June 2013
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects

Condition: Moderate to Severe Plaque Psoriasis
Interventions: Drug: 210 mg brodalumab; Drug: 140 mg brodalumab; Drug: ustekinumab; Drug: placebo
Sponsors: Amgen; Amgen
Recruiting - verified June 2013
A Study of Evacetrapib in High-Risk Vascular Disease

Condition: Cardiovascular Diseases
Interventions: Drug: Evacetrapib; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company; The Cleveland Clinic
Recruiting - verified June 2013
Oral Rivaroxaban in Children With Venous Thrombosis

Condition: Venous Thrombosis
Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939); Other: Standard of care
Sponsors: Bayer; Bayer; Janssen Research & Development, LLC
Recruiting - verified May 2013
Safety and Efficacy Study for Reverse Flow Used During Carotid Artery Stenting Procedure

Condition: Carotid Artery Disease
Intervention: Device: MICHI NPS+f
Sponsors: Silk Road Medical; Silk Road Medical
Recruiting - verified June 2013
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB in Patients With COPD Who Have Moderate to Severe Airflow Limitation

Condition: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Drug: QVA149; Drug: Long acting b2-agonist; Drug: QVA149; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified June 2013
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease

Condition: Diabetic Kidney Disease
Interventions: Drug: baricitinib; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company; Incyte Corporation
Recruiting - verified June 2013
LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib

Condition: Non-Small Cell Lung Cancer
Intervention: Drug: LDK378
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified June 2013
LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer

Condition: Non-Small Cell Lung Cancer
Intervention: Drug: LDK378
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified June 2013
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia

Condition: Schizophrenia
Interventions: Drug: ABT-126; Drug: ABT-126; Drug: Placebo
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified June 2013
TELESTAR (Telotristat Etiprate for Somatostatin Analogue Refractory Carcinoid Syndrome)

Condition: Carcinoid Syndrome
Interventions: Drug: Telotristat etiprate tablets (250 mg); Drug: Placebo tablets
Sponsors: Lexicon Pharmaceuticals; Lexicon Pharmaceuticals
Recruiting - verified May 2013
An Extension Study of RO5045337 in Patients Participating in Previous Cancer Studies

Condition: Myelogenous Leukemia, Chronic, Neoplasms, Myelogenous Leukemia, Acute
Intervention: Drug: RO5045337
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified June 2013
Adenoviral Vector Monotherapy or Combination With Chemotherapy Study in Subjects With Recurrent/Metastatic Breast Cancer and Accessible/Visible Lesions

Condition: Recurrent/Metastatic Breast Cancer With Accessible Lesions
Interventions: Genetic: Ad-RTS-hIL-12; Drug: Palifosfamide-tris
Sponsors: ZIOPHARM; ZIOPHARM
Recruiting - verified June 2013
Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Condition: Atrial Fibrillation
Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939); Drug: Vitamin K antagonist (VKA)
Sponsors: Bayer; Bayer; Janssen Research & Development, LLC
Recruiting - verified May 2013
Safety and Efficacy Study of ELND005 as an Adjunctive Maintenance Treatment in Bipolar I Disorder

Condition: Bipolar 1 Disorder
Interventions: Drug: ELND005; Drug: Lamotrigine; Drug: Valproic acid; Drug: Placebo
Sponsors: Elan Pharmaceuticals; Elan Pharma International Limited; Elan Pharmaceuticals
Recruiting - verified June 2013
Study of BMS-936558 Compared to Docetaxel in Previously Treated Advanced or Metastatic Non-squamous NSCLC

Condition: Non-Squamous Cell Non-small Cell Lung Cancer
Interventions: Biological: BMS-936558; Drug: Docetaxel
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified May 2013
Safety and Efficacy Study of Hydromorphone HCl by Intrathecal Administration Using a Programmable Implantable Pump

Condition: Management of Chronic Pain
Interventions: Drug: Hydromorphone Hydrochloride; Drug: Hydromorphone Hydrochloride
Sponsors: CNS Therapeutics; CNS Therapeutics; Pacific-Link Consulting LLC
Recruiting - verified June 2013
Renal Stent Placement for the Treatment of Renal Artery Stenosis in Patients With Resistant Hypertension

Conditions: Renal Artery Stenosis; Hypertension, Renovascular
Intervention: Device: iCAST™ Rx Stent System
Sponsors: Atrium Medical Corporation; Atrium Medical Corporation
Recruiting - verified May 2013
CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma

Condition: Moderate to Severe Allergic Asthma
Interventions: Biological: QbG10; Biological: Placebo
Sponsors: Cytos Biotechnology AG; Cytos Biotechnology AG
Recruiting - verified June 2013
A Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced Cancer

Condition: Neoplasm Malignant-
Interventions: Drug: SAR260301; Drug: Vemurafenib
Sponsors: Sanofi; Sanofi
Recruiting - verified June 2013
GS-6624 in the Treatment of Liver Fibrosis in Subjects With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)

Condition: Non-Alcoholic Steatohepatitis (NASH)
Interventions: Biological: GS-6624 75 mg; Biological: GS-6624 125 mg; Biological: Placebo
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013
GS-6624 in the Treatment of Cirrhosis Due to NASH

Condition: Non-Alcoholic Steatohepatitis (NASH)
Interventions: Biological: GS-6624 700mg; Biological: GS-6624 200mg; Biological: Placebo
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013
Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Symptomatic Severe Aortic Stenosis With Significant Comorbidities in Very High Risk Subjects Who Need Aortic Valve Replacement

Condition: Severe Aortic Stenosis
Intervention: Device: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)
Sponsors: Medtronic Cardiovascular; Medtronic Cardiovascular
Recruiting - verified May 2013
GS-6624 in the Prevention of Progression of Liver Fibrosis in Subjects With With Primary Sclerosing Cholangitis (PSC)

Condition: Primary Sclerosing Cholangitis (PSC)
Interventions: Biological: GS-6624; Biological: Placebo
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013
Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus

Condition: Diabetes Melliuts, Type 2
Interventions: Other: Placebo; Drug: 25 mg PF-05231023; Drug: 50 mg PF-05231023; Drug: 100 mg PF-05231023; Drug: 150 mg PF-05231023
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Pulmonary Vein Antrum Isolation (PVAI) Plus Isolation of Complex Fractionated Atrial Electrograms (CAFE) and Non-PV Triggers Ensure Long-term Recurrence-free Survival in Non-paroxysmal Atrial Fibrillation

Conditions: Persistent Atrial Fibrillation; Long-standing Persistent Atrial Fibrillation
Interventions: Procedure: Pulmonary Vein Antrum Isolation; Procedure: CFAE ablation; Procedure: Isolation of non-PV triggers
Sponsors: Texas Cardiac Arrhythmia Research Foundation; Texas Cardiac Arrhythmia Research Foundation; California Pacific Medical Center
Recruiting - verified August 2012
PV Reconnection After PVAI at Different Power Settings and Adenosine Provocation

Condition: Paroxysmal Atrial Fibrillation
Intervention: Procedure: PVAI followed by adenosine provocation
Sponsors: Texas Cardiac Arrhythmia Research Foundation; Texas Cardiac Arrhythmia Research Foundation; California Pacific Medical Center
Recruiting - verified August 2012
MyChoice: An Application of the TFEQ-R18v2

Condition: Central Nervous System Neoplasms
Interventions: Behavioral: Three-Factor Eating Questionnaire (TFEQ)-R18v2; Behavioral: Multifactor Screener; Behavioral: Eating Questionnaire-EMA (EQ-EMA)
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Baylor College of Medicine; Texas Children's Cancer Center
Recruiting - verified May 2013
Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia

Condition: Acute Schizophrenia
Interventions: Drug: Brexpiprazole; Drug: Placebo
Sponsors: Otsuka Pharmaceutical Development & Commercialization, Inc.; Otsuka Pharmaceutical Development & Commercialization, Inc.; Quintiles
Recruiting - verified June 2013
A Phase 2 Diagnostic Imaging Study With 99mTc-MIP-1404 in Men With High-Risk Prostate Cancer Scheduled for Radical Prostatectomy (RP) and Extended Pelvic Lymph Node Dissection (EPLND) Compared to Histopathology

Condition: Prostate Cancer
Intervention: Drug: Drug: 99mTc-MIP-1404
Sponsors: Molecular Insight Pharmaceuticals, Inc.; Molecular Insight Pharmaceuticals, Inc.
Recruiting - verified May 2013
Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis

Condition: Arthritis, Rheumatoid
Interventions: Drug: BI 695500; Drug: BI 695500; Drug: rituximab; Drug: rituximab; Drug: rituximab
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified June 2013
Pilot Phase II - Erlotinib for Acute Myeloid Leukemia (AML)

Condition: Leukemia
Intervention: Drug: Erlotinib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Astellas Pharma Inc
Recruiting - verified June 2013
CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies

Conditions: Lymphoma; Leukemia
Interventions: Drug: CMC-544; Drug: Fludarabine; Drug: Bendamustine; Drug: Rituximab; Procedure: Allogeneic Stem Cell Transplantation; Drug: Thymoglobulin; Drug: Tacrolimus; Drug: Methotrexate; Drug: G-CSF
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Pfizer
Recruiting - verified May 2013
Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 1

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: tiotropium bromide; Drug: Placebo
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified June 2013
Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Interventions: Drug: Paclitaxel; Drug: Bevacizumab [Avastin]; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified June 2013
Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 2

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: tiotropium bromide; Drug: Placebo
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified June 2013
An Observational Study on Spermatogenesis in Male Renal Transplant Recipients Receiving Valcyte (Valganciclovir) Versus Untreated Matched Controls

Condition: Transplantation, Cytomegalovirus Infections
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified June 2013
A Study of LY2228820 for Recurrent Ovarian Cancer

Conditions: Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer
Interventions: Drug: LY2228820; Drug: Carboplatin; Drug: Placebo; Drug: Gemcitabine
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified June 2013
Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With SAR236553 (REGN727) (ODYSSEY Outcomes)

Condition: Acute Coronary Syndrome
Interventions: Drug: SAR236553 (REGN727); Other: placebo
Sponsors: Sanofi; Sanofi; Regeneron Pharmaceuticals
Recruiting - verified June 2013
Technology and Navigation to Improve Survivorship Care

Condition: Breast Cancer
Interventions: Behavioral: Audio Recorded Interviews; Behavioral: Focus Group Session; Other: Website Session; Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified June 2013
Observational Study of Optical Coherence Tomography (OCT) in Patients Undergoing Fractional Flow Reserve (FFR) and Percutaneous Coronary Intervention

Condition: Single or Multi Vessel Disease
Intervention:
Sponsors: St. Jude Medical; St. Jude Medical
Recruiting - verified May 2013
A Phase I/II Evaluation of ADXS11-001, Mitomycin, 5-fluorouracil (5-FU) and IMRT for Anal Cancer

Condition: Anal Cancer
Intervention: Biological: Advaxis
Sponsors: Brown University; Brown University; Rhode Island Hospital; The Miriam Hospital; Montefiore Medical Center; M.D. Anderson Cancer Center; Boston Medical Center; Ohio State University Comprehensive Cancer Center; University of Pennsylvania
Recruiting - verified June 2013
Phase II Phosphatidylinositol 3-Kinase (PI3K) Inhibitor in Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas (NHL)

Condition: Lymphoma, Non-Hodgkin
Intervention: Drug: BAY80-6946
Sponsors: Bayer; Bayer
Recruiting - verified May 2013
Mechanisms of Improved Wound Healing and Protein Synthesis of Insulin and Metformin

Conditions: Insulin Resistance; Hypermetabolism; Hyperglycemia
Interventions: Drug: Metformin; Drug: Sugar pill
Sponsors: The University of Texas, Galveston; The University of Texas, Galveston; Shriners Hospitals for Children
Recruiting - verified May 2013
Efficacy and Safety of SAR339658 in Patients With Moderate to Severe Ulcerative Colitis

Condition: Ulcerative Colitis
Interventions: Drug: SAR339658; Other: Placebo
Sponsors: Sanofi; Sanofi
Recruiting - verified June 2013
A Study To Assess The Safety Of PF-05335810 In Hypercholesterolemic Subjects

Condition: Hypercholesterolemia
Interventions: Biological: PF-05335810 Dose A; Biological: PF-05335810 Dose B; Biological: Placebo; Biological: PF-05335810 Dose B; Biological: Placebo; Biological: PF-04950615 Dose A; Biological: PF-04950615 Dose A; Biological: PF-05335810 Dose C; Biological: Placebo; Biological: PF-05335810 Dose C; Biological: Placebo; Biological: PF-04950615; Biological: PF-05335810 Dose D; Biological: Placebo; Biological: PF-05335810 Dose E; Biological: PF-05335810 Dose D; Biological: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
Open Label Extension in Adults With Binge Eating Disorder (BED)

Condition: Binge Eating Disorder
Intervention: Drug: Lisdexamfetamine dimesylate
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified June 2013
Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers

Condition: Venous Leg Ulcers
Interventions: Biological: HP-802-247; Biological: Vehicle
Sponsors: Healthpoint; Healthpoint; Smith & Nephew, Inc.
Recruiting - verified June 2013
Trial of Low Field Magnetic Stimulation Augmentation of Antidepressant Therapy in Treatment-Resistant Depression

Condition: Treatment Resistant Depression
Interventions: Device: Low Frequency Magnetic Stimulation (LFMS); Device: Sham LFMS
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; National Institute of Mental Health (NIMH); Yale University; Mount Sinai School of Medicine; University of Texas Southwestern Medical Center; University of Alabama at Birmingham; Emory University
Recruiting - verified June 2013
CD19-specific T-cell for Chronic Lymphocytic Leukemia (CLL)

Conditions: Advanced Cancers; Leukemia
Interventions: Procedure: Leukapheresis; Drug: Fludarabine; Drug: Cyclophosphamide; Procedure: T-cell Infusion
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified June 2013
Phase 2 Efficacy Trial of Z160 in Lumbosacral Radiculopathy

Condition: Lumbosacral Radiculopathy
Interventions: Drug: z160; Drug: Placebo
Sponsors: Zalicus; Zalicus
Recruiting - verified June 2013
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)

Condition: Fibrosing Colonopathy in Patients With Cystic Fibrosis
Interventions: Biological: CREON; Biological: ZENPEP; Biological: ULTRESA; Biological: PANCREAZE; Biological: other non-sponsor pancreatic enzyme replacement therapy; Other: No pancreatic enzyme replacement therapy
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott); Aptalis Pharma; Cystic Fibrosis Foundation; Janssen Research & Development, LLC
Recruiting - verified May 2013
The Performance of the APPY1 Test in the Evaluation of Possible Acute Appendicitis

Condition: Acute Appendicitis
Intervention:
Sponsors: Venaxis, Inc.; Venaxis, Inc.
Recruiting - verified May 2013
Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer

Condition: Thyroid Cancer
Interventions: Drug: Vemurafenib (All Groups); Drug: Vemurafenib (Post Surgery) - Group A + C; Other: Post Surgery - Group B
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified June 2013
Evaluating the Efficacy, Safety and Tolerability of Tenofovir DF in Pediatric Patients With Chronic Hepatitis B Infection

Condition: Chronic Hepatitis B Infection
Interventions: Drug: Tenofovir DF; Drug: Tenofovir DF Placebo
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified February 2013
Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003 AM5)

Conditions: Genital Warts; Anal Cancer; Anal Intraepithelial Neoplasia
Intervention: Biological: V503 Vaccine
Sponsors: Merck; Merck
Recruiting - verified May 2013
Observational Study of Real World Effectiveness Data and Safety in Patients Receiving Pazopanib With Advanced or Metastatic Renal Cell Carcinoma

Condition: Carcinoma, Renal Cell
Intervention: Drug: Pazopanib
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified June 2013
A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: empagliflozin (low dose qd); Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Empagliflozin (high dose qd); Drug: empagliflozin (high dose bid); Drug: Placebo; Drug: empagliflozin (low dose bid)
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified June 2013
Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy

Condition: Systemic Lupus Erythematosus
Interventions: Drug: belimumab 10mg/kg; Other: placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline; Human Genome Sciences Inc., a GSK Company
Recruiting - verified May 2013
Efficacy at 16 Weeks and Long Term Efficacy, Safety and Tolerability up to 5 Years of Secukinumab in Patients With Active Ankylosing Spondylitis

Condition: Ankylosing Spondylitis
Interventions: Biological: AIN457; Biological: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013
A Phase IIb, Open-Label, Dose Ranging Study of 13-Valent Pneumococcal Conjugate Vaccine in Adults 55 Through 74 Years of Age Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine

Condition: Pneumococcal Infections
Intervention: Biological: Prevnar 13 (PVC13)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified January 2013
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Condition: Chronic Myeloid Leukemia
Interventions: Drug: ponatinib; Drug: imatinib (Gleevec/ Glivec)
Sponsors: Ariad Pharmaceuticals; Ariad Pharmaceuticals
Recruiting - verified June 2013
A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3)

Condition: Psoriasis
Interventions: Drug: 80 mg ixekizumab; Drug: 50 mg etanercept; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified June 2013
A Social Media Approach to Improve Genetic Risk Communication Phase I

Condition: Hereditary Diseases
Interventions: Behavioral: Audiotaped Focus Group; Behavioral: Demographic Questionnaire; Behavioral: Audiotaped Interview; Behavioral: WAMMI Inventory
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Duncan Family Institute
Recruiting - verified June 2013
Efficacy and Safety of SAR236553 (REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Combo II)

Condition: Hypercholesterolemia
Interventions: Drug: SAR236553 (REGN727); Drug: matching placebo SAR236553 (REGN727); Drug: Ezetimibe; Drug: matching placebo for Ezetimibe
Sponsors: Sanofi; Sanofi; Regeneron Pharmaceuticals
Recruiting - verified June 2013
Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF

Condition: Cystic Fibrosis
Interventions: Drug: Aztreonam for Inhalation Solution (AZLI); Drug: Placebo
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified July 2012
Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Rheumatoid Arthritis

Condition: Rheumatoid Arthritis
Intervention: Drug: Secukinumab
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified June 2013
Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis and Maintenance of Healed Erosive Esophagitis and Relief of Heartburn in Adolescents

Conditions: Gastroesophageal Reflux Disease; Erosive Esophagitis
Interventions: Drug: Dexlansoprazole; Drug: Dexlansoprazole; Drug: Placebo
Sponsors: Takeda; Takeda
Recruiting - verified June 2013
Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules in Treating Symptomatic Non-Erosive Gastroesophageal Reflux Disease in Adolescents

Condition: Gastroesophageal Reflux Disease
Intervention: Drug: Dexlansoprazole
Sponsors: Takeda; Takeda
Recruiting - verified June 2013
Phase 1b Safety and Efficacy Study of TRU-016 and Rituximab in Chronic Lymphocytic Leukemia

Condition: Chronic Lymphocytic Leukemia
Interventions: Biological: 20 mg/kg TRU-016 + Rituximab; Biological: 10 mg/kg TRU-016 + Rituximab
Sponsors: Emergent Product Development Seattle LLC; Emergent Product Development Seattle LLC
Recruiting - verified May 2013
Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Ischemic Heart Failure.

Condition: Ischemic Heart Failure
Interventions: Biological: JVS-100 15 mg dose Injection; Biological: Placebo Injection; Biological: JVS-100 30 mg dose injection
Sponsors: Juventas Therapeutics, Inc.; Juventas Therapeutics, Inc.
Recruiting - verified May 2013
A Phase 2 Study Evaluating Ganetespib in Women With Metastatic HER2+ or Triple Negative Breast Cancer

Conditions: Breast Cancer; HER-2 Positive Breast Cancer; Triple Negative Breast Cancer
Intervention: Drug: ganetespib
Sponsors: Synta Pharmaceuticals Corp.; Synta Pharmaceuticals Corp.
Recruiting - verified May 2013
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Conditions: Inflammation; Rheumatoid Arthritis
Interventions: Drug: NNC0109-0012; Drug: placebo
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified June 2013
Sacroiliac Joint Fusion With iFuse Implant System (SIFI)

Conditions: Degenerative Sacroiliitis; Sacroiliac Joint Disruption
Intervention:
Sponsors: SI-BONE, Inc.; SI-BONE, Inc.
Recruiting - verified June 2013
Rheumatoid Arthritis Extension Trial For Subjects Who Have Participated In Other PF-05280586 Trials (REFLECTIONS B328-04)

Condition: Rheumatoid Arthritis
Interventions: Biological: Rituximab-Pfizer (PF-05280586) x 3 courses; Biological: Rituximab-EU+ Rituximab-Pfizer x 2 Courses; Biological: Rituximab-US + Rituximab-Pfizer x 2 Courses
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
A Study of Oral CFG920 in Patients With Castration Resistant Prostate Cancer

Condition: Prostatic Neoplasms
Intervention: Drug: CFG920
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified June 2013
Study of Vemurafenib, Carboplatin, and Paclitaxel

Condition: Advanced Cancers
Interventions: Drug: Vemurafenib; Drug: Carboplatin; Drug: Paclitaxel
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified June 2013
Adjunctive Renal Sympathetic Denervation to Modify Hypertension as Upstream Therapy in the Treatment of Atrial Fibrillation

Conditions: Uncontrolled Hypertension; Atrial Fibrillation
Intervention: Device: Renal sympathetic denervation
Sponsors: Mount Sinai School of Medicine; Vivek Reddy
Recruiting - verified May 2013
Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Moderate Persistent Asthma

Condition: Asthma
Interventions: Drug: Tiotropium low dose QD; Drug: Tiotropium high dose QD; Drug: Placebo
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Pfizer
Recruiting - verified June 2013
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Condition: Relapsing-remitting Multiple Sclerosis (RRMS)
Interventions: Drug: fingolimod; Drug: copaxone
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified June 2013
Effectiveness of Beclomethasone Dipropionate Nasal Aerosol for Perennial Allergic Rhinitis

Condition: Perennial Allergic Rhinitis (PAR)
Intervention: Drug: Beclomethasone Dipropionate (BDP) Nasal Aerosol
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries; United BioSource Corporation
Recruiting - verified May 2013
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212

Condition: Cancer
Intervention: Drug: GSK1120212
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
A Phase 2 Dose Escalating Study to Evaluate the Safety and Efficacy of CB-03-01 Cream in Subjects With Facial Acne Vulgaris

Condition: Acne Vulgaris
Interventions: Drug: CB-03-01; Drug: Vehicle; Drug: CB-03-01
Sponsors: Intrepid Therapeutics, Inc.; Intrepid Therapeutics, Inc.
Recruiting - verified June 2013
A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer

Condition: Non-Small Cell Lung Cancer
Interventions: Drug: Custirsen + Docetaxel; Drug: Docetaxel
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Recruiting - verified June 2013
National Parkinson Foundation Quality Improvement Initiative

Condition: Parkinson's Disease
Intervention:
Sponsors: National Parkinson Foundation; National Parkinson Foundation
Recruiting - verified May 2013
A Study of Ketamine in Patients With Treatment-resistant Depression

Condition: Major Depressive Disorder
Interventions: Drug: Placebo; Drug: Ketamine
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified June 2013
Osteonecrosis of the Jaw (ONJ) Case Registry

Condition: Osteonecrosis of the Jaw (ONJ)
Intervention:
Sponsors: Amgen; Amgen
Recruiting - verified June 2013
Safety and Efficacy of the Journey II BCS Total Knee System

Condition: Osteoarthritis, Knee
Intervention: Device: TKA with Journey II BCS Total Knee System
Sponsors: Smith & Nephew, Inc.; Smith & Nephew, Inc.
Recruiting - verified June 2013
Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Armodafinil in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy

Condition: Narcolepsy
Intervention: Drug: Armodafinil
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Recruiting - verified May 2013
Study to Evaluate a New Device Designed to Collect Heart Activity and Body Movement Data

Condition: Epilepsy
Intervention: Device: Cyberonics Investigational Accelerometry Device & Cyberonics Investigational Weighted Simulant Device
Sponsors: Cyberonics, Inc.; Cyberonics, Inc.
Recruiting - verified June 2013
A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)

Conditions: Type 2 Diabetes; Chronic Kidney Disease
Interventions: Drug: Dulaglutide; Drug: Insulin glargine; Drug: Insulin lispro
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified June 2013
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age

Condition: Measles, Mumps and Rubella Diseases
Interventions: Biological: Priorix®; Biological: Merck's M-M-R®II, Measles, Mumps, and Rubella Virus Vaccine (also known as M-M-R Vax Pro™); Biological: Kinrix®; Biological: Varivax®
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
A Study Of PF-00547659 In Patients With Moderate To Severe Ulcerative Colitis

Condition: Ulcerative Colitis
Interventions: Drug: PF-00547659 SC Injection; Drug: PF-00547659 SC Injection; Drug: PF-00547659 SC Injection; Drug: PF-00547659 SC Injection; Drug: PF-00547659 SC Injection
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763

Condition: Type II Diabetes
Interventions: Drug: Placebo; Drug: Sitagliptin; Drug: LEZ763
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013
A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis

Condition: Idiopathic Pulmonary Fibrosis
Interventions: Biological: Tralokinumab; Biological: Tralokinumab; Other: Placebo
Sponsors: MedImmune LLC; MedImmune LLC
Recruiting - verified May 2013
A Study of RO5045337 in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia

Condition: Myelogenous Leukemia, Acute
Interventions: Drug: RO5045377; Drug: RO5045377; Drug: cytarabine; Drug: cytarabine
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
Assessment of the Effects of Enclomiphene Citrate on Bone Mineral Density in Men With Secondary Hypogonadism

Condition: Effect of Treatment on Bone Mineral Density
Interventions: Drug: enclomiphene citrate; Drug: Placebo
Sponsors: Repros Therapeutics Inc.; Repros Therapeutics Inc.
Recruiting - verified June 2013
Efficacy and Safety of SAR236553 (REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY High FH)

Condition: Hypercholesterolaemia
Interventions: Drug: SAR236553 (REGN727); Drug: placebo
Sponsors: Sanofi; Sanofi; Regeneron Pharmaceuticals
Recruiting - verified June 2013
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease

Condition: Management of Anemia in Chronic Kidney Disease Patients Not on Dialysis.
Intervention: Biological: Darbepoetin alfa
Sponsors: Amgen; Amgen
Recruiting - verified June 2013
Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3

Condition: Hepatitis C Virus (HCV)
Interventions: Biological: Pegylated interferon lambda (pegIFNλ); Biological: Pegylated interferon lambda (pegIFNλ); Biological: Pegylated interferon alfa-2a (pegIFNα-2a); Drug: Ribavirin; Drug: Ribavirin; Drug: Daclatasvir; Drug: Placebo matching Daclatasvir
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified June 2013
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Condition: Idiopathic Pulmonary Fibrosis
Intervention: Drug: BIBF 1120
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified June 2013
Comparison of Multiport Versus Uniport Soft-tip Catheter for Administering Epidural Pain Relief During Labor and Delivery

Condition: Pain During Labor and Delivery
Interventions: Device: Perifix soft-tip uniport catheter; Device: Perifix soft-tip multiport
Sponsors: Baylor Research Institute; Baylor Research Institute; University of Texas Southwestern Medical Center
Recruiting - verified May 2013
A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With LCL161 in Patients With Triple Negative Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Paclitaxel + LCL161; Drug: paclitaxel
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified June 2013
Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Conditions: Type 2 Diabetes; Cardiovascular Disease
Interventions: Drug: TAK-875; Drug: TAK-875 Placebo
Sponsors: Takeda; Takeda
Recruiting - verified June 2013
Lung Volume Reduction Coil for Treatment in Patients With Emphysema (RENEW) Study

Condition: Emphysema
Intervention: Device: PneumRx RePneu Lung Volume Reduction Coil (RePneu LVRC) System
Sponsors: PneumRx, Inc.; PneumRx, Inc.
Recruiting - verified December 2012
A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy (SIRROUND)

Condition: Arthritis, Rheumatoid
Interventions: Drug: Placebo; Drug: Placebo; Drug: Sirukumab; Drug: Sirukumab; Drug: Sirukumab
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified June 2013
Small Cell Cervix Survey

Condition: Cervical Cancer
Intervention: Behavioral: Questionnaires
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer

Condition: Metastatic Pancreatic Cancer
Interventions: Drug: nab-paclitaxel; Drug: gemcitabine; Drug: placebo; Drug: M402
Sponsors: Momenta Pharmaceuticals, Inc.; Momenta Pharmaceuticals, Inc.
Recruiting - verified June 2013
A Study of CNTO 136 (Sirukumab), Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Disease-Modifying Antirheumatic Drug (DMARD) Therapy (SIRROUND)

Condition: Arthritis, Rheumatoid
Interventions: Drug: Placebo; Drug: Placebo; Drug: Sirukumab; Drug: Sirukumab; Drug: Sirukumab
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified June 2013
Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors

Conditions: Childhood Central Nervous System Choriocarcinoma; Childhood Central Nervous System Embryonal Tumor; Childhood Central Nervous System Germ Cell Tumor; Childhood Central Nervous System Germinoma; Childhood Central Nervous System Mixed Germ Cell Tumor; Childhood Central Nervous System Teratoma; Childhood Central Nervous System Yolk Sac Tumor; Childhood Pineal Parenchymal Tumor
Interventions: Procedure: therapeutic conventional surgery; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy; Drug: carboplatin; Drug: etoposide; Drug: ifosfamide
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013
Efficacy and Safety of TBS-2 Testosterone Gel in Women With Acquired Female Orgasmic Disorder

Condition: Female Orgasmic Disorder
Interventions: Drug: Placebo; Drug: Low dose TBS-2; Drug: Medium dose TBS-2; Drug: High dose TBS-2
Sponsors: Trimel Biopharma SRL; Trimel Biopharma SRL
Recruiting - verified June 2013
A Mixed-Methods Approach to Understanding Factors Associated With Cervical Cancer Screening Utilization Among Low-Income, HIV-Positive Women

Conditions: Cancer Prevention; Cervix
Interventions: Behavioral: Cognitive Interview; Behavioral: Questionnaires; Behavioral: Focus Groups
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified May 2013
A Study to Evaluate the Safety and Efficacy of AC607 for the Treatment of Kidney Injury in Cardiac Surgery Subjects

Condition: Acute Kidney Injury
Interventions: Biological: AC607; Biological: Vehicle Only
Sponsors: AlloCure Inc.; AlloCure Inc.
Recruiting - verified June 2013
Preventing Sexual Dysfunction With Aromatase Inhibitors

Condition: Breast Cancer
Interventions: Behavioral: Questionnaires; Other: Education Materials; Other: Luvena; Other: Hyalo-Gyn; Other: Vaginal Lubricant; Behavioral: Interactive Internet-Based Website; Behavioral: Telephone Counseling.
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Fidia Farmaceutici s.p.a.; Laclede Inc. Healthcare Products
Recruiting - verified May 2013
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Interventions: Drug: Ibrutinib; Drug: Bendamustine hydrochloride; Drug: Rituximab; Drug: Placebo
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC; Pharmacyclics
Recruiting - verified June 2013
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Condition: Breast Cancer
Interventions: Drug: BKM120 Matching placebo; Drug: Fulvestrant; Drug: BKM120
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013
Comparison of a Novel 22-gauge Core Biopsy Needle

Condition: Solid Pancreatic Mass Lesions
Intervention: Device: Novel 22-gauge Core Biopsy Needle + Standard Biopsy Needle
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013
A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2)

Condition: Psoriasis
Interventions: Drug: 80 mg ixekizumab Dosing Regimen; Drug: 50 mg etanercept; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified June 2013
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Condition: Melanoma
Interventions: Drug: Dabrafenib; Drug: Vemurafenib; Drug: Trametinib
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified June 2013
A Noninferiority Study of Alglucosidase Alfa Manufactured at the 160 L and 4000 L Scales in Patients With Infantile-Onset Pompe Disease Who Have Never Been Treated

Conditions: Pompe Disease (Infantile-Onset); Glycogen Storage Disease Type II (GSD II); Glycogenosis 2; Acid Maltase Deficiency
Interventions: Biological: alglucosidase alfa; Biological: alglucosidase alfa
Sponsors: Genzyme; Genzyme
Recruiting - verified May 2013
A Study to Evaluate the Effect of Belimumab on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE)

Condition: Systemic Lupus Erythematosus
Interventions: Biological: Belimumab plus Early Vaccination; Biological: Belimumab plus Late Vaccination
Sponsors: GlaxoSmithKline; Human Genome Sciences Inc., a GSK Company; GlaxoSmithKline
Recruiting - verified February 2013
A Treatment Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma

Condition: Sarcoma
Interventions: Drug: Gemcitabine and Pazopanib; Drug: Gemcitabine and Docetaxel
Sponsors: Medical University of South Carolina; Medical University of South Carolina; GlaxoSmithKline
Recruiting - verified June 2013
A Prospective Phase III Trial to Compare Stereotactic Radiosurgery Versus Whole Brain Radiation Therapy

Condition: Brain Neoplasms
Interventions: Radiation: Stereotactic Radiosurgery (SRS); Radiation: Whole Brain Radiation Therapy (WBRT); Behavioral: Questionnaires; Behavioral: Cognitive Function Tests
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified June 2013
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative Gastroesophageal Cancer

Condition: Gastric Cancer
Interventions: Drug: onartuzumab; Drug: Placebo; Drug: mFOLFOX6
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche; Genentech
Recruiting - verified June 2013
A Study of LY2784544 in Participants With Myeloproliferative Neoplasms

Condition: Neoplasms, Hematologic
Intervention: Drug: 120 mg LY2784544
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified June 2013
Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial

Condition: Solid Tumors
Interventions: Drug: Iniparib (SAR240550/BSI-201); Drug: Carboplatin; Drug: Doxorubicin HCL liposome injection; Drug: Gemcitabine; Drug: Irinotecan; Drug: Paclitaxel; Drug: Topotecan
Sponsors: Sanofi; Sanofi
Recruiting - verified June 2013
Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Patients With Locally Advanced or Metastatic Pancreatic Cancer

Conditions: Adenocarcinoma of the Pancreas; BRCA1 Mutation Carrier; BRCA2 Mutation Carrier; Recurrent Pancreatic Cancer; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer
Interventions: Drug: veliparib; Drug: gemcitabine hydrochloride; Drug: cisplatin
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy

Condition: Locally Advanced (Unresectable) or Metastatic Adenocarcinoma of the Gastric and Gastro-esophageal Junction
Interventions: Biological: Ipilimumab; Other: Best Supportive care (BSC)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified June 2013
Preventative Trial of DFMO in Patients With High Risk Neuroblastoma in Remission

Condition: Neuroblastoma in Remission
Intervention: Drug: DFMO
Sponsors: Van Andel Research Institute; Giselle Sholler; Cancer Prevention Pharmaceuticals, Inc.; University of Arizona; University of Hawaii; University of Vermont
Recruiting - verified May 2013
Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement (SURTAVI).

Condition: Severe Aortic Stenosis
Interventions: Device: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI); Procedure: Surgical Aortic Valve Replacement (SAVR)
Sponsors: Medtronic Cardiovascular; Medtronic Cardiovascular
Recruiting - verified June 2013
Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)

Conditions: Advanced Renal Cell Carcinoma; Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma
Interventions: Drug: Standard Treatment; Biological: AGS-003
Sponsors: Argos Therapeutics; Argos Therapeutics
Recruiting - verified June 2013
A Study in Recurrent Glioblastoma (GB)

Condition: Glioblastoma
Interventions: Drug: LY2157299 monohydrate; Drug: Lomustine; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified June 2013
Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma

Conditions: Brain Neoplasms; Central Nervous System Neoplasms
Interventions: Drug: TPI287; Drug: Bevacizumab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Archer Biosciences, Inc.
Recruiting - verified May 2013
Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Condition: Venous Thromboembolism (VTE)
Interventions: Drug: Betrixaban; Drug: Enoxaparin
Sponsors: Portola Pharmaceuticals; Portola Pharmaceuticals
Recruiting - verified June 2013
Safety and Tolerability Study of SOR-C13 in Subjects With Advanced Cancers Commonly Known to Express the TRPV6 Channel

Condition: Cancer
Intervention: Drug: SOR-C13
Sponsors: Soricimed Biopharma Inc; Soricimed Biopharma Inc
Recruiting - verified May 2013
Efficacy, Safety And Tolerability Study Of RN6G In Subjects With Geographic Atrophy Secondary to Age-related Macular Degeneration

Condition: Age-Related Maculopathy
Interventions: Biological: RN6G; Biological: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications

Condition: Asthma
Interventions: Drug: Fluticasone propionate DPI Dose 1; Drug: Fluticasone propionate DPI Dose 2; Drug: Fluticasone propionate DPI Dose 3; Drug: Fluticasone propionate DPI Dose 4; Other: Placebo DPI; Drug: Flovent Diskus 250 mcg
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Recruiting - verified May 2013
A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours

Conditions: Carcinoid Tumor of the Small Bowel; Neuroendocrine Tumour
Interventions: Drug: Octreotide; Drug: Octreotide; Drug: 177Lu-DOTA0-Tyr3-Octreotate
Sponsors: Advanced Accelerator Applications; Advanced Accelerator Applications; Pierrel Research Europe GmbH
Recruiting - verified June 2013
Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing-Remitting Multiple Sclerosis

Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Biological: MEDI-551; Drug: Placebo
Sponsors: MedImmune LLC; MedImmune LLC; PPD
Recruiting - verified June 2013
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: cabazitaxel, prednisone, custirsen sodium; Drug: cabazitaxel, prednisone
Sponsors: OncoGenex Technologies; OncoGenex Technologies; Teva Pharmaceutical Industries
Recruiting - verified May 2013
Study To Evaluate Cardiac Assessments Following Different Treatments Of Smoking Cessation Medications In Subjects With And Without Psychiatric Disorders.

Condition: Smoking Cessation
Interventions: Drug: placebo; Drug: varenicline tartrate; Drug: bupropion hydrochloride; Drug: Nicotine Replacement Therapy Patch
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort

Condition: Huntington's Disease
Intervention:
Sponsors: CHDI Foundation, Inc.; CHDI Foundation, Inc.
Recruiting - verified May 2013
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation

Condition: Breast Cancer
Interventions: Drug: Paclitaxel; Drug: BKM120 matching placebo; Drug: BKM120
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified June 2013
Registrational Study With AMG 785 to Treat Postmenopausal Osteoporosis

Condition: Postmenopausal Osteoporosis
Interventions: Drug: AMG 785; Drug: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified June 2013
A Research Study of an Investigational Drug ALO-02 (Oxycodone Hydrochloride and Naltrexone Hydrochloride) in Patients With Moderate to Severe Chronic Low Back Pain

Conditions: Chronic Pain; Low Back Pain; Analgesia
Interventions: Drug: ALO-02; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Minerva Pivotal Study to Evaluate Safety and Efficacy of the Aurora Endometrial Ablation System Compared to Hysteroscopic Rollerball Ablation

Condition: Menorrhagia
Interventions: Device: Aurora Endometrial Ablation; Device: Rollerball Ablation/Resection
Sponsors: Minerva Surgical, Inc.; Minerva Surgical, Inc.
Recruiting - verified May 2013
Hepatic Impairment Study For Crizotinib In Advanced Cancer Patients

Condition: Advanced Cancer
Interventions: Drug: crizotinib; Drug: crizotinib; Drug: crizotinib; Drug: crizotinib; Drug: crizotinib
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
To Evaluate the Safety, Tolerability and Efficacy of Calcipotriene Foam, 0.005%, Versus Vehicle Foam in Pediatric Subjects (Ages 2-11) With Plaque Psoriasis

Condition: Psoriasis
Interventions: Drug: STF 115469 Foam; Drug: Vehicle Foam
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Condition: Multiple Myeloma
Interventions: Drug: Carfilzomib plus dexamethasone; Drug: Velcade plus dexamethasone
Sponsors: Onyx Pharmaceuticals; Onyx Pharmaceuticals
Recruiting - verified June 2013
This is an Open-label, Multi-center, Extension Study Designed to Evaluate the Longer Term Safety, Tolerability and Effectiveness of Lurasidone, Flexibly Dosed, Adjunctive to Lithium or Divalproex for the Treatment of Subjects With Bipolar I Disorder Who Have Participated in Study D1050296

Condition: Bipolar I Disorder
Intervention: Drug: Lurasidone
Sponsors: Sunovion; Sunovion
Recruiting - verified May 2013
A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A

Condition: Hemophilia A
Intervention: Biological: BAY94-9027
Sponsors: Bayer; Bayer
Recruiting - verified May 2013
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia

Condition: Schizophrenia
Intervention: Drug: Lurasidone
Sponsors: Sunovion; Sunovion
Recruiting - verified May 2013
Safety and Efficacy of RLX030 in Pregnant Women With Pre- Eclampsia

Condition: Pre-eclampsia
Interventions: Drug: Placebo; Drug: RLX030
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013
The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)

Condition: Myelodysplastic Syndrome
Interventions: Drug: Oral Azacitidine; Drug: Placebo
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified June 2013
A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis

Condition: Arthritis, Rheumatoid
Interventions: Drug: ASP015K; Drug: Placebo
Sponsors: Astellas Pharma Inc; Astellas Pharma Global Development, Inc.
Recruiting - verified June 2013
A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia

Condition: Acute Lymphoblastic Leukemia
Interventions: Drug: inotuzumab ozogamicin; Drug: FLAG (fludarabine, cytarabine and G-CSF); Drug: HIDAC (high dose cytarabine); Drug: cytarabine and mitoxantrone
Sponsors: Pfizer; Pfizer; Union Chimique Belge
Recruiting - verified June 2013
Effects of a Walking Program and Inspiratory Muscle Training on Individuals With Chronic Heart Failure

Conditions: Heart Failure NYHA Class III; Heart Failure NYHA Class II
Interventions: Behavioral: High-intensity IMT plus walking; Behavioral: Low-intensity IMT plus walking
Sponsors: Texas Woman's University; Texas Woman's University; Presbyterian Hospital of Dallas, Texas Health Resources
Recruiting - verified May 2013
To Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Calcipotriene 0.005%, Applied Under Maximal Use Conditions in 12-16 Year Olds With Plaque Psoriasis

Condition: Psoriasis
Intervention: Drug: calcipotriene
Sponsors: GlaxoSmithKline; Stiefel, a GSK Company; GlaxoSmithKline
Recruiting - verified May 2013
Safety and Feasibility Trial of Adipose-Derived Regenerative Cells in the Treatment of Chronic Myocardial Ischemia

Condition: Myocardial Ischemia
Interventions: Device: ADRCs processed by the Celution System; Device: Placebo Comparator: Lactated Ringer's and Subject's Blood
Sponsors: Cytori Therapeutics; Cytori Therapeutics
Recruiting - verified June 2013
A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects Who Have Had an Inadequate Response to Methotrexate

Condition: Arthritis, Rheumatoid
Interventions: Drug: ASP015K; Drug: Placebo
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc
Recruiting - verified June 2013
Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022 AM3)

Condition: Major Depressive Disorder, Recurrent
Interventions: Drug: MK-6096; Drug: Placebo
Sponsors: Merck; Merck
Recruiting - verified May 2013
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma

Conditions: Neurofibromatosis Type 1; Recurrent Childhood Pilocytic Astrocytoma; Recurrent Childhood Visual Pathway Glioma
Intervention: Drug: lenalidomide
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified June 2013
An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension

Condition: Pulmonary Arterial Hypertension
Intervention: Drug: UT-15C (treprostinil diethanolamine)
Sponsors: United Therapeutics; United Therapeutics
Not yet recruiting - verified June 2013
Trial of the Early Combination of Oral Treprostinil With a PDE-5 Inhibitor or ERA in Subjects With Pulmonary Arterial Hypertension

Condition: Pulmonary Arterial Hypertension
Interventions: Drug: UT-15C (treprostinil diethanolamine); Drug: Placebo
Sponsors: United Therapeutics; United Therapeutics
Recruiting - verified June 2013
Study to Evaluate the Pharmacodynamic and Pharmacokinetic Effects of LX4211 in Subjects With Type 2 Diabetes and Renal Impairment

Conditions: Type 2 Diabetes Mellitus; Renal Impairment
Interventions: Drug: LX4211; Drug: LX4211 Placebo
Sponsors: Lexicon Pharmaceuticals; Lexicon Pharmaceuticals
Recruiting - verified May 2013
Bevacizumab, Temsirolimus, Valproic Acid, Cetuximab

Condition: Advanced Cancers
Interventions: Drug: Temsirolimus; Drug: Bevacizumab; Drug: Valproic Acid; Drug: Cetuximab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified June 2013
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder

Condition: Attention-deficit/Hyperactivity Disorder
Interventions: Drug: Lisdexamfetamine dimesylate; Drug: Methylphenidate Hydrochloride; Drug: Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified May 2013
Comparison of TAK-875 to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes

Condition: Glycemic Control
Interventions: Drug: TAK-875; Drug: Sitagliptin; Drug: Placebo
Sponsors: Takeda; Takeda Global Research & Development Centre (Europe) Ltd.
Recruiting - verified June 2013
A Trial of 18F-AV-133 Positron Emission Tomography (PET) Imaging to Differentiate Subjects With Parkinson's Disease (PD) From Other Movement Disorders

Conditions: Parkinson's Disease; Primary Parkinsonism; Lewy Body Parkinson's Disease
Intervention: Drug: 18F-AV-133
Sponsors: Avid Radiopharmaceuticals; Avid Radiopharmaceuticals
Recruiting - verified June 2013
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)

Conditions: Chronic Inflammatory Demyelinating Polyneuropathy; Polyradiculoneuropathy
Interventions: Biological: IgPro20; Biological: Placebo
Sponsors: CSL Behring; CSL Behring; Parexel
Recruiting - verified May 2013
A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Condition: Acute Myeloid Leukemia
Interventions: Drug: PF-04449913; Drug: Low dose ARA-C (LDAC); Drug: PF-04449913; Drug: Decitabine; Drug: PF-04449913; Drug: Daunorubicin; Drug: Cytarabine; Drug: Pf-04449913; Drug: Daunorubicin; Drug: Cytarabine; Drug: PF-04449913; Drug: Low dose ARA-C (LDAC)
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
Prospective Collection of Female and Male Specimens for PANTHER® System Testing

Conditions: Chlamydia Infections; Gonorrhea
Intervention: Device: APTIMA Assays; PANTHER System
Sponsors: Gen-Probe, Incorporated; Gen-Probe, Incorporated
Recruiting - verified June 2013
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755 AM2)

Condition: Hepatitis C, Chronic
Interventions: Biological: peginterferon alfa-2a; Drug: ribavirin; Drug: boceprevir
Sponsors: Merck; Merck
Recruiting - verified May 2013
Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) On A Background Of Tiotropium Bromide

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: PH-797804; Drug: PH-797804; Drug: PH-797804; Drug: PH-797804; Drug: PH-797804; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
Gadobutrol Pharmacokinetic and Safety Study in Pediatric Subjects Aged <2 Years (Term Newborn Infants to Toddlers 23 Months of Age Inclusive)

Condition: Magnetic Resonance Imaging
Intervention: Drug: Gadobutrol (Gadavist, BAY86-4875)
Sponsors: Bayer; Bayer
Recruiting - verified May 2013
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study

Condition: Irritable Bowel Syndrome With Diarrhea
Interventions: Drug: rifaximin; Drug: placebo
Sponsors: Salix Pharmaceuticals; Salix Pharmaceuticals
Recruiting - verified January 2013
A Comparison of the Safety and Immunogenicity of Various Schedules of Dengue Vaccine in Healthy Adult Volunteers

Condition: Healthy
Intervention: Biological: DENVax
Sponsors: Inviragen Inc.; Inviragen Inc.
Recruiting - verified June 2013
Safety Study of Ornithine Phenylacetate to Treat Patients With Acute Liver Failure Due to Acetaminophen

Conditions: Acute Liver Failure; Acute Liver Injury
Intervention: Drug: Ornithine phenylacetate
Sponsors: University of Texas Southwestern Medical Center; William Lee; Medical University of South Carolina; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Ocera Therapeutics
Recruiting - verified June 2013
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy

Condition: Colorectal Neoplasms
Intervention: Drug: Regorafenib (BAY73-4506)
Sponsors: Bayer; Bayer
Available - verified June 2013
Mechanism and Repository Study for the Red Cell Storage Duration Study

Conditions: Cardiac Surgery; Erythrocyte Transfusion
Intervention:
Sponsors: New England Research Institutes; New England Research Institutes; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified May 2013
Effect of Weight on the Population Pharmacokinetic Analysis of Doxorubicin and Cyclophosphamide

Conditions: Breast Cancer; Obesity
Interventions: Drug: Doxorubicin; Drug: Cyclophosphamide
Sponsors: Texas Tech University Health Sciences Center; Texas Tech University Health Sciences Center; University of Texas
Recruiting - verified June 2013
A Sleep Laboratory Study to Investigate the Safety and Efficacy of the Rotigotine Skin Patch in Subjects With Restless Legs Syndrome and End-Stage Renal Disease Requiring Hemodialysis

Conditions: Restless Legs Syndrome; End-Stage Renal Disease
Interventions: Drug: Rotigotine; Drug: Placebo
Sponsors: UCB, Inc.; UCB BIOSCIENCES GmbH
Recruiting - verified May 2013
Cornea Preservation Time Study

Condition: Cornea Tissue Preservation Time
Intervention: Biological: Cornea tissue transplant
Sponsors: Case Western Reserve University; Case Western Reserve University; National Eye Institute (NEI); Jaeb Center for Health Research
Recruiting - verified May 2013
Effect of Rotigotine on Motor Symptoms in Patients With Advanced Parkinson's Disease (PD) With Motor Fluctuations and Symptoms of Gastrointestinal Dysfunction

Condition: Advanced Parkinson's Disease
Interventions: Drug: Rotigotine; Drug: Placebo
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified June 2013
Deviating the Esophagus in Atrial Fibrillation Ablation

Conditions: Esophageal Deviation; Atrial Fibrillation; Ablation
Intervention: Procedure: esophageal deviation
Sponsors: Mount Sinai School of Medicine; Vivek Reddy; Boston Scientific Corporation
Recruiting - verified May 2013
A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis

Condition: Sclerosis, Systemic
Interventions: Drug: tocilizumab [RoActemra/Actemra]; Drug: Placebo; Drug: tocilizumab [RoActemra/Actemra]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified June 2013
Efficacy and Safety of NVC-422 in the Treatment of Adenoviral Conjunctivitis

Condition: Adenoviral Conjunctivitis
Interventions: Drug: NVC-422 Ophthalmic Solution, 0.33%; Drug: Vehicle Ophthalmic Solution
Sponsors: NovaBay Pharmaceuticals, Inc.; NovaBay Pharmaceuticals, Inc.
Recruiting - verified June 2013
A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients With Schizophrenia

Condition: Schizophrenia
Interventions: Drug: PP3M 175 mg eq.; Drug: PP3M 263 mg eq.; Drug: PP3M 350 mg eq.; Drug: PP3M 525 mg eq.; Drug: Placebo (20% Intralipid emulsion)
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified June 2013
Safety and Efficacy Continued Access Study of the Medtronic CoreValve® System in the Treatment of Symptomatic Severe Aortic Stenosis in Very High Risk Subjects and High Risk Subjects Who Need Aortic Valve Replacement

Condition: Severe Aortic Stenosis
Intervention: Device: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)
Sponsors: Medtronic Cardiovascular; Medtronic Cardiovascular
Recruiting - verified May 2013
Effectiveness of the Compression Belt for Patients With Sacroiliac Joint Pain

Condition: Low Back Pain
Interventions: Behavioral: Lumbopelvic stabilization exercise; Device: Sacroiliac joint belt
Sponsors: Texas Woman's University; Texas Woman's University; Texas Physical Therapy Foundation
Recruiting - verified May 2013
A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)

Condition: Rheumatoid Arthritis
Interventions: Biological: PF-05280586; Biological: MabThera; Biological: Rituxan
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors

Condition: Solid Tumors Harboring a BRAF V600 Mutation
Interventions: Drug: LGX818; Drug: MEK162
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified June 2013
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy

Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: afatinib; Drug: erlotinib
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified June 2013
Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib

Condition: Hematopoietic Neoplasm
Intervention: Drug: SAR302503
Sponsors: Sanofi; Sanofi
Recruiting - verified June 2013
Safety Study of 3 mg/mL Baclofen Injection (Intrathecal) Using A Programmable Pump

Condition: Severe Spasticity
Intervention: Drug: Gablofen® 3 mg/mL (baclofen injection)
Sponsors: CNS Therapeutics; CNS Therapeutics; Pacific-Link Regulatory Consulting LLC
Recruiting - verified June 2013
A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate

Conditions: Metastatic Castration-resistant Prostate Cancer; Metastatic Breast Cancer
Interventions: Drug: Abiraterone acetate; Drug: Abiraterone acetate
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2013
Radium-223 Dichloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases

Condition: Prostatic Neoplasms
Intervention: Drug: Radium-223 dichloride (BAY88-8223)
Sponsors: Bayer; Bayer
Available - verified June 2013
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis

Condition: Rheumatoid Arthritis
Interventions: Biological: Certolizumab Pegol + Methotrexate (MTX); Biological: Placebo + Methotrexate (MTX)
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified June 2013
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis

Condition: Rheumatoid Arthritis
Interventions: Biological: Certolizumab Pegol + Methotrexate (MTX); Biological: Placebo + Methotrexate (MTX)
Sponsors: UCB, Inc.; UCB Pharma SA
Recruiting - verified June 2013
Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects

Condition: Metastatic Breast Cancer
Interventions: Biological: OPT-822/OPT-821; Biological: Phosphate Buffer Saline (PBS)
Sponsors: OBI Pharma, Inc; OBI Pharma, Inc
Recruiting - verified July 2012
Tilt-Table Study of the Clinical Efficacy of Midodrine in Symptomatic Orthostatic Hypotension

Condition: Orthostatic Hypotension
Interventions: Drug: Midodrine HCl; Drug: Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified May 2013
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia

Condition: Schizophrenia
Interventions: Drug: PP3M 175 mg eq.; Drug: PP3M 263 mg eq.; Drug: PP3M 350 mg eq.; Drug: PP3M 525 mg eq.; Drug: Placebo (20% Intralipid); Drug: PP1M 50 mg eq.; Drug: PP1M 75 mg eq.; Drug: PP1M 100 mg eq.; Drug: PP1M 150 mg eq.
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified June 2013
Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab

Condition: Psoriasis
Intervention: Drug: etanercept
Sponsors: Amgen; Amgen
Recruiting - verified June 2013
Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Conditions: Prostate Cancer; Castration Resistant Prostate Cancer; Pain; Prostatic Neoplasms
Interventions: Drug: cabozantinib; Drug: mitoxantrone; Drug: prednisone
Sponsors: Exelixis; Exelixis
Recruiting - verified June 2013
Stereotactic Body Radiotherapy (SBRT) Versus Stereotactic Body Proton Therapy (SBPT)

Condition: Non-small-cell Lung Cancer
Interventions: Radiation: SBRT (stereotactic body radiotherapy); Radiation: SBPT (stereotactic body proton therapy)
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Institutes of Health (NIH)
Recruiting - verified June 2013
Study of Zevalin Versus Observation in Patients at Least 60 Yrs Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy

Conditions: Diffuse Large B-cell Lymphoma; Follicle Center Lymphoma
Intervention: Drug: Zevalin (ibritumomab tiuxetan)
Sponsors: Spectrum Pharmaceuticals, Inc; Spectrum Pharmaceuticals, Inc
Recruiting - verified June 2013
A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer

Condition: Pancreatic Cancer
Interventions: Drug: LY2495655; Drug: Gemcitabine; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified June 2013
Adding Liraglutide to High Dose Insulin: Breaking the Cycle

Conditions: Type 2 Diabetes Mellitus; Obesity
Interventions: Drug: Liraglutide; Drug: Saline
Sponsors: University of Texas Southwestern Medical Center; Ildiko Lingvay; Novo Nordisk
Recruiting - verified June 2013
Pravastatin for Prevention of Preeclampsia

Condition: Preeclampsia
Interventions: Drug: Pravastatin; Drug: Placebo
Sponsors: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); University of Texas; University of Pittsburgh; University of Washington; Indiana University; RTI International
Recruiting - verified May 2013
Beta-Blocker / Ovarian

Conditions: Ovarian Cancer; Primary Peritoneal Carcinoma; Fallopian Tube Cancer
Interventions: Drug: Propranolol; Drug: Chemotherapy; Procedure: Surgery; Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified June 2013
Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and Children

Condition: HIV Infections
Intervention: Drug: Etravirine (ETR)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified June 2013
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer

Conditions: Childhood Hepatocellular Carcinoma; Papillary Thyroid Cancer; Previously Treated Childhood Rhabdomyosarcoma; Recurrent Childhood Liver Cancer; Recurrent Childhood Rhabdomyosarcoma; Recurrent Thyroid Cancer; Recurrent Wilms Tumor and Other Childhood Kidney Tumors
Interventions: Drug: sorafenib tosylate; Other: pharmacological study; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified June 2013
Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Condition: Rheumatoid Arthritis
Interventions: Biological: Certolizumab Pegol + Methotrexate (CZP + MTX); Biological: Adalimumab + Methotrexate (ADA + MTX)
Sponsors: UCB, Inc.; UCB Pharma SA
Recruiting - verified June 2013
Study to Learn if 200mg Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer

Condition: Diffuse Large B-Cell Lymphoma
Intervention: Drug: Fostamatinib
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified June 2013
A Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B

Condition: Hemophilia B
Intervention: Biological: rIX-FP
Sponsors: CSL Behring; CSL Behring
Recruiting - verified June 2013
Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections

Condition: Complicated Skin and Soft Tissue Infection
Interventions: Drug: Ceftaroline fosamil; Drug: Vancomycin; Drug: Aztreonam
Sponsors: AstraZeneca; AstraZeneca; Cerexa, Inc.
Recruiting - verified June 2013
Study of MM-398 With or Without 5-Fluorouracil and Leucovorin, Versus 5-Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer

Condition: Metastatic Pancreatic Cancer
Interventions: Drug: MM-398; Drug: 5 Fluorouracil; Drug: Leucovorin
Sponsors: Merrimack Pharmaceuticals; Merrimack Pharmaceuticals
Recruiting - verified June 2013
The BEACON Study (Breast Cancer Outcomes With NKTR-102)

Conditions: Locally Recurrent Breast Cancer; Metastatic Breast Cancer
Interventions: Drug: NKTR-102; Drug: Treatment of Physician's Choice (TPC)
Sponsors: Nektar Therapeutics; Nektar Therapeutics
Recruiting - verified June 2013
Study of Brentuximab Vedotin (SGN-35) in Pediatric Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma

Conditions: Hodgkin Lymphoma; Anaplastic Large-cell Lymphoma
Intervention: Drug: brentuximab vedotin
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified June 2013
AMR-001 Versus Placebo Post ST Segment Elevation Myocardial Infarction

Condition: ST Segment Elevation Myocardial Infarction
Interventions: Biological: AMR-001; Other: placebo
Sponsors: Amorcyte, Inc.; Amorcyte, Inc.
Recruiting - verified February 2013
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam

Condition: Epilepsy
Intervention: Drug: Lacosamide
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified May 2013
Study to Assess Safety & Efficacy of Sitagliptin as Initial Monotherapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants (MK-0431-083 AM4)

Conditions: Diabetes Mellitus; Type 2 Diabetes
Interventions: Drug: Sitagliptin; Drug: Metformin; Drug: Placebo to sitagliptin; Drug: Placebo to metformin
Sponsors: Merck; Merck
Recruiting - verified May 2013
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma

Condition: High-risk Smoldering Multiple Myeloma
Interventions: Drug: Siltuximab; Drug: Placebo
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified June 2013
A Pharmacokinetics Study for Pediatric Participants With Pulmonary Arterial Hypertension

Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Tadalafil- Tablet
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified June 2013
Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation

Conditions: Atrial Fibrillation; Paroxysmal Atrial Fibrillation; Persistent Atrial Fibrillation
Interventions: Drug: OPC-108459; Drug: Placebo
Sponsors: Otsuka Pharmaceutical Development & Commercialization, Inc.; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified May 2013
Communication Skills Intervention to Promote Transition Into Survivorship

Conditions: Hodgkin's Lymphoma; Diffuse Large B-cell Lymphoma
Intervention:
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; M.D. Anderson Cancer Center; Maimonides Medical Center; H. Lee Moffitt Cancer Center and Research Institute; Rutgers University; University of California, Los Angeles
Recruiting - verified June 2013
Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection

Conditions: HIV Infections; Hepatitis C
Interventions: Drug: Pegylated-Interferon Alfa 2b (PEG-IFN); Drug: Ribavirin (RBV); Drug: Boceprevir (BOC)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified June 2013
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: TAK-875; Drug: TAK-875; Drug: Glimepiride
Sponsors: Takeda; Takeda
Recruiting - verified June 2013
Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A

Conditions: Congenital Bleeding Disorder; Haemophilia A
Intervention: Drug: NNC 0129-0000-1003
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified June 2013
A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids

Condition: Asthma
Interventions: Drug: Placebo; Drug: Flovent Diskus; Drug: Fluticasone propionate DPI Dose 1; Drug: Fluticasone propionate DPI Dose 2; Drug: Fluticasone propionate DPI Dose 3; Drug: Fluticasone propionate DPI Dose 4
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries; PPD
Recruiting - verified May 2013
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma

Conditions: Glioblastoma; Small Cell Glioblastoma; Giant Cell Glioblastoma; Gliosarcoma; Glioblastoma With Oligodendroglial Component
Interventions: Drug: Rindopepimut (CDX-110) with GM-CSF; Drug: Temozolomide; Drug: KLH
Sponsors: Celldex Therapeutics; Celldex Therapeutics
Recruiting - verified June 2013
Efficacy and Safety Study of NeuVax(TM)(Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence

Condition: HER2 Negative Breast Cancer
Interventions: Biological: NeuVax vaccine; Biological: Leukine (sargramostim, GM-CSF) and water for injection
Sponsors: Galena Biopharma, Inc.; Galena Biopharma, Inc.
Recruiting - verified June 2013
An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A

Condition: Hemophilia A
Intervention: Biological: Recombinant Factor VIII (rFVIII)
Sponsors: CSL Behring; CSL Behring
Recruiting - verified June 2013
NBRST: Prospective Neo-adjuvant REGISTRY Trial

Condition: Breast Cancer
Interventions: Device: MammaPrint; Device: BluePrint; Device: TargetPrint; Device: TheraPrint
Sponsors: Agendia; Agendia
Recruiting - verified June 2013
Veliparib With Radiation Therapy in Patients With Inflammatory or Loco-regionally Recurrent Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Veliparib; Radiation: Standard radiation treatment
Sponsors: University of Michigan Cancer Center; University of Michigan Cancer Center
Recruiting - verified June 2013
A Study of the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol

Conditions: Hypercholesterolemia; Coronary Heart Disease
Interventions: Drug: mipomersen sodium 200 mg; Drug: Placebo; Drug: mipomersen sodium 70 mg
Sponsors: Genzyme; Genzyme
Recruiting - verified June 2013
A Phase 1 Study of IPI-145 in Patients With Advanced Hematologic Malignancies

Condition: Hematologic Malignancies
Intervention: Drug: IPI-145
Sponsors: Infinity Pharmaceuticals, Inc.; Infinity Pharmaceuticals, Inc.
Recruiting - verified May 2013
ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia

Condition: Acute Myeloid Leukemia
Interventions: Drug: G-CSF; Drug: Cytarabine; Drug: Fludarabine; Biological: Donor Natural Killer (NK) cells; Biological: ALT-801
Sponsors: Altor Bioscience Corporation; Altor Bioscience Corporation; M.D. Anderson Cancer Center
Recruiting - verified June 2013
Efficacy and Safety Study of Pregabalin in the Treatment of Pain on Walking in Patients With Diabetic Peripheral Neuropathy (DPN)

Condition: Diabetic Peripheral Neuropathy
Interventions: Drug: Pregabalin; Other: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Study of Heart Failure Hospitalizations After Aquapheresis Therapy Compared to Intravenous (IV) Diuretic Treatment

Conditions: Heart Failure; Cardiac Failure; Acute Decompensated Heart Failure (ADHF)
Interventions: Device: Isolated veno-venous ultrafiltration (AQ); Drug: IV Loop Diuretics (LD)
Sponsors: Gambro Renal Products, Inc.; Gambro Renal Products, Inc.; Gambro UF Solutions, Inc.
Recruiting - verified May 2013
Follicular Lymphoma

Condition: Lymphoma
Interventions: Drug: Rituximab; Radiation: Radiation
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013
Evaluation of Specific Biomarkers in Primary Invasive Breast Cancer

Condition: Immunologic Tests
Intervention:
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified June 2013
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Condition: Colorectal Cancer
Interventions: Drug: GS-6624; Drug: FOLFIRI; Drug: GS-6624; Drug: FOLFIRI; Drug: GS-6624; Drug: FOLFIRI; Drug: Placebo; Drug: FOLFIRI
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013
Efficacy of LCQ908 on Cardiovascular Risk

Conditions: Coronary Artery Disease; Hypertriglyceridemia
Interventions: Drug: LCQ908; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013
Efficacy, Safety, and PK of Triptorelin 6-month Formulation in Patients With Central Precocious Puberty

Condition: Central Precocious Puberty
Intervention: Drug: Triptorelin 22.5 mg
Sponsors: Debiopharm S.A.; Debiopharm S.A.
Recruiting - verified May 2013
Diffuse Intrinsic Pontine Glioma (DIPG) Reirradiation (ReRT)

Condition: Brain Cancer
Intervention: Radiation: Radiation Therapy
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke

Condition: Post-stroke Spasticity of the Lower Limb.
Interventions: Drug: IncobotulinumtoxinA (400 Units); Drug: Placebo Comparator
Sponsors: Merz Pharmaceuticals GmbH; Merz Pharmaceuticals GmbH
Recruiting - verified June 2013
Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients

Conditions: Systemic Sclerosis; Ulcers
Interventions: Drug: macitentan 3mg; Drug: macitentan 10mg; Drug: placebo
Sponsors: Actelion; Actelion
Recruiting - verified June 2013
GLORIA-AF Registry Program - Second and Third Phases

Conditions: Stroke; Atrial Fibrillation
Intervention:
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified June 2013
A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease

Condition: Crohn's Disease
Interventions: Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
Evaluating the Effectiveness of the Quadrivalent Human Papillomavirus (HPV) Vaccine at Preventing Anal HPV Infection in HIV-Infected Men and Women

Condition: HIV Infections
Interventions: Biological: Quadrivalent HPV Vaccine; Biological: Placebo Vaccine for Male Participants Only; Biological: Placebo Vaccine for Female Participants Only
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified June 2013
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Conditions: Acute Lymphoid Leukemia; Acute Myeloid Leukemia; Chronic Lymphocytic Leukemia; Multiple Myeloma; Solid Tumors
Interventions: Drug: brentuximab vedotin; Drug: brentuximab vedotin
Sponsors: Seattle Genetics, Inc.; Seattle Genetics, Inc.
Recruiting - verified May 2013
A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis

Condition: Ulcerative Colitis
Interventions: Drug: tofacitinib; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis

Condition: Ulcerative Colitis
Interventions: Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
A Study Of Oral CP-690550 As A Maintenance Therapy For Ulcerative Colitis

Condition: Ulcerative Colitis
Interventions: Drug: Placebo; Drug: CP690,550; Drug: CP690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis

Condition: Ulcerative Colitis
Interventions: Drug: tofacitinib; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
Study Of Dacomitinib In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO

Condition: Non Small Cell Lung Cancer (NSCLC)
Interventions: Drug: Dacomitinib Plus Blinded Doxycycline or Placebo; Drug: Dacomitinib Plus Probiotic Plus Topical Alclometasone cream; Drug: Dacomitinib
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
Study of Dalantercept in Patients With Squamous Cell Carcinoma of the Head and Neck

Condition: Squamous Cell Carcinoma of the Head and Neck
Intervention: Biological: Dalantercept
Sponsors: Acceleron Pharma, Inc.; Acceleron Pharma, Inc.
Recruiting - verified May 2013
A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors

Conditions: Multiple Myeloma; Solid Tumors; Non-Small Cell Lung Cancer
Intervention: Drug: DKN-01
Sponsors: Dekkun Corporation; Dekkun Corporation
Recruiting - verified June 2013
Effect Of Pregabalin Treatment In Patients With Diabetic Nerve Pain Who Currently Use A Non-Steroid Anti-Inflammatory Drug (NSAID) For Another Pain

Condition: Painful Diabetic Peripheral Neuropathy
Interventions: Drug: pregabalin; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures

Condition: Epilepsy, Partial Seizures
Intervention: Drug: Pregabalin
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
A Study to Evaluate Safety and Efficacy of LX1606 in Subjects With Acute, Mild to Moderate Ulcerative Colitis

Condition: Ulcerative Colitis
Interventions: Drug: 500 mg LX1606 QD; Drug: 500 mg LX1606 TID; Drug: Placebo
Sponsors: Lexicon Pharmaceuticals; Lexicon Pharmaceuticals
Recruiting - verified June 2013
Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders

Condition: Smoking Cessation
Interventions: Drug: Placebo; Drug: varenicline tartrate; Drug: bupropion hydrochloride; Drug: Nicotine Replacement Therapy Patch
Sponsors: Pfizer; Pfizer; GlaxoSmithKline
Recruiting - verified May 2013
Efficacy, Safety and Tolerability of a Self-Administered Subcutaneous Formulation of Icatibant for the Treatment of Acute Attacks of Hereditary Angioedema

Condition: Hereditary Angioedema
Intervention: Drug: Icatibant
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Shire Human Genetic Therapies, Inc.
Recruiting - verified June 2013
Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device (LVAD) and Medical Management

Condition: Heart Failure
Interventions: Device: HM II (HeartMate II LVAD); Drug: OMM (Optimal Medical Management)
Sponsors: Thoratec Corporation; Thoratec Corporation
Recruiting - verified May 2013
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)

Conditions: Pulmonary Arterial Hypertension; Pulmonary Hypertension
Interventions: Drug: Nitric Oxide; Other: Placebo; Drug: Nitric Oxide
Sponsors: INO Therapeutics; INO Therapeutics
Recruiting - verified May 2013
A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers

Conditions: CD27 Expressing B-cell Malignancies; CD27 Expressing Solid Tumors; Chronic Lymphocytic Leukemia; Burkett's Lymphoma; Mantle Cell Lymphoma; Primary Lymphoma of the Central Nervous System; Marginal Zone B Cell Lymphoma; Solid Tumor; Metastatic Melanoma; Renal (Clear) Cell Carcinoma; Hormone-refractory Prostate Adenocarcinoma; Ovarian Cancer; Colorectal Adenocarcinoma; Non-small Cell Lung Cancer; Melanoma (Solid Tumor Expansion Arm Only)
Intervention: Drug: CDX-1127
Sponsors: Celldex Therapeutics; Celldex Therapeutics
Recruiting - verified May 2013
Study of the AeriSeal System for HyPerInflation Reduction in Emphysema (ASPIRE)

Condition: Pulmonary Emphysema
Interventions: Device: Treatment plus Optimal Medical Therapy; Other: Optimal Medical Therapy
Sponsors: Aeris Therapeutics; Aeris Therapeutics
Recruiting - verified June 2013
Pharmacokinetics (PK) of Liquid Hydroxyurea in Pediatric Patients With Sickle Cell Anemia

Condition: Sickle Cell Anemia
Intervention: Drug: Hydroxyurea
Sponsors: Children's Mercy Hospital Kansas City; Children's Mercy Hospital Kansas City; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified May 2013
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cancer
Interventions: Drug: AMG 386; Drug: Paclitaxel; Drug: AMG 386 Placebo; Drug: Carboplatin
Sponsors: Amgen; Amgen
Recruiting - verified June 2013
Safety and Efficacy Study of Romiplostim to Treat ITP in Pediatric Subjects

Conditions: Idiopathic Thrombocytopenic Purpura; Thrombocytopenia; Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP); Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP); Thrombocytopenic Purpura
Interventions: Drug: romiplostim; Drug: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified May 2013
Efficacy and Safety of Chloroquine in Combination With Taxane or Taxane-like Chemotherapy in the Treatment of Advanced or Metastatic Breast Cancer Patients Who Have Failed an Anthracycline

Conditions: Breast Neoplasms; Breast Cancer
Interventions: Drug: Taxane; Drug: Taxotere; Drug: Abraxane; Drug: Ixabepilone
Sponsors: The Methodist Hospital System; The Methodist Hospital System
Recruiting - verified June 2013
Open Label Study of Long Term Evaluation Against LDL-C Trial

Condition: Hypercholesterolemia
Interventions: Drug: AMG 145 and standard of care; Other: Standard of care
Sponsors: Amgen; Amgen
Recruiting - verified May 2013
SAR3419 in Acute Lymphoblastic Leukemia

Condition: Acute Lymphocytic Leukaemia
Intervention: Drug: SAR3419
Sponsors: Sanofi; Sanofi
Recruiting - verified June 2013
A Multi-Center, Randomized, Controlled Evaluation of the Safety and Efficacy of the KXL System With VibeX (Riboflavin Ophthalmic Solution) for Corneal Collagen Cross-Linking in Eyes With Keratoconus or Corneal Ectasia After Refractive Surgery

Conditions: Keratoconus; Corneal Ectasia
Interventions: Device: KXL System (15 mW/cm2); Device: KXL System (30 mW/cm2); Device: KXL System (45 mW/cm2); Drug: riboflavin ophthalmic solution
Sponsors: ACOS; ACOS
Recruiting - verified June 2013
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

Condition: Major Depressive Disorder
Interventions: Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate ); Drug: Antidepressant + Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified June 2013
Pazopanib in Von Hippel-Lindau (VHL) Syndrome

Condition: Von Hippel-Lindau Syndrome
Intervention: Drug: Pazopanib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; GlaxoSmithKline
Recruiting - verified June 2013
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

Condition: Major Depressive Disorder
Interventions: Drug: SPD489 (Lisdexamfetamine dimesylate ); Drug: Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified June 2013
Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer

Condition: Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer
Interventions: Drug: MEDI-573; Drug: Aromatase Inhibitor
Sponsors: MedImmune LLC; MedImmune LLC
Recruiting - verified May 2013
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

Condition: Breast Cancer
Interventions: Drug: fulvestrant; Drug: GDC-0941; Drug: GDC-0980; Drug: placebo; Drug: GDC-0941; Drug: placebo
Sponsors: Genentech; Genentech
Recruiting - verified June 2013
Inflammatory Response and Tissue Fibrosis/ Lymphatico-venous Bypass

Conditions: Breast Cancer; Genitourinary Cancer; Malignant Female Reproductive System Neoplasm; Melanoma; Sarcoma
Intervention: Procedure: Punch Biopsy
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Department of Defense
Recruiting - verified May 2013
A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression

Condition: Fibromyalgia
Interventions: Drug: Pregabalin; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Phase I Study to Determine the Maximum Tolerable Dose of BAY94-9343 in Patients With Advanced Solid Tumors.

Condition: Oncology
Intervention: Drug: BAY94-9343
Sponsors: Bayer; Bayer
Recruiting - verified June 2013
Safety and Pharmacokinetics of Ifetroban in Hepatorenal Syndrome Patients

Condition: Hepatorenal Syndrome
Interventions: Drug: 5mg Ifetroban Injection; Drug: 15mg Ifetroban Injection; Drug: 50mg Ifetroban Injection; Drug: 150mg Ifetroban Injection; Other: 5% Dextrose in Water
Sponsors: Cumberland Pharmaceuticals; Cumberland Pharmaceuticals
Recruiting - verified June 2013
Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) for Uncontrolled Moderate - Severe Low Back Pain

Condition: Low Back Pain
Interventions: Drug: Oxycodone/Naloxone controlled-release; Drug: Oxycodone HCl controlled-release; Drug: Placebo
Sponsors: Purdue Pharma LP; Purdue Pharma LP
Recruiting - verified June 2013
Safety and Efficacy of OsmoPrep® Tablets Versus HalfLytely® and Bisacodyl Tablet Bowel Prep Kit for Colon Cleansing

Condition: Colon Cleansing
Interventions: Drug: Polyethylene glycol; Drug: Oral sodium phosphate solution
Sponsors: Salix Pharmaceuticals; Salix Pharmaceuticals
Recruiting - verified July 2012
Tasimelteon for the Treatment of Non-24-hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light Perception

Condition: Non-24-Hour Sleep-Wake Disorder
Intervention: Drug: tasimelteon
Sponsors: Vanda Pharmaceuticals; Vanda Pharmaceuticals
Recruiting - verified May 2013
Intracardiac CrYoablation for AtrioVentricular Nodal Reentrant Tachycardia

Conditions: AtrioVentricular Nodal Reentrant Tachycardia; Supraventricular Tachycardia; Heart Disease
Intervention: Device: Freezor Xtra Cryoablation Catheter
Sponsors: Medtronic Atrial Fibrillation Solutions; Medtronic Atrial Fibrillation Solutions
Recruiting - verified January 2013
Patient Controlled Tissue Expansion for Breast Reconstruction

Condition: Breast Cancer
Interventions: Device: AeroForm Tissue Expansion; Procedure: Saline Tissue Expansion
Sponsors: AirXpanders, Inc.; AirXpanders, Inc.
Recruiting - verified June 2013
A 12-week Study to Compare the Efficacy and Safety of Albuterol Spiromax® Versus a Placebo in People 12 Years and Older With Persistent Asthma

Condition: Asthma
Interventions: Drug: Placebo; Drug: Albuterol Spiromax®
Sponsors: Teva Pharmaceutical Industries; Teva Branded Pharmaceutical Products, R&D Inc.
Recruiting - verified May 2013
Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma

Conditions: Solid Tumors; Thyroid Cancer; Soft-tissue Sarcoma; Cholangiocarcinoma
Interventions: Drug: Pazopanib; Drug: GSK1120212
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center; National Comprehensive Cancer Network; GlaxoSmithKline
Recruiting - verified June 2013
A Study of Brentuximab Vedotin in Relapsed or Refractory CD30-positive Non-Hodgkin Lymphoma

Conditions: Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell
Interventions: Drug: brentuximab vedotin; Drug: rituximab
Sponsors: Seattle Genetics, Inc.; Seattle Genetics, Inc.
Recruiting - verified May 2013
A Phase I Dose Escalation Study of BKM120 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma

Condition: Glioblastoma
Interventions: Drug: BKM120 + temozolomide; Drug: BKM120 +temozolomide with/without radiotherapy
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified June 2013
A Study of Ejaculatory Dysfunction in Men With Low Testosterone Levels

Conditions: Ejaculatory Dysfunction; Hypogonadism
Interventions: Drug: Testosterone Solution 2%; Drug: Placebo Solution
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified June 2013
The Effects of Long Term Cyclic Testosterone Administration on Muscle Function and Bone in Older Men

Condition: Sarcopenia
Interventions: Drug: Testosterone enanthate; Drug: Testosterone enanthate; Drug: Placebo
Sponsors: The University of Texas, Galveston; The University of Texas, Galveston
Not yet recruiting - verified May 2013
Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced Cancer

Condition: Neoplasms
Intervention: Drug: BAY80-6946
Sponsors: Bayer; Bayer
Recruiting - verified May 2013
Cariprazine Relative to Placebo in the Prevention of Relapse of Symptoms in Patients With Schizophrenia

Condition: Schizophrenia
Interventions: Drug: Cariprazine; Drug: Placebo
Sponsors: Forest Laboratories; Forest Laboratories; Gedeon Richter Ltd.
Recruiting - verified June 2013
Acute Promyelocytic Leukemia (APL) Treated With ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin

Condition: Leukemia
Interventions: Drug: ATRA; Drug: ATO; Drug: GO (Gemtuzumab ozogamicin); Drug: Methylprednisolone
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Pfizer
Recruiting - verified June 2013
An Open-Label Study to Assess the Pharmacokinetics and Safety of HALAVENTM in Subjects With Cancer Who Also Have Impaired Renal Function

Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: E7389; Drug: E7389; Drug: E7389
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified June 2013
Evaluating the Safety and Effectiveness of Short-Course Rifapentine/Isoniazid for the Prevention of Active Tuberculosis in HIV-Infected Individuals With Latent Tuberculosis Infection

Conditions: Tuberculosis; HIV Infections
Interventions: Drug: Rifapentine (RPT); Drug: Isoniazid (INH); Dietary Supplement: Pyridoxine (Vitamin B6)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2013
An Observational Study to Understand Challenges Associated With Progression of Insulin Therapy in Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Intervention:
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified June 2013
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)

Conditions: Alzheimer Disease; Mild Cognitive Impairment; Neurodegenerative Diseases
Intervention: Drug: Florbetapir F 18
Sponsors: Avid Radiopharmaceuticals; Avid Radiopharmaceuticals
Recruiting - verified June 2013
Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Skin Infections

Condition: Infections, Pediatrics
Interventions: Drug: Ceftaroline fosamil; Drug: Vancomycin +/- Aztreonam or Cefazolin +/- Aztreonam; Drug: Cephalexin or Clindamycin or Linezolid
Sponsors: Cerexa, Inc.; Cerexa, Inc.; AstraZeneca
Recruiting - verified June 2013
Safety, Tolerability, and Efficacy of Cariprazine for Patients With Bipolar Depression

Condition: Depression, Bipolar
Interventions: Drug: Placebo; Drug: Cariprazine; Drug: Cariprazine; Drug: Cariprazine
Sponsors: Forest Laboratories; Forest Laboratories; Gedeon Richter Ltd.
Recruiting - verified May 2013
Study to Assess Safety, Tolerability and Preliminary Efficacy of BKM120, PI3K Kinase Inhibitor, With Advanced Leukemias

Condition: Leukemia
Intervention: Drug: BKM120
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Novartis
Recruiting - verified May 2013
Long-Term Safety Extension Trial of Asenapine in Bipolar 1 Disorder Participants Who Completed Protocol P05691 (P05692AM2)

Condition: Bipolar I Disorder
Interventions: Drug: asenapine; Drug: asenapine
Sponsors: Merck; Merck
Recruiting - verified May 2013
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

Conditions: Cardiovascular Disease; Diabetes Mellitus, Type 2
Interventions: Drug: Dulaglutide; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified June 2013
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Condition: Crohn's Disease
Interventions: Drug: Placebo; Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)

Condition: Kidney Cancer
Interventions: Drug: Pazopanib; Drug: Temsirolimus; Behavioral: Quality of Life Assessment; Drug: Benadryl
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; GlaxoSmithKline
Recruiting - verified May 2013
End of Life Treatment Preferences

Condition: Advanced Cancers
Intervention: Behavioral: Telephone Survey
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified May 2013
A Study of the Efficacy and Safety of Pregabalin as Add-On Therapy for Partial Onset Seizures in Children Ages 4-16 Years

Condition: Epilepsy, Partial Seizures
Interventions: Drug: Pregabalin add-on therapy; Drug: Pregabalin add-on therapy; Drug: Pregabalin add-on therapy
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With MEK (Mitogen-activated Protein Kinase) Inhibitor BAY86-9766 in Patients With Advanced Cancer

Condition: Neoplasms
Interventions: Drug: BAY80-6946 + BAY86-9766; Drug: BAY80-6946 + BAY86-9766
Sponsors: Bayer; Bayer
Recruiting - verified June 2013
MRD Testing Before and After Hematopoietic Cell Transplantation Transplantation for Pediatric Acute Myeloid Leukemia

Condition: Acute Myeloid Leukemia
Intervention:
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; Resource for Clinical Investigations in Blood and Marrow Transplantation (RCI-BMT); Pediatric Blood and Marrow Transplant Consortium; St. Baldrick's Foundation; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified June 2013
Safety Study of AMG 557 in Subjects With Subacute Cutaneous Lupus Erythematosus

Conditions: Cutaneous Lupus; Lupus
Interventions: Drug: AMG 557; Drug: AMG 557 Placebo
Sponsors: Amgen; Amgen
Recruiting - verified May 2013
Modafinil in Treating Children With Memory and Attention Problems Caused by Cancer Treatment for a Brain Tumor

Conditions: Brain and Central Nervous System Tumors; Cognitive/Functional Effects; Fatigue; Neurotoxicity; Psychosocial Effects of Cancer and Its Treatment
Interventions: Drug: modafinil; Other: placebo
Sponsors: University of South Florida; University of South Florida; National Cancer Institute (NCI)
Recruiting - verified September 2011
Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer

Condition: Non-Small-Cell Lung Carcinoma
Interventions: Biological: TG4010; Drug: placebo
Sponsors: Transgene; Transgene
Recruiting - verified June 2013
A Safety and Efficacy Study of Uvadex and Extracorporeal Photopheresis (ECP) in Chronic Graft Versus Host Disease

Condition: Chronic Graft Versus Host Disease
Interventions: Drug: ECP(Methoxsalen)+Corticosteroids+Cyclosporine or Tacrolimus; Drug: Corticosteroids/Cyclosporine/Tacrolimus
Sponsors: Therakos; Therakos; Parexel
Recruiting - verified June 2013
Intramedullary Nail Versus Sliding Hip Screw Inter-Trochanteric Evaluation

Conditions: Femoral Neck Fractures; Intertrochanteric Fracture
Interventions: Procedure: Gamma3 Intramedullary Nails (Stryker); Procedure: Sliding Hip Screws
Sponsors: Stryker Trauma GmbH; Stryker Trauma GmbH; Stryker Osteosynthesis; Global Research Solutions
Recruiting - verified May 2013
Ginseng on Cancer-Related Fatigue

Conditions: Advanced Cancers; Solid Tumors
Interventions: Drug: Panax Ginseng; Dietary Supplement: Placebo; Behavioral: Questionnaires
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Indena
Recruiting - verified June 2013
Ruxolitinib and Lenalidomide for Patients With Myelofibrosis

Condition: Myeloproliferative Diseases
Interventions: Drug: Ruxolitinib; Drug: Lenalidomide; Drug: Prednisone
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Incyte Corporation
Recruiting - verified May 2013
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease

Condition: Cushing's Disease
Interventions: Drug: SOM230 LAR 30 mg; Drug: SOM230 LAR 10 mg
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified June 2013
Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis

Condition: Rheumatoid Arthritis
Interventions: Drug: PF-04171327; Drug: PF-04171327; Drug: PF-04171327; Drug: PF-04171327; Drug: prednisone; Other: prednisone; Other: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD

Condition: Major Depressive Disorder
Interventions: Drug: Desvenlafaxine Succinate Sustained-Release; Drug: Desvenlafaxine Succinate Sustained-Release; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
A 6-Month Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability, And Efficacy Of DVS SR In The Treatment Of Child And Adolescent Outpatients With MDD

Condition: Major Depressive Disorder
Intervention: Drug: DVS SR
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD

Condition: Major Depressive Disorder
Intervention: Drug: DVS SR
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD

Condition: Major Depressive Disorder
Interventions: Drug: desvenlafaxine succinate sustained release; Drug: fluoxetine; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Synchronized Transcranial Magnetic Stimulation (sTMS) in Major Depressive Disorder

Condition: Major Depressive Disorder
Interventions: Device: NEST-1 (NeoSync EEG Synchronized TMS); Device: SHAM
Sponsors: NeoSync, Inc.; NeoSync, Inc.
Recruiting - verified June 2013
Proteomic Assessment of Preterm Birth

Condition: Preterm Birth
Intervention:
Sponsors: Sera Prognostics, Inc.; Sera Prognostics, Inc.
Recruiting - verified May 2013
A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Conditions: Crohn's Disease; Colitis; IBD; Inflammatory Bowel Disease
Interventions: Drug: Placebo; Drug: Ustekinumab; Drug: Ustekinumab; Drug: Ustekinumab; Drug: Ustekinumab
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified June 2013
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Conditions: Crohn's Disease; Inflammatory Bowel Disease; IBD; Colitis
Interventions: Drug: Group 3: ustekinumab approximately 6 mg/kg; Drug: Group 1: Placebo; Drug: Group 2 ustekinumab 130 mg
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified June 2013
Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial

Conditions: Acute Ischemic Stroke; Diabetes; Hyperglycemia
Interventions: Drug: IV insulin to maintain target glucose concentration of 80-130 mg/dL; Drug: Standard Care control - sliding scale insulin to keep glucose less than 180 mg/dL
Sponsors: University of Virginia; University of Virginia; Neurological Emergencies Treatment Trials Network (NETT); Medical University of South Carolina; Medical Automation Systems, an Alere Company; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified June 2013
Hyper CVAD Plus Ofatumumab in CD - 20 Positive Acute Lymphoblastic Leukemia (ALL)

Condition: Leukemia
Interventions: Drug: Cyclophosphamide; Drug: Mesna; Drug: Doxorubicin; Drug: Vincristine; Drug: Dexamethasone; Drug: Ofatumumab; Drug: Methotrexate; Drug: Cytarabine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; GlaxoSmithKline
Recruiting - verified May 2013
National Marrow Donor Program Long-Term Donor Follow-Up

Condition: Hematologic Neoplasms
Intervention:
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; National Marrow Donor Program
Recruiting - verified May 2013
Effect of Catheter Ablation on Clinical Course of Migraine in AF Patients With or Without Previous History of Migraine

Conditions: Migraine; Atrial Fibrillation
Interventions: Procedure: Radiofrequency catheter ablation; Procedure: Radiofrequency catheter ablation
Sponsors: Texas Cardiac Arrhythmia Research Foundation; Texas Cardiac Arrhythmia Research Foundation
Recruiting - verified July 2011
Effect of Empirical Left Atrial Appendage Isolation on Long-term Procedure Outcome in Patients With Persistent or Long-standing Persistent Atrial Fibrillation Undergoing Catheter Ablation

Condition: Persistent Atrial Fibrillation
Interventions: Procedure: RFCA of PV and extra-PV triggers; Procedure: LAA isolation along with the conventional ablation strategy
Sponsors: Texas Cardiac Arrhythmia Research Foundation; Texas Cardiac Arrhythmia Research Foundation
Recruiting - verified May 2011
Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Patients With Non-Small Cell Lung Cancer and Platinum Resistant Ovarian Cancer

Condition: Non-Small Cell Lung Cancer, Ovarian Cancer
Intervention: Drug: DNIB0600A
Sponsors: Genentech; Genentech
Recruiting - verified June 2013
Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer

Conditions: Pain; Advanced Cancer
Interventions: Drug: Sativex®; Drug: Placebo (GA-0034)
Sponsors: GW Pharmaceuticals Ltd.; GW Pharmaceuticals Ltd.; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified August 2011
Bipolar Maintenance Study of Lurasidone Adjunctive to Lithium or Divalproex

Condition: Bipolar I Disorder
Interventions: Drug: Lurasidone; Drug: Placebo
Sponsors: Sunovion; Sunovion
Recruiting - verified June 2013
A Study of RO5429083 in Patients With Metastatic and/or Locally Advanced, CD44-Expressing, Malignant Solid Tumors

Condition: Neoplasms
Interventions: Drug: RO5429083; Drug: RO5429083
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified June 2013
Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.

Conditions: Multiple Myeloma; Non-Hodgkin Lymphoma; Glioblastoma Multiforme; Squamous Cell Carcinoma of Head and Neck; Prostate Cancer; Ewing's Osteosarcoma; Chronic Lymphocytic Leukemia
Intervention: Drug: CC-115
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified June 2013
A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

Condition: Meningitis, Meningococcal
Interventions: Biological: rLP2086 vaccine; Biological: control
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)

Conditions: CD-30 Positive Anaplastic Large T-cell Cutaneous Lymphoma; Lymphoma, Primary Cutaneous Anaplastic Large Cell; Lymphomatoid Papulosis; Mycosis Fungoides; Skin Lymphoma; Cutaneous Lymphomas; Lymphoma; Hematologic Disorder
Intervention: Drug: SGN-35
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Seattle Genetics, Inc.
Recruiting - verified May 2013
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 1 Year of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents.

Condition: Rheumatoid Arthritis
Interventions: Drug: Secukinumab (75 mg); Drug: Secukinumab (150 mg); Drug: Placebo; Drug: Abatacept
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified June 2013
A Study of Avastin (Bevacizumab) in Combination With Standard of Care Treatment in Patients With Lung Cancer

Condition: Non-Small Cell Lung Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: Standard of care treatment
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified June 2013
A Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands

Conditions: Melanoma; Breast Neoplasms; Lobular Carcinoma; Triple-negative Breast Cancer; Pancreatic Adenocarcinoma
Intervention: Drug: LGK974
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013
Patients Treated for SCID (1968-2010)

Conditions: SCID; ADA-SCID; XSCID; Leaky SCID; Omenn Syndrome; Reticular Dysgenesis
Intervention:
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); Office of Rare Diseases (ORD)
Recruiting - verified May 2013
LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy

Conditions: Head and Neck Neoplasms; Carcinoma, Squamous Cell
Interventions: Drug: Afatinib; Drug: Methotrexate
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified June 2013
LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy

Condition: Head and Neck Neoplasms
Interventions: Drug: Placebo; Drug: Afatinib
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified June 2013
Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With Ccr5 Tropic HIV 1

Condition: HIV-1
Interventions: Drug: Maraviroc; Drug: Emtricitabine/tenofovir
Sponsors: ViiV Healthcare; ViiV Healthcare; Pfizer
Recruiting - verified June 2013
Clinical Study to Investigate Safety and Efficacy of GSK933776 in Adult Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration

Condition: Atrophy, Geographic
Interventions: Drug: GSK933776; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma

Condition: Advanced Liposarcoma or Leiomyosarcoma
Interventions: Drug: Trabectedin; Drug: Dacarbazine
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC; Pharma Mar, S.A.U.
Recruiting - verified June 2013
Finding a Safe and Effective Dose of Linagliptin in Pediatric Patients With Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: placebo; Drug: BI1356 low dose; Drug: BI1356 high dose
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified June 2013
A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's Disease

Condition: Multicentric Castleman's Disease
Intervention: Drug: Siltuximab
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2013
A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD.

Condition: Coronary Artery Disease
Intervention: Drug: Flurpiridaz F18
Sponsors: Lantheus Medical Imaging; Lantheus Medical Imaging
Recruiting - verified February 2013
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer

Condition: Hepatocellular Carcinoma
Interventions: Device: HepaSphere/QuadraSphere Microspheres; Procedure: PVA, lipiodol, doxorubicin
Sponsors: Merit Medical Systems, Inc.; Merit Medical Systems, Inc.
Recruiting - verified March 2013
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients

Condition: Hepatitis C
Interventions: Drug: BI 201335; Drug: PegIFN/RBV
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified June 2013
Stem Cell Collection With Ofatumumab

Condition: Lymphoma
Interventions: Drug: Ofatumumab; Drug: Ifosfamide; Drug: Etoposide; Drug: Mesna; Drug: G-CSF; Procedure: Stem Cell Collection
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; GlaxoSmithKline
Recruiting - verified May 2013
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma

Conditions: Chronic Lymphocytic Leukemia; Non-Hodgkin Lymphoma
Intervention: Drug: ABT-199
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott); Genentech
Recruiting - verified May 2013
Effect of Exercise and Biofeedback on Symptoms of Incontinence in Women With Stress Urinary Incontinence

Condition: Stress Urinary Incontinence
Intervention: Other: Pelvic floor muscle exercises with biofeedback
Sponsors: Texas Woman's University; Texas Woman's University
Recruiting - verified May 2013
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Fluticasone Furoate/Vilanterol; Drug: Vilanterol; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
Afatinib (BIBW2992) in HER2-overexpressing Inflammatory Breast Cancer

Condition: Breast Neoplasms
Interventions: Drug: Afatinib once daily (OD); Drug: Vinorelbine Weekly
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified June 2013
Preventing Aggression in Veterans With Dementia

Conditions: Dementia; Aggression; Pain
Interventions: Behavioral: PAVeD Intervention; Behavioral: Enhanced Usual Care
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified May 2013
A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study

Condition: Hepatitis C
Intervention: Drug: TMC435
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified May 2013
A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer

Condition: Prostate Cancer Metastatic
Interventions: Biological: PROSTVAC-V; Biological: PROSTVAC-F; Drug: GM-CSF; Other: GM-CSF Placebo; Biological: Placebo
Sponsors: BN ImmunoTherapeutics; BN ImmunoTherapeutics
Recruiting - verified February 2013
Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma

Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Peripheral T-cell Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma
Interventions: Drug: carfilzomib; Other: laboratory biomarker analysis
Sponsors: University of Nebraska; University of Nebraska; National Cancer Institute (NCI); Onyx Pharmaceuticals
Recruiting - verified June 2013
18-F-Fluoroacetate as PET Imaging Agent

Conditions: Brain Cancer; Breast Cancer; Prostate Cancer
Intervention: Drug: 18F-fluoroacetate
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Not yet recruiting - verified June 2013
Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: Rituximab; Drug: Imatinib; Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Mesna; Drug: VSLI; Drug: Solu-Medrol; Drug: Methotrexate; Drug: Ara-C; Drug: G-CSF; Drug: Pegfilgrastim; Drug: Dexamethasone
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Talon Therapeutics, Inc
Recruiting - verified June 2013
Study of 18F-Fluoro-PEG6-IPQA

Condition: Lung Cancer
Interventions: Drug: 18F-PEG6-IPQA; Procedure: Positron emission tomography (PET)
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified June 2013
Smoking Cessation Study In Healthy Adolescent Smokers

Condition: Smoking Cessation
Interventions: Drug: Varenicline 1mg BID; Drug: Varenicline 0.5mg BID; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves

Condition: Symptomatic Severe Aortic Stenosis
Interventions: Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: AVR with a surgical heart valve; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: AVR with a surgical heart valve; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis
Sponsors: Edwards Lifesciences; Edwards Lifesciences
Recruiting - verified May 2013
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Conditions: Prostate Cancer; Prostatic Neoplasm
Intervention: Drug: abiraterone acetate in combination with prednisone
Sponsors: Janssen Biotech, Inc.; Janssen Biotech, Inc.
Recruiting - verified May 2013
Caspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients With Acute Myeloid Leukemia Who Are Undergoing Chemotherapy

Conditions: Fungal Infection; Leukemia; Neutropenia
Interventions: Drug: caspofungin acetate; Drug: fluconazole
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2013
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)

Condition: Warfarin Therapy
Intervention: Device: Warfarin GenoSTAT Test
Sponsors: Iverson Genetic Diagnostics, Inc.; Iverson Genetic Diagnostics, Inc.
Recruiting - verified May 2013
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

Condition: Depression
Interventions: Drug: Armodafinil; Drug: Placebo
Sponsors: Teva Pharmaceutical Industries; Cephalon
Recruiting - verified May 2013
Carfilzomib Plus Panobinostat in Relapsed/Refractory Multiple Myeloma (MM)

Condition: Myeloma
Interventions: Drug: Carfilzomib; Drug: Panobinostat
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Novartis; Onyx Therapeutics, Inc.
Recruiting - verified May 2013
INcrease Of VAgal TonE in CHF

Conditions: Left Ventricular Dysfunction; Heart Failure
Interventions: Device: CardioFit® System; Other: Standard of Care
Sponsors: BioControl Medical; BioControl Medical
Recruiting - verified May 2013
Efficacy and Safety of E-101 Solution for Preventing Surgical Site Infections After Colorectal Surgery

Condition: Infections
Interventions: Drug: E-101 Solution 300 GU/ml; Drug: Saline solution
Sponsors: Excited States, LLC; Excited States, LLC; Beardsworth Consulting Group, Inc.; Veristat, Inc.; Biotec Services International Ltd; Eurofins Medinet; CBR International Corp.
Recruiting - verified June 2013
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia

Conditions: Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Chronic Myeloid Leukemia; Myelodysplasia
Interventions: Biological: human myeloid progenitor cells; Drug: G-CSF
Sponsors: Cellerant Therapeutics; Cellerant Therapeutics; Department of Health and Human Services
Recruiting - verified June 2013
Cidofovir Versus Best Supportive Care for Hemorrhagic Cystitis

Condition: Transplantation Infection
Interventions: Drug: Cidofovir; Other: No Cidofovir
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013
Androgenetic Alopecia in Fabry Disease

Condition: Fabry Disease
Intervention:
Sponsors: Baylor Research Institute; Baylor Research Institute
Recruiting - verified May 2013
Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors

Conditions: Solid Tumors; Relapsed/Refractory Sarcomas
Intervention: Drug: Vorinostat and Etoposide
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Merck; Phoenix Children's Hospital; Milton S. Hershey Medical Center; Johns Hopkins University; Sidney Kimmel Comprehensive Cancer Center; Children's Hospital Colorado; University of Florida; Alberta Children's Hospital; M.D. Anderson Cancer Center; Dana-Farber Cancer Institute; Children's Mercy Hospital & Clinics; All Children's Hospital; Arnold Palmer Hospital for Children/MD Anderson Cancer Center Orlando
Recruiting - verified May 2013
GSK1120212 Rollover Study

Condition: Cancer
Interventions: Drug: GSK1120212; Drug: Docetaxel + GSK1120212; Drug: Erlotinib + GSK1120212; Drug: Pemetrexed + GSK1120212; Drug: Carboplatin + GSK1120212; Drug: Nab-paclitaxel + GSK1120212; Drug: Gemcitabine + GSK1120212; Drug: Everolimus + GSK1120212
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
A Study of DS-2248, in Subjects With Advanced Solid Tumors

Conditions: Solid Tumors; Non-small Cell Lung Carcinoma
Intervention: Drug: DS-2248
Sponsors: Daiichi Sankyo Inc.; Daiichi Sankyo Inc.; Daiichi Sankyo Development Ltd
Recruiting - verified June 2013
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Condition: Crohn's Disease
Interventions: Drug: PF-04236921 SC injection; Drug: PF-04236921 SC injection; Drug: PF-04236921 SC injection; Drug: PF-04236921 SC injection
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
Study to Improve Renal Function After Kidney Transplantation

Condition: Delayed Graft Function
Intervention: Drug: BB3
Sponsors: Angion Biomedica Corp; Angion Biomedica Corp
Recruiting - verified December 2011
TRINOVA-2: Trebananib in Ovarian Cancer-2

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cancer
Interventions: Drug: AMG386 plus PLD; Drug: Placebo plus PLD
Sponsors: Amgen; Amgen
Recruiting - verified June 2013
A Trial of Levodopa in Angelman Syndrome

Condition: Angelman Syndrome
Intervention: Drug: Levodopa/carbidopa
Sponsors: Children's Hospital Boston; Wen-Hann Tan; Rady Children's Hospital, San Diego; University of California, San Francisco; Baylor College of Medicine; Vanderbilt University; Greenwood Genetic Center; Children's Hospital Medical Center, Cincinnati; Angelman Syndrome Foundation; FDA Office of Orphan Products Development
Recruiting - verified May 2013
Prevention of Cardiac Allograft Vasculopathy Using Rituximab (Rituxan) Therapy in Cardiac Transplantation

Condition: Cardiac Allograft Vasculopathy
Interventions: Biological: Rituximab induction/conventional immunosuppression (tacrolimus, MMF, and steroid taper); Drug: Rituximab placebo/conventional immunosuppression (tacrolimus, MMF, and steroid taper)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified June 2013
Akt Inhibitor MK2206 in Treating Patients With Advanced Breast Cancer

Conditions: Male Breast Cancer; Recurrent Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer
Interventions: Drug: Akt inhibitor MK2206; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
SOLX Gold Shunt for Refractory Glaucoma

Conditions: Glaucoma; Glaucoma, Open Angle
Intervention: Device: SOLX Gold Shunt
Sponsors: SOLX, Inc.; SOLX, Inc.
Recruiting - verified June 2013
Safety And Efficacy Study Of Once Daily Controlled Release Pregabalin In The Treatment Of Patients With Postherpetic Neuralgia

Condition: Post Herpetic Neuralgia
Interventions: Drug: Pregabalin; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer

Condition: Advanced Cancers
Interventions: Drug: Hydroxychloroquine; Drug: Sirolimus; Drug: Vorinostat
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified June 2013
A Randomized Trial of Medical and Surgical Treatments for Patients With GERD Symptoms That Are Refractory to Proton Pump Inhibitors

Condition: GERD
Interventions: Device: Nissen fundoplication; Drug: baclofen; Drug: Desipramine
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified May 2013
High-dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI

Condition: Melanoma
Interventions: Drug: HDIL-2; Biological: recMAGE-A3 + AS15
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; GlaxoSmithKline
Recruiting - verified June 2013
A Study of Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer

Condition: Pain
Interventions: Drug: Sativex®; Drug: Placebo (GA-0034)
Sponsors: GW Pharmaceuticals Ltd.; GW Pharmaceuticals Ltd.; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified May 2011
Manuka Honey in Preventing Esophagitis-Related Pain in Patients Receiving Chemotherapy and Radiation Therapy For Lung Cancer

Conditions: Dysphagia; Lung Cancer; Pain
Interventions: Drug: Manuka honey; Drug: chemotherapy; Other: questionnaire administration; Procedure: adjuvant therapy; Procedure: assessment of therapy complications; Procedure: quality-of-life assessment; Procedure: standard follow-up care; Radiation: radiation therapy
Sponsors: Radiation Therapy Oncology Group; Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013
Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE)

Condition: Systemic Lupus Erythematosus
Interventions: Drug: Placebo; Drug: Epratuzumab; Drug: Epratuzumab
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified May 2013
Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus

Condition: Systemic Lupus Erythematosus
Interventions: Drug: Epratuzumab; Drug: Epratuzumab; Drug: Placebo
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified May 2013
Brivaracetam Efficacy and Safety Study in Subjects With Partial Onset Seizures

Condition: Epilepsy
Interventions: Drug: Placebo; Drug: Brivaracetam; Drug: Brivaracetam
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified May 2013
Impact of Prevnar 13 on Ear Infections in Children

Conditions: Acute Otitis Media; Mastoiditis
Intervention:
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies

Conditions: Colorectal Neoplasms; Digestive System Diseases; Colonic Diseases; Colorectal Cancer
Intervention:
Sponsors: Exact Sciences Corporation; Exact Sciences Corporation
Recruiting - verified May 2013
BRCA Mutations in Latinas

Condition: Breast Neoplasms
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified May 2013
Dysport® Adult Lower Limb Spasticity Study

Condition: Leg Spasticity
Interventions: Drug: Botulinum type A toxin (Dysport®); Drug: Placebo
Sponsors: Ipsen; Ipsen
Recruiting - verified May 2013
BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study

Condition: Lung Cancer
Interventions: Drug: Erlotinib; Drug: AZD6244; Drug: MK-2206; Drug: Sorafenib; Drug: Erlotinib; Drug: MK-2206
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; AstraZeneca; Bayer; Merck; National Cancer Institute (NCI); OSI Pharmaceuticals; Yale University
Recruiting - verified May 2013
Efficacy and Safety of Asenapine Treatment for Pediatric Bipolar Disorder {P06107 Has an Extension (P05898; NCT01349907)}(P06107 AM4)

Condition: Bipolar Disorder, Pediatric
Interventions: Drug: asenapine; Drug: Placebo to match asenapine; Drug: Rescue medication
Sponsors: Merck; Merck
Recruiting - verified May 2013
Bone Marrow Aspirate Concentrate (BMAC) for Treatment of Critical Limb Ischemia (CLI)

Condition: Critical Limb Ischemia
Interventions: Device: BMAC injection; Device: Placebo injection
Sponsors: Harvest Technologies; Harvest Technologies
Recruiting - verified May 2013
Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older

Conditions: Epilepsy; Monotherapy
Interventions: Drug: Lacosamide; Drug: Carbamazepine-Controlled Release
Sponsors: UCB, Inc.; UCB BIOSCIENCES GmbH; EDEV S.À.R.L
Recruiting - verified June 2013
Colonoscopy Versus Fecal Immunochemical Test in Reducing Mortality From Colorectal Cancer (CONFIRM)

Condition: Colorectal Cancer
Interventions: Procedure: Colonoscopy; Procedure: FIT
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified May 2013
A Study to Test Safety and Efficacy of IMGN901 in Combination With Carboplatin/Etoposide in Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung Cancer

Condition: Small Cell Lung Cancer
Interventions: Drug: IMGN901; Drug: Carboplatin and Etoposide
Sponsors: ImmunoGen, Inc.; ImmunoGen, Inc.
Recruiting - verified June 2013
Safety and Efficacy of Multiple Daily Dosing of Oral LFF571 in Patients With Moderate Clostridium Difficile Infections

Condition: Moderate Clostridium Difficile Infection
Interventions: Drug: LFF571; Drug: Vancomycin (POC)
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified June 2013
Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma

Conditions: Adult Supratentorial Primitive Neuroectodermal Tumor (PNET); Childhood Supratentorial Primitive Neuroectodermal Tumor; Ewing Sarcoma of Bone; Extraosseous Ewing Sarcoma; Extraosseous Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Peripheral Primitive Neuroectodermal Tumor of the Kidney; Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
Interventions: Drug: vincristine sulfate; Drug: doxorubicin hydrochloride; Drug: cyclophosphamide; Drug: ifosfamide; Drug: etoposide; Drug: topotecan hydrochloride; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013
Bosutinib For Autosomal Dominant Polycystic Kidney Disease

Condition: Polycystic Kidney, Autosomal Dominant
Interventions: Drug: Bosutinib; Drug: Bosutinib; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza.

Condition: Influenza, Human
Interventions: Drug: 300mg intravenous (IV) zanamivir and oral oseltamivir placebo; Drug: 600mg intravenous (IV) zanamivir and oral oseltamivir placebo; Drug: 75mg oral oseltamivir and intravenous zanamivir placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified June 2013
Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for Complications

Condition: Influenza
Interventions: Drug: Amantadine, Ribavirin, Oseltamivir; Drug: Oseltamivir
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2013
A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)

Condition: Cancer
Interventions: Drug: pazopanib; Drug: placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery

Condition: Head and Neck Cancer
Interventions: Drug: cisplatin; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Radiation Therapy Oncology Group; Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013
Phase 2/3 Study of IGSC, 20% in PIDD

Condition: Primary Immunodeficiency Diseases(PIDD)
Interventions: Biological: Immune Globulin Intravenous (Human), 10% Solution; Drug: Immune Globulin Subcutaneous (Human), 20% Solution
Sponsors: Baxter Healthcare Corporation; Baxter Healthcare Corporation
Recruiting - verified June 2013
Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer

Conditions: Prostate Neoplasms; Genital Neoplasms, Male; Urogenital Neoplasms; Genital Diseases, Male
Intervention: Drug: Abiraterone Acetate
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified May 2013
Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial

Condition: Kidney Cancer
Interventions: Drug: Pazopanib; Drug: Bevacizumab; Drug: Everolimus
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified June 2013
Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma

Condition: NY-ESO-1-positive, Unresectable and Progressive Metastatic Cutaneous Melanoma
Intervention: Biological: GSK Biologicals' 2241658A Antigen-Specific Cancer Immunotherapeutic (ASCI)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified June 2013
Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab

Condition: Advanced Cancers
Interventions: Drug: Oxaliplatin; Drug: Capecitabine; Drug: Bevacizumab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013
Immunotherapy for Asymptomatic Phase Lymphoplasmacytic Lymphoma

Condition: Lymphoma
Intervention: Biological: DNA Vaccine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Not yet recruiting - verified May 2013
Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke

Condition: Ischemic Stroke
Interventions: Drug: PF-03049423; Drug: PF-03049423; Drug: PF-03049423; Other: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
A Study of LY2127399 in Patients With Systemic Lupus Erythematosus

Conditions: Systemic Lupus Erythematosus; Connective Tissue Disease; Autoimmune Disease
Interventions: Drug: LY2127399; Drug: Placebo every 2 weeks; Drug: Placebo every 4 weeks
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified June 2013
Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric Subjects

Condition: Post Operative Pain
Intervention: Drug: oxymorphone HCl
Sponsors: Endo Pharmaceuticals; Endo Pharmaceuticals
Recruiting - verified May 2013
Administration of CMV-Specific Cytotoxic T Cells in Patients With Glioblastoma Multiforme

Conditions: Glioblastoma Multiforme; GBM; Brain Cancer
Intervention: Biological: Autologous CMV-specific CTL
Sponsors: Baylor College of Medicine; Baylor College of Medicine; Texas Children's Hospital; Center for Cell and Gene Therapy, Baylor College of Medicine; The Methodist Hospital System
Recruiting - verified May 2013
CAPOX in KRAS Wild-Type Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater

Condition: Gastrointestinal Cancer
Interventions: Drug: Capecitabine; Drug: Oxaliplatin; Drug: Panitumumab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Amgen
Recruiting - verified June 2013
PKC412 and 5-Azacytidine

Condition: Leukemia
Interventions: Drug: 5-azacytidine; Drug: PKC412
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Novartis Pharmaceuticals
Recruiting - verified June 2013
A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy

Condition: Diabetic Nephropathies
Interventions: Drug: PF-00489791; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy

Condition: Lymphoma, Follicular
Interventions: Biological: Ofatumumab; Biological: Rituximab
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
Study of Erlotinib in the Treatment of Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC) of the Skin

Condition: Skin Cancer
Intervention: Drug: Erlotinib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; OSI Pharmaceuticals
Recruiting - verified May 2013
Hormone Blockade in Combination With Targeted Agents

Conditions: Solid Tumors; Advanced Cancer
Interventions: Drug: Anastrozole; Drug: Bevacizumab; Drug: Everolimus; Drug: Sorafenib; Drug: Erlotinib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013
A Study of LY2127399 in Patients With Systemic Lupus Erythematosus

Conditions: Systemic Lupus Erythematosus; Connective Tissue Disease; Autoimmune Disease
Interventions: Drug: LY2127399; Drug: Placebo every 2 weeks; Drug: Placebo every 4 weeks
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified June 2013
RO4929097 in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Recently Completed Treatment With Front-Line Chemotherapy

Conditions: Recurrent Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer
Interventions: Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified June 2013
Risk-Adapted Chemotherapy in Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: thioguanine; Drug: vincristine sulfate
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013
OrthoIllustrated Web Based Orthopaedic Sports Medicine Registry

Conditions: Degenerative and Traumatic Pathology of the Knee; Degenerative and Traumatic Pathology of the Shoulder and Elbow; Degenerative and Traumatic Pathology of the Foot and Ankle; Degenerative and Traumatic Pathology of the Hand and Wrist; Degenerative and Traumatic Pathology of the Hip
Intervention:
Sponsors: Arthrex, Inc.; Arthrex, Inc.
Recruiting - verified June 2013
Natural History Study of SCID Disorders

Conditions: SCID; Leaky SCID; Omenn Syndrome; Reticular Dysgenesis; ADA Deficiency; XSCID
Intervention:
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); Office of Rare Diseases (ORD)
Recruiting - verified May 2013
EVAHEART LVAS Bridge-to-Transplant Pivotal Study

Condition: Heart Failure
Intervention: Device: EVAHEART Left Ventricular Assist System (LVAS)
Sponsors: Evaheart Medical USA, Inc.; Evaheart Medical USA, Inc.
Recruiting - verified May 2013
A Study in Second Line Metastatic Colorectal Cancer

Condition: Colorectal Cancer
Interventions: Biological: Ramucirumab; Drug: Irinotecan; Biological: Placebo; Drug: Folinic Acid; Drug: 5-Fluorouracil
Sponsors: Eli Lilly and Company; Eli Lilly and Company; ImClone LLC
Recruiting - verified June 2013
Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH-II)

Condition: Intracerebral Hemorrhage
Intervention: Drug: Nicardipine hydrochloride
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute; Medical University of South Carolina; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified June 2013
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder

Condition: Major Depressive Disorder
Interventions: Drug: LY2216684; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified June 2013
Effect of Amiodarone on the Procedure Outcome in Long-standing Persistent Atrial Fibrillation Undergoing Pulmonary Vein Antral Isolation

Condition: Atrial Fibrillation
Interventions: Drug: Amiodarone; Drug: Amiodarone
Sponsors: Texas Cardiac Arrhythmia Research Foundation; Texas Cardiac Arrhythmia Research Foundation; University of Kansas; California Pacific Medical Center; Stanford University; Case Western Reserve University; Southlake Regional Health Centre; Catholic University, Italy
Recruiting - verified November 2010
Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

Conditions: Light Chain Deposition Disease; Smoldering Multiple Myeloma
Interventions: Other: clinical observation; Drug: lenalidomide; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
Contrast Media Reduction and Removal in Patients With CKD (PRESERV)

Condition: Contrast Induced Nephropathy
Interventions: Device: CINCOR™ System; Drug: Peri-procedural hydration
Sponsors: Osprey Medical, Inc; Osprey Medical, Inc
Recruiting - verified June 2013
A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)

Condition: Hypertension, Pulmonary
Interventions: Drug: ambrisentan; Drug: tadalafil
Sponsors: GlaxoSmithKline; GlaxoSmithKline; Gilead Sciences
Recruiting - verified May 2013
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis

Condition: Psoriasis
Interventions: Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer

Condition: Neoplasms, Breast
Interventions: Drug: lapatinib; Drug: trastuzumab; Drug: Aromatase inhibitor; Drug: lapatinib
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia

Conditions: Childhood Hepatoblastoma; Previously Treated Childhood Rhabdomyosarcoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Malignant Germ Cell Tumor; Recurrent Childhood Rhabdomyosarcoma; Recurrent Childhood Soft Tissue Sarcoma; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Neuroblastoma; Recurrent Osteosarcoma; Recurrent Wilms Tumor and Other Childhood Kidney Tumors
Interventions: Drug: alisertib; Other: pharmacological study; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013
A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung

Condition: Non Squamous Lung Cancer
Interventions: Drug: treatment; Drug: treatment
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
Paclitaxel, Carboplatin and Cetuximab (PCC) Versus Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)

Condition: Head and Neck Squamous Cell Carcinoma
Interventions: Drug: Paclitaxel; Drug: Carboplatin; Drug: Cetuximab; Drug: Cetuximab; Drug: Docetaxel; Drug: Cisplatin; Drug: Fluorouracil; Radiation: Radiotherapy (RT); Other: Chemotherapy
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified June 2013
Study to Assess Efficacy and Safety of Anti-von Willebrand Factor Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (TTP)

Condition: Thrombotic Thrombocytopenic Purpura
Interventions: Biological: anti-vWF Nanobody; Biological: Placebo
Sponsors: Ablynx; Ablynx
Recruiting - verified June 2013
Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)

Condition: Acute Coronary Syndrome
Interventions: Drug: lixisenatide (AVE0010); Drug: placebo
Sponsors: Sanofi; Sanofi
Recruiting - verified June 2013
A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects

Condition: Smallpox
Interventions: Biological: IMVAMUNE; Biological: IMVAMUNE; Biological: IMVAMUNE; Other: Placebo
Sponsors: Bavarian Nordic; Bavarian Nordic
Recruiting - verified May 2013
Acupuncture in Treating Dry Mouth Caused By Radiation Therapy in Patients With Head and Neck Cancer

Conditions: Head and Neck Cancer; Long-term Effects Secondary to Cancer Therapy in Adults; Oral Complications of Chemotherapy and Head/Neck Radiation; Radiation Toxicity; Xerostomia
Intervention: Procedure: Acupuncture
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified May 2013
Randomized EsophyX Versus Sham / Placebo Controlled TIF Trial: The RESPECT Study

Conditions: Gastroesophageal Reflux Disease; Hiatal Hernia
Interventions: Device: Transoral Incisionless Fundoplication; Other: Sham Procedure
Sponsors: EndoGastric Solutions; EndoGastric Solutions
Recruiting - verified June 2013
Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly

Condition: Acromegaly
Interventions: Drug: Pasireotide (SOM230); Drug: octreotide LAR 30mg; Drug: lanreotide ATG 120mg; Drug: octreotide LAR 30mg or lanreotide ATG 120mg
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified June 2013
Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer

Condition: Cancer
Interventions: Drug: cyproheptadine hydrochloride; Other: placebo
Sponsors: University of South Florida; University of South Florida; National Cancer Institute (NCI)
Recruiting - verified May 2013
Efficacy and Safety of Adalimumab in Subjects With Inactive Uveitis

Condition: Uveitis
Interventions: Drug: adalimumab; Drug: prednisone; Drug: prednisone; Drug: adalimumab placebo
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified April 2013
Efficacy and Safety of Adalimumab in Subjects With Active Uveitis

Condition: Uveitis
Interventions: Drug: adalimumab; Drug: prednisone; Drug: adalimumab placebo; Drug: prednisone
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified April 2013
A Study to Determine if There is a Possible Association Between Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) and Phosphodiesterase Type 5 (PDE5) Inhibitors

Condition: Nonarteritic Anterior Ischemic Optic Neuropathy
Intervention: Drug: PDE5 Inhibitors
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified June 2013
AMPLATZER Cardiac Plug Clinical Trial

Conditions: Atrial Fibrillation; Ischemic Stroke; Peripheral Thromboembolism
Intervention: Device: AMPLATZER Cardiac Plug
Sponsors: AGA Medical Corporation; AGA Medical Corporation
Recruiting - verified June 2013
Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection

Condition: Hepatitis C, Chronic
Interventions: Drug: BI 207127; Drug: BI 201335; Drug: BI 207127; Drug: BI 201335; Drug: Ribavirin; Drug: Ribavirin; Drug: Ribavirin; Drug: BI 207127; Drug: BI 207127; Drug: BI 207127; Drug: BI 201335; Drug: Ribavirin; Drug: Ribavirin; Drug: BI 207127; Drug: BI 207127; Drug: BI 201335; Drug: BI 201335; Drug: Ribavirin; Drug: BI 201335; Drug: BI 201335; Drug: BI 207127; Drug: BI 201335; Drug: BI 201335; Drug: BI 207127; Drug: BI 201335; Drug: Ribavirin; Drug: Ribavirin; Drug: BI 207217; Drug: BI 201335; Drug: BI 207127; Drug: Ribavirin; Drug: BI 207127; Drug: BI 201335; Drug: Ribavirin; Drug: Ribavirin
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified June 2013
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension

Condition: Pulmonary Arterial Hypertension
Interventions: Drug: imatinib; Drug: imatinib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified June 2013
A Study in Patients With Diabetic Kidney Disease

Conditions: Diabetic Kidney Disease; Diabetic Nephropathy; Diabetic Glomerulosclerosis
Interventions: Drug: LY2382770; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified June 2013
Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801)

Condition: Chronic GVHD
Interventions: Drug: Sirolimus + calcineurin inhibitor + prednisone; Drug: Sirolimus + prednisone
Sponsors: Medical College of Wisconsin; Medical College of Wisconsin; National Heart, Lung, and Blood Institute (NHLBI); National Cancer Institute (NCI); Blood and Marrow Transplant Clinical Trials Network
Recruiting - verified May 2013
CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients With GBM

Condition: Glioblastoma Multiforme (GBM)
Intervention: Genetic: Genetically modified HER.CAR CMV-specific CTLs
Sponsors: Baylor College of Medicine; Baylor College of Medicine; The Methodist Hospital System; Center for Cell and Gene Therapy, Baylor College of Medicine; Texas Children's Hospital
Recruiting - verified May 2013
Patient Registry Study of Berinert® in Normal Clinical Practice

Condition: Includes: Hereditary Angioedema
Intervention: Biological: Berinert® (C1 Esterase Inhibitor)
Sponsors: CSL Behring; CSL Behring; Chiltern International Inc.
Recruiting - verified May 2013
Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

Condition: Cardiovascular Disease
Interventions: Drug: Febuxostat; Drug: Allopurinol
Sponsors: Takeda; Takeda
Recruiting - verified June 2013
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer

Conditions: brca1 Mutation Carrier; brca2 Mutation Carrier; Breast Cancer
Interventions: Dietary Supplement: cholecalciferol; Other: placebo
Sponsors: Southwest Oncology Group; Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2013
First-line Treatment of Weekly Paclitaxel With Carboplatin and Bevacizumab in Ovarian Cancer

Conditions: Epithelial Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer
Interventions: Drug: Carboplatin; Drug: Paclitaxel; Drug: Bevacizumab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Genentech
Recruiting - verified June 2013
Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma

Conditions: Childhood Infratentorial Ependymoma; Childhood Supratentorial Ependymoma; Newly Diagnosed Childhood Ependymoma
Interventions: Drug: liposomal vincristine sulfate; Other: clinical observation; Radiation: 3-dimensional conformal radiation therapy; Drug: carboplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: cisplatin; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013
Neo-Adjuvant Study in Triple Negative Breast Cancer Patients

Condition: Breast Cancer
Interventions: Drug: Cetuximab; Drug: Ixabepilone
Sponsors: The Methodist Hospital System; The Methodist Hospital System; Bristol-Myers Squibb
Recruiting - verified June 2013
ABT-348 as Monotherapy or Combination With Carboplatin or Docetaxel to Treat Advanced Solid Tumors

Condition: Advanced Solid Tumors
Interventions: Drug: ABT-348; Drug: ABT-348 and carboplatin; Drug: ABT-348 and docetaxel; Drug: ABT-348; Drug: ABT-348
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified May 2013
Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Nelarabine in Patients With Relapsed/Refractory Lymphoid Malignancies

Condition: Leukemia
Intervention: Drug: Nelarabine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; GlaxoSmithKline
Recruiting - verified May 2013
Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma

Conditions: Burkitt Lymphoma; Diffuse Large B-cell Lymphoma, c-MYC Positive
Interventions: Drug: rituximab; Drug: etoposide; Drug: cyclophosphamide; Drug: doxorubicin; Drug: vincristine; Drug: prednisone; Drug: filgrastim
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified July 2012
Lapatinib With Sirolimus or Metformin

Condition: Advanced Cancers
Interventions: Drug: Lapatinib; Drug: Sirolimus; Drug: Metformin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified June 2013
Radiation Therapy in Treating Women With Locally Recurrent Breast Cancer Previously Treated With Repeat Breast-Preserving Surgery

Condition: Breast Cancer
Interventions: Other: circulating tumor cell analysis; Other: laboratory biomarker analysis; Other: questionnaire administration; Procedure: adjuvant therapy; Radiation: 3-dimensional conformal accelerated partial breast irradiation
Sponsors: Radiation Therapy Oncology Group; Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013
Immunotherapy Study for Surgically Resected Pancreatic Cancer

Condition: Pancreatic Cancer
Interventions: Biological: HyperAcute-Pancreas Immunotherapy; Drug: Gemcitabine; Radiation: 5FU Chemoradiation
Sponsors: NewLink Genetics Corporation; NewLink Genetics Corporation
Recruiting - verified June 2013
A Clinical Study of the Safety and Efficacy of MEBO Wound Ointment in Subjects With Diabetic Foot Ulcers

Condition: Diabetic Foot Ulcers
Interventions: Drug: MEBO Wound Ointment (MEBO); Procedure: Standard of Care
Sponsors: Skingenix, Inc.; Skingenix, Inc.
Recruiting - verified May 2013
Moxifloxacin in Pediatric Subjects With Complicated Intra-abdominal Infection

Condition: Intraabdominal Infections
Interventions: Drug: Moxifloxacin (Avelox, BAY12-8039); Drug: Ertapenem, Amoxicillin/clavulanate
Sponsors: Bayer; Bayer
Recruiting - verified May 2013
The Natural History of Mucolipidosis Type IV

Condition: Mucolipidosis Type IV
Intervention:
Sponsors: Baylor Research Institute; Baylor Research Institute; Rare Diseases Clinical Research Network; National Center for Advancing Translational Science (NCATS); National Institute of Neurological Disorders and Stroke (NINDS); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified May 2013
A Phase I/II Study of TPI 287 - Temozolomide Combination in Melanoma

Condition: Melanoma
Interventions: Drug: TPI 287; Drug: Temodar (Temozolomide)
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Archer Biosciences, Inc.
Recruiting - verified June 2013
Docetaxel And Cisplatin With or Without Erlotinib For Metastatic Or Recurrent Squamous Cell Carcinoma Of Head And Neck

Conditions: Head and Neck Cancer; Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: Cisplatin; Drug: Docetaxel; Drug: Erlotinib; Other: Placebo; Drug: Carboplatin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified June 2013
Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: everolimus; Drug: temozolomide; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Radiation Therapy Oncology Group; Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013
Long-Term Outcomes in HIV-Infected Infants, Children, and Adolescents

Condition: HIV Infections
Intervention:
Sponsors: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; International Maternal Pediatric Adolescent AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified June 2013
A Safety and Efficacy Study of INTEGRA® Dermal Regeneration Template for the Treatment of Diabetic Foot Ulcers

Condition: Foot Ulcer, Diabetic
Interventions: Device: Integra® Dermal Regeneration Template; Other: Conventional Wound Therapy
Sponsors: Integra LifeSciences Corporation; Integra LifeSciences Corporation
Recruiting - verified June 2013
INSIGHT Influenza Outpatient Study (FLU 002)

Condition: Influenza
Intervention:
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute; National Institute of Allergy and Infectious Diseases (NIAID); National Institutes of Health (NIH)
Recruiting - verified June 2013
INSIGHT Influenza Hospitalization Study (FLU 003)

Conditions: Influenza; (Influenza A and Subtypes Such as H3N2 and 2009 H1N1 or Influenza B)
Intervention:
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute; National Institute of Allergy and Infectious Diseases (NIAID); National Institutes of Health (NIH)
Recruiting - verified June 2013
Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma

Condition: Lymphoma, B-Cell
Interventions: Drug: inotuzumab ozogamicin+rituximab +cyclophosphamide+vincristine+prednisone; Drug: inotuzumab ozogamicin+rituximab+gemcitabine+cisplatinum+dexamethasone
Sponsors: Pfizer; Pfizer; UCB, Inc.
Recruiting - verified May 2013
Ablation of Clinical Ventricular Tachycardia Versus Addition of Substrate Ablation on the Long Term Success Rate of VT Ablation

Condition: Ventricular Tachycardia
Interventions: Procedure: Radiofrequency Catheter Ablation (RFCA); Procedure: Radiofrequency Catheter Ablation (RFCA)
Sponsors: Texas Cardiac Arrhythmia Research Foundation; Texas Cardiac Arrhythmia Research Foundation; University of Kansas; California Pacific Medical Center; Stanford University; Case Western Reserve University; Southlake Regional Health Centre; Catholic University, Italy
Recruiting - verified May 2012
5-Azacytidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

Condition: Leukemia
Interventions: Drug: 5-Azacytidine; Drug: Lenalidomide
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Celgene Corporation
Recruiting - verified June 2013
A Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune (Idiopathic) Thrombocytopenia Purpura

Condition: Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Intervention: Biological: Romiplostim
Sponsors: Amgen; Amgen
Recruiting - verified May 2013
Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Panitumumab; Drug: Nab-paclitaxel; Drug: Carboplatin; Drug: 5-Fluorouracil; Drug: Epirubicin; Drug: Cyclophosphamide
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Celgene Corporation; Amgen
Recruiting - verified June 2013
Teplizumab for Prevention of Type 1 Diabetes In Relatives "At-Risk"

Conditions: Autoantibody Positive; Non-diabetic Relatives at Risk for Type 1 Diabetes; High Risk; Impaired Glucose Tolerance
Intervention: Drug: Teplizumab
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Center for Research Resources (NCRR); Juvenile Diabetes Research Foundation; American Diabetes Association
Recruiting - verified May 2013
Fabry Screening Study

Condition: Fabry Disease
Intervention:
Sponsors: Baylor Research Institute; Baylor Research Institute
Recruiting - verified May 2013
Trial of Late Surfactant for Prevention of Bronchopulmonary Dysplasia

Condition: Bronchopulmonary Dysplasia
Intervention: Drug: Infasurf surfactant (ONY, Inc.)
Sponsors: University of California, San Francisco; University of California, San Francisco; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified May 2013
Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors

Conditions: Brain Cancer; Choroid Plexus Tumors
Interventions: Drug: Carboplatin; Drug: Cisplatin; Drug: Cyclophosphamide; Drug: Dactinomycin; Drug: Doxorubicin; Drug: Etoposide; Drug: Irinotecan; Drug: Leucovorin; Drug: Methotrexate; Drug: Temozolomide; Drug: Vincristine
Sponsors: Tufts Medical Center; Tufts Medical Center
Recruiting - verified June 2013
Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma

Conditions: Recurrent Uterine Sarcoma; Stage IIIA Uterine Sarcoma; Stage IIIB Uterine Sarcoma; Stage IIIC Uterine Sarcoma; Stage IVA Uterine Sarcoma; Stage IVB Uterine Sarcoma; Uterine Leiomyosarcoma
Interventions: Other: placebo; Biological: bevacizumab; Drug: gemcitabine hydrochloride; Drug: docetaxel; Biological: filgrastim; Biological: pegfilgrastim
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
Physician Perceptions About Parenteral Hydration in Latin America and Spain

Conditions: Dehydration; Advanced Cancers
Intervention: Behavioral: Survey
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified June 2013
Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer

Conditions: Adult Primary Hepatocellular Carcinoma; Advanced Adult Primary Liver Cancer; Endometrial Papillary Serous Carcinoma; Localized Unresectable Adult Primary Liver Cancer; Metastatic Gastrointestinal Carcinoid Tumor; Ovarian Carcinosarcoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mixed Epithelial Carcinoma; Ovarian Papillary Serous Carcinoma; Pancreatic Alpha Cell Adenoma; Pancreatic Alpha Cell Carcinoma; Pancreatic Beta Islet Cell Adenoma; Pancreatic Beta Islet Cell Carcinoma; Pancreatic Delta Cell Adenoma; Pancreatic Delta Cell Carcinoma; Pancreatic G-cell Adenoma; Pancreatic G-cell Carcinoma; Pancreatic Polypeptide Tumor; Pulmonary Carcinoid Tumor; Recurrent Adult Primary Liver Cancer; Recurrent Endometrial Carcinoma; Recurrent Fallopian Tube Cancer; Recurrent Gastrointestinal Carcinoid Tumor; Recurrent Islet Cell Carcinoma; Recurrent Ovarian Epithelial Cancer; Recurrent Primary Peritoneal Cavity Cancer; Regional Gastrointestinal Carcinoid Tumor; Stage IIIA Endometrial Carcinoma; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Epithelial Cancer; Stage IIIA Primary Peritoneal Cavity Cancer; Stage IIIB Endometrial Carcinoma; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Epithelial Cancer; Stage IIIB Primary Peritoneal Cavity Cancer; Stage IIIC Endometrial Carcinoma; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Epithelial Cancer; Stage IIIC Primary Peritoneal Cavity Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Epithelial Cancer; Stage IV Primary Peritoneal Cavity Cancer; Stage IVA Endometrial Carcinoma; Stage IVB Endometrial Carcinoma; Uterine Carcinosarcoma
Interventions: Drug: temsirolimus; Biological: bevacizumab
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified June 2013
Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL)

Condition: Refractory Cutaneous T-cell Lymphoma
Interventions: Drug: bexarotene; Drug: bexarotene
Sponsors: Valeant Pharmaceuticals International, Inc.; Valeant Pharmaceuticals International, Inc.
Recruiting - verified June 2013
Eltrombopag for Post Transplant Thrombocytopenia

Condition: Thrombocytopenia
Interventions: Drug: Eltrombopag; Drug: Placebo
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified June 2013
A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer

Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: MM-121 (SAR256212) + erlotinib; Drug: Erlotinib
Sponsors: Merrimack Pharmaceuticals; Merrimack Pharmaceuticals; Sanofi
Recruiting - verified May 2013
Red Cell Storage Duration Study

Conditions: Cardiac Surgery; Erythrocyte Transfusion
Interventions: Biological: Red blood cell units stored <= 10 days; Biological: Red blood cell units stored >= 21 days
Sponsors: New England Research Institutes; New England Research Institutes; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified May 2013
Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation

Conditions: Leukemia; Lymphoma; Allogeneic Haematopoietic Stem Cell Transplantation; Acute Lymphoblastic Leukemia
Interventions: Drug: Busulfan; Drug: Clofarabine; Drug: Thymoglobulin; Procedure: Stem Cell Transplant
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified June 2013
Doctor-Recommended Home-Based Exercise Program or Relaxation Training in Improving Physical Function and Controlling Symptoms in Patients With Stage IV or Recurrent Colon Cancer That Cannot Be Removed By Surgery

Condition: Colorectal Cancer
Interventions: Behavioral: Exercise Program; Behavioral: Telephone-based intervention; Other: Counseling intervention; Other: Questionnaire administration; Behavioral: Relaxation Program
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified May 2013
ExAblate Conformal Bone System Treatment of Metastatic Bone Tumors for the Palliation of Pain

Condition: Bone Metastases
Intervention: Device: ExAblate 2100
Sponsors: InSightec; InSightec
Recruiting - verified May 2013
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Liver Cancer

Conditions: Childhood Hepatoblastoma; Stage I Childhood Liver Cancer; Stage II Childhood Liver Cancer; Stage III Childhood Liver Cancer; Stage IV Childhood Liver Cancer
Interventions: Procedure: therapeutic conventional surgery; Drug: cisplatin; Drug: fluorouracil; Drug: vincristine sulfate; Drug: doxorubicin hydrochloride; Drug: irinotecan hydrochloride; Procedure: liver transplantation; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013
TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Children and Adolescents

Conditions: HIV Infections; HIV-1
Intervention: Drug: Etravirine
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified June 2013
Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults

Condition: HIV Infections
Interventions: Drug: Raltegravir (RAL); Drug: Atazanavir (ATV); Drug: Ritonavir (RTV); Drug: Tenofovir (TDF); Drug: Etravirine (ETV); Drug: Darunavir (DRV); Drug: Maraviroc (MVC); Drug: Lopinavir/ritonavir (LPV/r)
Sponsors: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; International Maternal Pediatric Adolescent AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified June 2013
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

Condition: Cancer
Interventions: Drug: Lapatinib; Biological: Trastuzumab
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
BAY80-6946 Open Label, Phase I Study in Patients With Advanced Cancer

Condition: Neoplasms
Intervention: Drug: BAY80-6946
Sponsors: Bayer; Bayer
Recruiting - verified June 2013
Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist

Condition: Melanoma
Interventions: Drug: gp100; Drug: R848 gel; Drug: MAGE-3
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified June 2013
Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer

Condition: Head and Neck Cancer
Interventions: Biological: cetuximab; Radiation: intensity-modulated radiation therapy
Sponsors: Radiation Therapy Oncology Group; Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013
Examining Benefits of HAART Continuation in Postpartum Mothers

Condition: HIV Infections
Intervention: Drug: Highly active antiretroviral therapy (HAART)
Sponsors: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; International Maternal Pediatric Adolescent AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified June 2013
Stem Cell Related Donor Safety Study

Condition: Related Hematopoietic Stem Cell Donors
Intervention:
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; National Institutes of Health (NIH); University of Utah; University of Pittsburgh
Recruiting - verified May 2013
Complementary and Alternative Medicine Usage Among Participants Enrolled in Phase I Oncology Clinical Trials

Condition: Advanced Cancer
Intervention: Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013
Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Condition: Leukemia
Interventions: Drug: Vorinostat; Drug: Azacitidine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Merck
Recruiting - verified June 2013
Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations

Conditions: Acute Myelogenous Leukemia; Leukemia
Interventions: Drug: G-CSF; Drug: Plerixafor; Drug: Sorafenib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Bayer; Genzyme; Onyx Pharmaceuticals
Recruiting - verified May 2013
College Students and Smoking Cessation

Conditions: Smoking Cessation; Habits; Smoking
Interventions: Behavioral: Survey; Behavioral: Counseling; Behavioral: Survey; Behavioral: Counseling
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified May 2013
Sirolimus and Cetuximab in Advanced Malignancies

Condition: Advanced Cancer
Interventions: Drug: Sirolimus; Drug: Cetuximab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified June 2013
High-dose Chemotherapy for Poor-prognosis Relapsed Germ-Cell Tumors

Condition: Testicular Cancer
Interventions: Drug: Bevacizumab; Drug: Gemcitabine; Drug: Docetaxel; Drug: Melphalan; Drug: Carboplatin; Drug: Mesna; Drug: Ifosfamide; Drug: Etoposide; Procedure: Stem Cell Transplant
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified June 2013
A Multicenter, Open-Label Study To Investigate The Safety And Pharmacokinetics Of Lacosamide In Children With Partial Seizures

Condition: Epilepsy
Intervention: Drug: Lacosamide
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified May 2013
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: PF-02341066
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
A Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Cancer-related Pain

Conditions: Pain, Burning; Pain, Crushing; Pain, Migratory; Pain, Radiating; Pain, Splitting
Interventions: Drug: JNJ-42160443; Drug: Placebo
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2013
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Conditions: Cancer; Cataract; Low Bone Mineral Density; Osteopenia; Osteoporosis; Prostate Cancer
Interventions: Biological: Denosumab; Biological: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified June 2013
Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma

Conditions: Adult Rhabdomyosarcoma; Childhood Desmoplastic Small Round Cell Tumor; Chordoma; Desmoid Tumor; Metastatic Childhood Soft Tissue Sarcoma; Nonmetastatic Childhood Soft Tissue Sarcoma; Previously Treated Childhood Rhabdomyosarcoma; Previously Untreated Childhood Rhabdomyosarcoma; Recurrent Adult Soft Tissue Sarcoma; Recurrent Childhood Rhabdomyosarcoma; Recurrent Childhood Soft Tissue Sarcoma; Stage I Adult Soft Tissue Sarcoma; Stage II Adult Soft Tissue Sarcoma; Stage III Adult Soft Tissue Sarcoma; Stage IV Adult Soft Tissue Sarcoma
Interventions: Other: biologic sample preservation procedure; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013
Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)

Condition: Glioblastoma Multiforme
Interventions: Device: NovoTTF-100A device; Drug: Temozolomide
Sponsors: NovoCure Ltd.; NovoCure Ltd.
Recruiting - verified May 2013
Image-Guided Adaptive Conformal Photon Versus Proton Therapy

Condition: Non-Small-Cell Lung Carcinoma
Interventions: Radiation: Photon Therapy; Radiation: Proton Therapy
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified June 2013
Decitabine and Clofarabine in Higher Risk Myelodysplastic Syndromes (MDS)

Condition: Myelodysplastic Syndrome
Interventions: Drug: Decitabine; Drug: Clofarabine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Genzyme
Recruiting - verified May 2013
Study Evaluating A Planned Transition From Tacrolimus To Sirolimus In Kidney Transplant Recipients

Conditions: Graft Rejection; Kidney Transplant; Renal Allograft Recipients; Renal Transplant
Interventions: Drug: Tacrolimus; Drug: Sirolimus; Drug: Tacrolimus
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Nutritional and Contractile Regulation of Muscle Growth

Condition: Sarcopenia
Interventions: Drug: Rapamycin; Other: Amino acid supplementation; Other: Low-intensity resistance exercise; Drug: Sodium nitroprusside; Device: Blood flow restriction cuff; Other: Low-intensity resistance exercise
Sponsors: The University of Texas, Galveston; The University of Texas, Galveston; National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified May 2013
Study Evaluating The Effects Of Oprelvekin On Cardiac Repolarization In Subjects With Chemotherapy Induced Thrombocytopenia

Condition: Severe Thrombocytopenia
Intervention: Drug: oprelvekin
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma

Condition: Neuroblastoma
Interventions: Drug: Bevacizumab; Drug: cyclophosphamide; Drug: zoledronic acid
Sponsors: New Approaches to Neuroblastoma Therapy Consortium; New Approaches to Neuroblastoma Therapy Consortium; National Cancer Institute (NCI)
Recruiting - verified June 2013
Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Conditions: Leukemia; Lymphoma
Interventions: Biological: filgrastim; Drug: asparaginase; Drug: bortezomib; Drug: cyclophosphamide; Drug: cytarabine; Drug: doxorubicin hydrochloride; Drug: etoposide phosphate; Drug: leucovorin calcium; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013
PDE5 Inhibitor Use and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)

Condition: Anterior Ischemic Optic Neuropathy
Intervention: Drug: Diagnostic procedures
Sponsors: Bayer; Bayer
Recruiting - verified May 2013
Strategic Timing of Antiretroviral Treatment

Condition: HIV Infection
Intervention: Drug: All licensed antiretroviral medications
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute; National Institute of Allergy and Infectious Diseases (NIAID); Copenhagen HIV Programme (CHIP) -- Copenhagen, Denmark; Medical Research Council (MRC) Clinical Trials Unit -- London, United Kingdom; The Kirby Institute for Infection and Immunity in Society; The Institute for Clinical Research at the Veterans Affairs Medical Center -- Washington, D.C., USA; French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS); German Federal Ministry of Education and Research; NEAT - European AIDS Treatment Network; National Health and Medical Research Council, Australia; National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI); National Heart, Lung, and Blood Institute (NHLBI); National Institute of Mental Health (NIMH); National Institute of Neurological Disorders and Stroke (NINDS); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); Abbott; Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline; Merck; Tibotec Pharmaceutical Limited
Recruiting - verified June 2013
A Study To Evaluate The Safety Of Voriconazole As Treatment Of Invasive Aspergillosis (Fungal Infection) And Other Rare Molds In Children

Condition: Invasive Aspergillosis
Intervention: Drug: Voriconazole
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
TKI258 in Castrate Resistant Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: TK1258
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Novartis
Recruiting - verified May 2013
Continuing Access To AG- 013736 (A406) For Patients Previously Receiving AG 013736 In Clinical Trials

Condition: Solid Tumors
Intervention: Drug: axitinib
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma

Conditions: Brain Tumors; Spinal Cord Tumors
Interventions: Drug: Temozolomide; Drug: Lapatinib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified June 2013
Implant for Augmentation of Cerebral Blood Flow Trial, Effectiveness and Safety in a 24 Hour Window

Condition: Ischemic Stroke
Interventions: Device: The Ischemic Stroke System; Device: Sham control
Sponsors: BrainsGate; BrainsGate
Recruiting - verified June 2013
Radical Trachelectomy for Cervical Cancer

Condition: Cervical Cancer
Intervention: Behavioral: Questionnaires
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013
Study of NNZ-2566 in Patients With Traumatic Brain Injury

Condition: Brain Injuries
Intervention: Drug: NNZ-2566
Sponsors: Neuren Pharmaceuticals Limited; Neuren Pharmaceuticals Limited
Recruiting - verified May 2013
A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Efficacy of TMC278 in Human Immunodeficiency Virus Infected Adolescents

Condition: Human Immuno Deficiency (HIV) Infections
Interventions: Drug: TMC278; Drug: Zidovudine; Drug: Abacavir; Drug: Tenofovir disoproxil fumarate; Drug: Lamivudine; Drug: Emtricitabine
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified June 2013
Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia

Conditions: Adult Acute Lymphoblastic Leukemia in Remission; B-cell Adult Acute Lymphoblastic Leukemia; L1 Adult Acute Lymphoblastic Leukemia; L2 Adult Acute Lymphoblastic Leukemia; Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia; T-cell Adult Acute Lymphoblastic Leukemia; Untreated Adult Acute Lymphoblastic Leukemia
Interventions: Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: vincristine sulfate; Drug: dexamethasone; Drug: dasatinib; Drug: cytarabine; Drug: methotrexate; Biological: filgrastim; Drug: methylprednisolone; Drug: leucovorin calcium; Drug: prednisone; Radiation: total-body irradiation; Drug: etoposide; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Drug: sirolimus; Drug: tacrolimus; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified June 2013
An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children

Condition: Human Immunodeficiency Virus (HIV)
Intervention: Drug: Maraviroc
Sponsors: ViiV Healthcare; ViiV Healthcare; Pfizer
Recruiting - verified June 2013
Levonorgestrel Intrauterine Device (IUD) to Treat Complex Atypical Hyperplasia (CAH) and Grade 1 Endometrioid Endometrial Carcinoma (G1EEC)

Conditions: Hyperplasia; Endometrial Cancer
Intervention: Device: Levonorgestrel IUD
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013
Filgrastim-Mobilized Stem Cells for Transplantation Using Unrelated Donors

Condition: Healthy
Intervention: Drug: Filgrastim
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; National Marrow Donor Program
Recruiting - verified May 2013
Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage Phase III

Condition: Intraventricular Hemorrhage
Interventions: Drug: Cathflo Activase; Other: Normal saline
Sponsors: Johns Hopkins University; Daniel Hanley; National Institute of Neurological Disorders and Stroke (NINDS); Genentech; Emissary International LLC
Recruiting - verified June 2013
Neuropsychological and Behavioral Testing in Young Patients With Cancer

Conditions: Chemotherapeutic Agent Toxicity; Cognitive/Functional Effects; Neurotoxicity; Psychosocial Effects of Cancer and Its Treatment; Radiation Toxicity; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Other: questionnaire administration; Procedure: cognitive assessment; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013
Doxil, Bevacizumab and Temsirolimus Trial

Condition: Advanced Cancer
Interventions: Drug: Doxil; Drug: Bevacizumab; Drug: Temsirolimus
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013
Study To Assess The Safety, Pharmacokinetics, And Evaluate The Response To Anidulafungin When Treating Children With Invasive Candidiasis

Conditions: Candidemia; Candidiasis
Interventions: Drug: anidulafungin; Drug: fluconazole
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Prophylactic Cranial Irradiation (PCI) for Small Cell Carcinoma of the Urothelium

Condition: Bladder Cancer
Interventions: Radiation: Prophylactic Cranial Irradiation (PCI); Other: Brain X-ray
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013
Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer

Condition: Lung Cancer
Intervention: Radiation: stereotactic body radiation therapy (SBRT)
Sponsors: Radiation Therapy Oncology Group; Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013
Evaluating the Safety and Effectiveness of Bone Marrow Transplants in Children With Sickle Cell Disease (BMT CTN #0601) (The SCURT Study)

Condition: Sickle Cell Disease
Intervention: Biological: Hematopoietic Stem Cell Transplantation
Sponsors: Medical College of Wisconsin; Medical College of Wisconsin; National Heart, Lung, and Blood Institute (NHLBI); Blood and Marrow Transplant Clinical Trials Network; National Cancer Institute (NCI); National Marrow Donor Program; Sickle Cell Disease Clinical Research Network
Recruiting - verified May 2013
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Acute Myeloid Leukemia/Transient Myeloproliferative Disorder; Acute Undifferentiated Leukemia; Angioimmunoblastic T-cell Lymphoma; Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blastic Phase Chronic Myelogenous Leukemia; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Burkitt Lymphoma; Childhood Chronic Myelogenous Leukemia; Childhood Diffuse Large Cell Lymphoma; Childhood Grade III Lymphomatoid Granulomatosis; Childhood Immunoblastic Large Cell Lymphoma; Childhood Myelodysplastic Syndromes; Childhood Nasal Type Extranodal NK/T-cell Lymphoma; Chronic Eosinophilic Leukemia; Chronic Myelomonocytic Leukemia; Chronic Neutrophilic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; Cutaneous B-cell Non-Hodgkin Lymphoma; Essential Thrombocythemia; Extramedullary Plasmacytoma; Intraocular Lymphoma; Isolated Plasmacytoma of Bone; Juvenile Myelomonocytic Leukemia; Long-term Effects Secondary to Cancer Therapy in Children; Mast Cell Leukemia; Meningeal Chronic Myelogenous Leukemia; Monoclonal Gammopathy of Undetermined Significance; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Polycythemia Vera; Post-transplant Lymphoproliferative Disorder; Primary Central Nervous System Hodgkin Lymphoma; Primary Central Nervous System Non-Hodgkin Lymphoma; Primary Myelofibrosis; Primary Systemic Amyloidosis; Progressive Hairy Cell Leukemia, Initial Treatment; Prolymphocytic Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Stage 0 Chronic Lymphocytic Leukemia; Stage I Childhood Anaplastic Large Cell Lymphoma; Stage I Childhood Hodgkin Lymphoma; Stage I Childhood Large Cell Lymphoma; Stage I Childhood Lymphoblastic Lymphoma; Stage I Childhood Small Noncleaved Cell Lymphoma; Stage I Chronic Lymphocytic Leukemia; Stage I Cutaneous T-cell Non-Hodgkin Lymphoma; Stage I Multiple Myeloma; Stage I Mycosis Fungoides/Sezary Syndrome; Stage II Childhood Anaplastic Large Cell Lymphoma; Stage II Childhood Hodgkin Lymphoma; Stage II Childhood Large Cell Lymphoma; Stage II Childhood Lymphoblastic Lymphoma; Stage II Childhood Small Noncleaved Cell Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Cutaneous T-cell Non-Hodgkin Lymphoma; Stage II Multiple Myeloma; Stage II Mycosis Fungoides/Sezary Syndrome; Stage III Childhood Anaplastic Large Cell Lymphoma; Stage III Childhood Hodgkin Lymphoma; Stage III Childhood Large Cell Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage III Childhood Small Noncleaved Cell Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Cutaneous T-cell Non-Hodgkin Lymphoma; Stage III Multiple Myeloma; Stage III Mycosis Fungoides/Sezary Syndrome; Stage IV Childhood Anaplastic Large Cell Lymphoma; Stage IV Childhood Hodgkin Lymphoma; Stage IV Childhood Large Cell Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Stage IV Childhood Small Noncleaved Cell Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma; Stage IV Mycosis Fungoides/Sezary Syndrome; T-cell Large Granular Lymphocyte Leukemia; Unspecified Childhood Solid Tumor, Protocol Specific; Untreated Childhood Acute Lymphoblastic Leukemia; Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies; Untreated Hairy Cell Leukemia; Waldenström Macroglobulinemia
Interventions: Other: survey administration; Procedure: assessment of therapy complications; Procedure: long-term screening; Procedure: study of high risk factors
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013
Ablation vs Amiodarone for Treatment of AFib in Patients With CHF and an ICD

Condition: Heart Failure
Interventions: Procedure: Atrial Fibrillation ablation; Drug: Amiodarone
Sponsors: Texas Cardiac Arrhythmia Research Foundation; Texas Cardiac Arrhythmia Research Foundation; Casa Sollievo della Sofferenza IRCCS; Catholic University, Italy; Southlake Regional Health Centre; Stanford University; University of Kansas; The University of Texas, Galveston; University of Foggia; Sutter Health
Recruiting - verified October 2009
Study Using Chemotherapy +/- Pleurectomy/Decortication Followed By Intensity Modulated Radiation Therapy

Condition: Mesothelioma
Intervention: Other: Pemetrexed + Cisplatin or Carboplatin AUC=5 Pleurectomy/decortication (if feasible) Intensity Modulated Radiation Therapy
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Eli Lilly and Company; M.D. Anderson Cancer Center
Recruiting - verified June 2013
Quantitative Analysis of Outcomes in Breast Reconstruction

Condition: Breast Cancer
Interventions: Behavioral: Questionnaire; Procedure: Digital Imaging
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013
Evaluation of Robot-Assisted Surgery in Gynecologic Oncology

Condition: Gynecologic Cancer
Intervention: Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013
Prospective Observational Epidemiologic Study of Maraviroc's Safety

Condition: Human Immunodeficiency Virus
Interventions: Drug: Maraviroc along with an optimized background antiretroviral drug regimen; Drug: Optimized background antiretroviral drug regimen without maraviroc
Sponsors: ViiV Healthcare; ViiV Healthcare; Pfizer
Recruiting - verified May 2013
Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients

Condition: Kidney Transplantation
Interventions: Drug: Cyclosporine; Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Evaluate Safety of T/I on Diabetic Subjects With Mild Obstructive Pulmonary Disease

Conditions: Diabetic Type 1 With Obstructive Pulmonary Disease; Diabetic Type 2 With Obstructive Pulmonary Disease; Asthma; COPD; Type 1 Diabetes; Type 2 Diabetes; Indeterminate Obstructive Lung Disease
Interventions: Drug: Technosphere Insulin; Drug: Usual Care
Sponsors: Mannkind Corporation; Mannkind Corporation
Recruiting - verified May 2013
Three Different Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide

Condition: Lung Cancer
Interventions: Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy; Drug: cisplatin; Drug: etoposide
Sponsors: Alliance for Clinical Oncology Trials; Cancer and Leukemia Group B; National Cancer Institute (NCI); Radiation Therapy Oncology Group; Eastern Cooperative Oncology Group; North Central Cancer Treatment Group; Southwestern Oncology Group (SWOG)
Recruiting - verified June 2013
Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi

Conditions: Aspergillosis; Invasive Fungal Infections
Intervention: Drug: isavuconazole
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc; Basilea Pharmaceutica
Recruiting - verified June 2013
Sorafenib Long Term Extension Program (STEP)

Condition: Neoplasms
Intervention: Drug: Sorafenib (Nexavar, BAY43-9006)
Sponsors: Bayer; Bayer; ICON Clinical Research
Recruiting - verified May 2013
Laparoscopic Approach to Cervical Cancer

Condition: Cervical Cancer
Interventions: Procedure: Total Abdominal Radical Hysterectomy; Procedure: Total Laparoscopic or Robotic Radical Hysterectomy
Sponsors: Queensland Centre for Gynaecological Cancer; Queensland Centre for Gynaecological Cancer; M.D. Anderson Cancer Center
Recruiting - verified June 2013
Photopheresis for the Treatment of Acute Graft Versus Host Disease

Condition: Graft Versus Host Disease
Interventions: Procedure: Photopheresis; Drug: Methylprednisolone
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013
A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Conditions: Crohn's Disease; Ulcerative Colitis; Indeterminate Colitis; Inflammatory Bowel Diseases
Interventions: Biological: Anti TNF therapy including infliximab; Drug: No Biologics
Sponsors: Janssen Biotech, Inc.; Janssen Biotech, Inc.
Recruiting - verified June 2013
Assessment of the Treatment of Severely Burned With Anabolic Agents on Clinical Outcomes, Recovery and Rehabilitation

Condition: Burns
Interventions: Procedure: Stable Isotope Infusion Study; Procedure: Collection of blood and tissues; Procedure: Radiology testing: Dual-energy X-ray absorptiometry (DEXA), K+ counter, ultrasound, MRI; Drug: Humatrope; Drug: Ketoconazole; Drug: Oxandrolone; Drug: Propranolol; Drug: Oxandrolone and propranolol combined; Drug: Humatrope and propranolol combined; Drug: Placebo; Behavioral: Exercise--Hospital supervised intensive exercise program; Behavioral: Home exercise program
Sponsors: The University of Texas, Galveston; The University of Texas, Galveston; U.S. Department of Education; National Institutes of Health (NIH); Shriners Hospitals for Children
Recruiting - verified May 2013
CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL

Conditions: B Cell Lymphoma; Chronic Lymphocytic Leukemia
Interventions: Genetic: CD19CAR-zeta and CD19CAR-28-zeta T cells; Drug: Ipilimumab
Sponsors: Baylor College of Medicine; Baylor College of Medicine; Texas Children's Hospital; The Methodist Hospital System; Center for Cell and Gene Therapy, Baylor College of Medicine
Recruiting - verified May 2013
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: flutamide; Radiation: radiation therapy
Sponsors: Radiation Therapy Oncology Group; Radiation Therapy Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B
Recruiting - verified June 2013
Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia

Condition: Leukemia
Interventions: Biological: anti-thymocyte globulin; Drug: busulfan; Drug: cyclophosphamide; Drug: cyclosporine; Drug: methotrexate; Drug: methylprednisolone; Drug: tacrolimus; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: allogeneic bone marrow transplantation; Procedure: allogeneic hematopoietic stem cell transplantation
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2013
A Study of Tamiflu (Oseltamivir) for Treatment of Influenza in Immunocompromised Patients.

Condition: Influenza
Interventions: Drug: oseltamivir; Drug: oseltamivir; Other: Alternative Control
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified June 2013
Study Evaluating Prophylaxis Treatment & Characterizing Efficacy, Safety, & PK Of B-Domain Deleted Recombinant FVIII

Condition: Hemophilia A
Interventions: Biological: Moroctocog alfa (AF-CC); Biological: Moroctocog alfa (AF-CC)
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine

Condition: Influenza
Interventions: Biological: 13 valent pneumococcal conjugate vaccine; Biological: 13 valent pneumococcal conjugate vaccine
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
A Multi-Center Trial to Study Acute Liver Failure in Adults

Conditions: Acute Liver Failure; Fulminant Hepatic Failure; Acute Liver Injury
Intervention:
Sponsors: University of Texas Southwestern Medical Center; William Lee; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified June 2013
Psychophysical Studies of Cancer Therapy-Induced Pain

Conditions: Advanced Cancer; Pain
Intervention: Other: Sensory Tests
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013
Psoriasis Longitudinal Assessment and Registry (PSOLAR)

Conditions: Psoriasis; Arthritis, Psoriatic
Interventions: Biological: ustekinumab; Biological: Biological therapies other than infliximab and ustekinumab; Drug: conventional systemic agents; Biological: infliximab
Sponsors: Centocor Ortho Biotech Services, L.L.C.; Centocor Ortho Biotech Services, L.L.C.
Recruiting - verified June 2013
Sample Collection From Melanoma Patients

Condition: Melanoma
Interventions: Procedure: Blood Sample; Procedure: Tumor Sample
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013
Measuring Sleep Disturbance Among Cancer Patients

Condition: Advanced Cancer
Interventions: Behavioral: Questionnaire; Device: Actigraph
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013
M.D. Anderson Symptom Inventory (MDASI) Validation Study in Cancer Patients

Condition: Advanced Cancer
Intervention: Behavioral: Survey
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013
Hyper-CVAD Plus Nelarabine in Untreated T-ALL/Lymphoblastic Lymphoma

Conditions: Leukemia; Lymphoblastic Lymphoma; Leukemia, Lymphoblastic, Acute
Interventions: Drug: Doxorubicin; Drug: Cyclophosphamide; Drug: Cytarabine; Drug: Dexamethasone; Drug: Methotrexate; Drug: Vincristine; Drug: Nelarabine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013
FOLFOX Chemotherapy Regimen (5-FU, Leucovorin, Oxaliplatin) in Metastatic Colorectal Cancer

Condition: Colorectal Cancer
Interventions: Drug: 5-FU; Drug: Cetuximab; Drug: Dasatinib; Drug: Leucovorin; Drug: Oxaliplatin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Bristol-Myers Squibb
Recruiting - verified June 2013
Cord Blood Expansion on Mesenchymal Stem Cells

Conditions: Myelodysplastic Syndrome; Leukemia
Interventions: Procedure: Cord Blood Infusion; Drug: Busulfan; Drug: Fludarabine; Drug: Rituximab; Other: ATG; Drug: Cyclophosphamide; Drug: Clofarabine; Radiation: Total Body Irradiation (TBI); Drug: Melphalan; Drug: Tacrolimus; Drug: Mycophenolate Mofetil; Drug: G-CSF
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified June 2013
Study of the Safety and Effectiveness of DIAM™ Spinal Stabilization System Versus Conservative Care

Condition: Lumbar Degenerative Disc Disease
Interventions: Device: DIAM™ Spinal Stabilization System; Procedure: Conservative care
Sponsors: Medtronic Spinal and Biologics; Medtronic Spinal and Biologics
Recruiting - verified April 2013
Open-Label Extension Study Of Safety And Tolerability Of Pregabalin In Pediatric Patients With Partial-Onset Seizures

Condition: Epilepsies, Partial
Intervention: Drug: Pregabalin
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.

Conditions: Metastatic Breast Cancer; Advanced Breast Cancer; Advanced Gastric Cancer; Advanced/Metastatic Non-small Cell Lung Cancer; Gastrointestinal Stromal Tumor; Hepatocellular Carcinoma; Metastatic Castration-resistant Prostate Cancer; Metastatic Renal Cell Cancer; Non Small Cell Lung Cancer; Pancreatic Islet Cell Carcinoma; Pancreatic Neuroendocrine Tumor; Thyroid Cancer
Intervention: Drug: sunitinib
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus

Condition: Diabetes Mellitus, Type 1
Intervention: Drug: Oral Insulin
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute of Allergy and Infectious Diseases (NIAID); National Center for Research Resources (NCRR); American Diabetes Association; Juvenile Diabetes Research Foundation
Recruiting - verified May 2013
Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid Arthritis

Condition: Arthritis, Rheumatoid
Interventions: Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013
A Pivotal Study of a Facet Replacement System to Treat Spinal Stenosis

Condition: Lumbar Spinal Stenosis
Interventions: Device: ACADIA® Facet Replacement System; Device: Instrumented posterolateral fusion
Sponsors: Globus Medical Inc; Globus Medical Inc
Recruiting - verified June 2013
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor

Conditions: Untreated Childhood Medulloblastoma; Untreated Childhood Pineoblastoma; Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
Interventions: Drug: carboplatin; Drug: cyclophosphamide; Biological: filgrastim; Drug: cisplatin; Drug: isotretinoin; Drug: vincristine sulfate; Radiation: radiation therapy; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013
Azacitidine and MS-275 in Treating Patients With Recurrent Advanced Non-Small Cell Lung Cancer

Conditions: Recurrent Non-small Cell Lung Cancer; Stage IIIA Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer
Interventions: Drug: entinostat; Drug: azacitidine; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
Spousal Relationships and Pain in Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Behavioral: Questionnaire; Behavioral: Interview
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Department of Defense
Recruiting - verified May 2013
Repository for Inherited Eye Diseases

Conditions: Retinitis Pigmentosa; Inherited Ophthalmic Diseases
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Eye Institute (NEI)
Recruiting - verified May 2013
Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo

Condition: Epilepsies, Partial
Interventions: Drug: Lyrica (pregabalin); Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen

Conditions: Arthritis, Rheumatoid; Osteoarthritis
Interventions: Drug: celecoxib; Drug: Ibuprofen; Drug: Naproxen
Sponsors: Pfizer; Pfizer; The Cleveland Clinic
Recruiting - verified June 2013
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Conditions: Breast Cancer; Neoplasm Metastasis
Interventions: Other: Standard supportive care (packed RBC transfusion); Drug: epoetin alfa + packed RBC transfusion
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2013
Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors

Condition: Kidney Cancer
Interventions: Biological: dactinomycin; Drug: carboplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: irinotecan hydrochloride; Drug: vincristine sulfate; Procedure: therapeutic conventional surgery; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013
Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma

Conditions: Untreated Childhood Medulloblastoma; Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
Interventions: Drug: etoposide; Drug: cyclophosphamide; Drug: cisplatin; Biological: filgrastim; Drug: carboplatin; Drug: thiotepa; Drug: methotrexate; Drug: leucovorin calcium; Drug: vincristine sulfate; Procedure: autologous hematopoietic stem cell transplantation; Other: laboratory biomarker analysis; Procedure: quality-of-life assessment
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013
Fludarabine-based Conditioning for Severe Aplastic Anemia

Condition: Anemia, Aplastic
Interventions: Drug: Cyclophosphamide; Drug: Cyclophosphamide; Drug: Cyclophosphamide; Drug: Cyclophosphamide
Sponsors: Medical College of Wisconsin; Medical College of Wisconsin; National Heart, Lung, and Blood Institute (NHLBI); Blood and Marrow Transplant Clinical Trials Network; National Cancer Institute (NCI)
Recruiting - verified June 2013
Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension

Condition: Pulmonary Arterial Hypertension
Interventions: Drug: Bosentan; Drug: Sildenafil Citrate
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Efficacy and Safety of Vanquix for the Management of Selected, Refractory, Patients With Epilepsy Who Require Intermittent Caregiver Medical Intervention to Control Episodes of Acute Repetitive Seizures.

Conditions: Seizures; Epilepsies, Partial; Epilepsy, Complex Partial; Epilepsy, Generalized; Epilepsy
Interventions: Drug: Placebo; Drug: Vanquix Auto-Injector (Diazepam Injection)
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)

Condition: Melanoma
Interventions: Procedure: Completion Lymphadenectomy; Procedure: Monitoring with nodal ultrasound
Sponsors: John Wayne Cancer Institute; John Wayne Cancer Institute; National Institutes of Health (NIH)
Recruiting - verified June 2013
Group Therapy for Nicotine Dependence: Mindfulness and Smoking

Conditions: Smoking; Tobacco Use Cessation
Interventions: Behavioral: MBAT Group Therapy; Drug: Nicotine; Behavioral: Group Therapy; Behavioral: Individual Therapy
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Institute on Drug Abuse (NIDA)
Recruiting - verified May 2013
Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization

Condition: Melanoma
Interventions: Biological: Dendritic Cell Immunization; Drug: Cyclophosphamide; Drug: Fludarabine; Biological: T Cells; Biological: Interleukin-2; Drug: Mesna
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Chiron Corporation
Recruiting - verified May 2013
Compassionate Use of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES)

Condition: Hypereosinophilic Syndrome
Intervention: Drug: mepolizumab
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
A Study to Provide Access to Trabectedin in Patients With Non L-type Soft Tissue Sarcoma Who Have Persistent or Recurrent Disease and Who Are Not Expected to Benefit From Currently Available Standard of Care Treatment

Condition: Sarcoma
Intervention: Drug: Trabectedin
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2013
Covalent Tolerance Induction to Factor VIII-Prediction of Inhibitors in Hemophilia

Condition: Hemophilia A
Intervention:
Sponsors: The University of Texas Health Science Center, Houston; The University of Texas Health Science Center, Houston
Recruiting - verified June 2013
Evaluation of Hemostasis in Bleeding and Thrombotic Disorders

Conditions: Congenital Bleeding; Thrombotic Disorder
Intervention:
Sponsors: The University of Texas Health Science Center, Houston; The University of Texas Health Science Center, Houston
Recruiting - verified June 2013
An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection

Condition: HIV Infection
Intervention: Drug: Efavirenz
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Available - verified May 2013
Natural History Study of the Development of Type 1 Diabetes

Condition: Diabetes Mellitus, Type 1
Intervention:
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Center for Research Resources (NCRR); Juvenile Diabetes Research Foundation; American Diabetes Association
Recruiting - verified May 2013
Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma

Conditions: Brain Tumor; Central Nervous System Tumor
Interventions: Drug: cisplatin; Drug: cyclophosphamide; Drug: lomustine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013
Study of Late-Occurring Complications in Childhood Cancer Survivors

Conditions: Cancer Survivor; Cardiovascular Complications; Hematopoietic/Lymphoid Cancer; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Other: questionnaire administration; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2013
Emergency Use Program for HTE HIV+ Patients Who Need Tipranavir Treatment

Condition: HIV Infections
Intervention: Drug: Tipranavir
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Available - verified June 2013
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer

Conditions: Glioblastoma Multiforme; Glioblastoma; GBM; Grade IV Astrocytoma; Glioma; Brain Cancer; Brain Tumor
Intervention: Drug: Dendritic cell immunotherapy
Sponsors: Northwest Biotherapeutics; Northwest Biotherapeutics
Recruiting - verified May 2013
Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

Condition: HIV Infections
Interventions: Drug: Current ARV medications; Drug: Current TB medications; Drug: Current hormonal contraceptive medications
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified May 2013
Therapy of HES, PV, Atypical CML or CMML, and Mastocytosis With Imatinib Mesylate

Conditions: Chronic Myelomonocytic Leukemia; Chronic Myeloid Leukemia; Polycythemia Vera; Hypereosinophilic Syndrome; Mastocytosis
Intervention: Drug: Imatinib Mesylate (Gleevec)
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Novartis Pharmaceuticals
Recruiting - verified June 2013
Prenatal and Postnatal Studies of Interventions for Prevention of Mother-To-Child Transmission

Conditions: HIV Infections; Pregnancy Complications, Infectious
Intervention: Behavioral: Adherence assessment
Sponsors: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; International Maternal Pediatric Adolescent AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified June 2013
Genetic Markers for Focal Segmental Glomerulosclerosis

Conditions: AIDS Associated Nephropathy; Focal Glomerulosclerosis; HIV Infections
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified April 2013

Find Paid Research Studies in Texas

Welcome to Paid Research Studies.